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ABSTRACT 
Adult neurogenesis is a highly plastic process-exhibiting enhancement by 
rewarding experiences and suppression by stressful experiences. Animal models have 
demonstrated that pro-inflammatory challenges suppress neurogenesis. A growing body 
of evidence suggests a role for microRNAs (miRNA) in the regulation of the acute 
inflammatory response in peripheral macrophages. However, little is known about the 
role miRNAs play in microglia , the CNS resident immune cell , or their impact on 
neurogenesis. To elucidate the role that miRNAs have on influencing the acute 
inflammatory response, primary murine microglia were stimulated with 
lipopolysaccharide (LPS), an M1 -classically activating stimulus, and profiled for gene 
and miRNA expression. miR-155 and Interleukin-6 (IL-6) were the most up-regulated 
viii 
miRNA and mRNA respectively, identified under M1-classical activation when 
compared to resting microglia. IL-6, the founding member of the neuropoietic family of 
cytokines, is a known negative regulator of neurogenesis. The ability of IL-6 to regulate 
neurogenesis was tested with the application of an IL-6 neutralizing antibody in a 
transwell co-culture system with neural stem cells (NSC) and primary microglia. During 
a pro-inflammatory challenge, NSCs altered their differentiation pattern with a 20% 
increase in astrocytic and a 50% reduction in neuronal differentiation. These alterations 
were greatly reduced with treatment by an IL-6 neutralizing antibody. To test if miR-155 
can regulate IL-6levels both miR-15s-1- mice and anti-miR-155 inhibitors were employed 
in vitro. Knockout and knockdown of miR-155 demonstrated a 60% and 50% reduction 
in IL-6 expression, respectively, when compared to wildtype LPS challenged controls. 
To determine if miR-155 has the ability to regulate the observed suppression of 
neurogenesis after inflammation, miR-15s-1- mice were subjected to 
intracerebroventricular injection of LPS. The pro-inflammatory induced suppression of 
neurogenesis along the Sub Granular Zone (SGZ) was completely ablated in miR-155_1_ 
mice. Specifically, proliferation and neuronal differentiation were both suppressed by 
~30% along the SGZ in wildtype animals given a pro-inflammatory challenge. In a 
similar pro-inflammatory challenge in miR-155_1_ mice, these levels were restored to 
unchallenged wildtype levels. This work demonstrates that miR-155 has the ability to 
suppress neurogenesis observed after inflammation, potentially through mediation of 
neuropoietic cytokine levels e.g. IL-6. 
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Chapter 1: GENERAL INTRODUCTION 
1 
The Acute Inflammatory Response 
One of the most widely studied environmentally cued physiological and 
pathological conditions known to mammalian systems is that of inflammation. Today, 
inflammation is thought of more as an adaptive response to either infection or tissue 
injury, with the goal of restoring homeostatic balance to the affected region [1]. While 
acute inflammation is a physiological process and in general is beneficial, if dysregulated 
inflammation can be equally detrimental to the host, e.g. sepsis or various autoimmune 
disorders [ 1]. 
The Acute Inflammatory Response in the Periphery 
Typically, cells of the innate immune system including both resident macrophages 
and mast cells mediate the acute inflammatory response. In response to the detection of 
either pathogenic stimuli or tissue damage the innate immune cells produce a plethora of 
cytokines, chemokines, and many other bioactive compounds [1]. These chemical 
messengers trigger the inflammatory response encompassing and recruiting many cell 
types to the surrounding vicinity [1]. For example, cytokines signal local endothelial 
post-capillary cells to activate, which in turn become more leaky and allow for the 
extravasation of neutrophils [1] . Chemokines then direct the infiltrating neutrophils to 
the target site and once there they attempt to kill the detected pathogen or affected injured 
cells via release of reactive oxygen and reactive nitrogen species (ROS/RNS) from their 
granules [1]. After the affected region is cleared of the infection or damage the acute 
2 
inflammation response then transitions into a repair and regenerative response mediated 
by different biochemical signals , e.g . Resolvins and/or Transforming Growth Factor-
Beta (TGF-~) [1] . Resolvins and TGF-~ recruit monocytes which work to remove dead 
cells and initiate tissue remodeling or scar formation if the tissue cannot be regenerated 
[1]. Simply put , the ultimate goal of this process is remove the pathogen while 
minimizing damage to the affected tissue , then clean-up and reconstitute the damaged 
region to restore homeostasis, as depicted in Figure 1 [1] . 
The Acute Inflammatory Response in the CNS 
There is a long-standing belief that the Central Nervous System (CNS) was 
thought of as 'immune-privileged' [2,3]. A concept initially put forth due to the 
observation of the Blood-Brain Barrier (BBB) restricted cytokine and leukocyte entry, 
lack of lymphatic drainage in the CNS, and lower levels of constitutive MHC-Class I and 
II expression [2,3]. A more realistic view of the CNS is that where the immune response 
is more tightly controlled than elsewhere in the body through multiple mechanisms as 
well as those listed above [4]. For example, CD200 expression on the surface of neurons, 
astrocytes , and oligodendrocytes interacting with CD200 receptor on microglia maintains 
microglia in resting state and secretion of TGF-~ all function to suppress activation of an 
immune response in the CNS from insult and maintain microglia in a resting state [ 4-6]. 
Overall , these facets all constitute key ways in which the immune response in the CNS 
differs from the periphery, i.e., microglia are actively suppressed requiring a higher 
threshold of insulting agent before microglia respond. 
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Microglia have long been described as the resident immune cell of the CNS , with 
key roles in homeostasis maintenance , host defense, and repair [2 ,7]. Microglia comprise 
5-l 0% of the cells in the CNS and are found in higher concentration in grey matter versus 
white matter of the brain [7]. Unlike resident macrophages in peripheral organs that 
originate from recruited monocytes, microglia are thought to originate from early 
embryonic macrophage-like mesodermal precursor cells prior to the closure of the BBB 
[7 ,8] . In the adult , there is "overwhelming evidence" that microglia coordinate and 
orchestrate the inflammatory response in the CNS [2,7 ,8]. 
Initially, prior to a disruption in the homeostatic balance, microglia's role is one 
of surveillance/recognition of stimuli and scavengers of debris that can potentially 
perturb the steady-state homeostatic balance in the CNS [1 ,2]. In microglia, this 
surveillance state is referred to as "resting (monitoring) microglia" and has a 
characteristic phenotype of small soma and highly ramified processes , i.e. very long and 
arborized cytoplasmic projections [9]. Microglia cells themselves are non-motile at rest, 
but their cytoplasmic processes are highly motile sampling repetitively a particular 
territory with little overlap [7-9] . Further , microglia posses an array of sensors that 
sample the local micro-environment and surrounding cellular elements ranging from the 
ability to detect pathogens and to asses neuronal functionality [7] . 
Typically , the acute inflammatory response in the CNS is initiated when microglia 
detect an invading pathogen, tissue injury , or upon neuronal disconnection (e .g. 
peripheral nerve/spinal cord lesion) resulting in microglia activation [1 ,4,9]. Microglial 
activation is hallmark of the neuro-inflammatory response [2,4]. Microglia , like 
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peripheral macrophages, recognize potential non-self pathogens via a series of pathogen-
associated molecular patterns (PAMPs) receptors that detect various motifs specific to 
pathogens, e.g. toll-like receptor-4 (TLR-4) recognition of gram-negative bacteria via 
lipopolysaccharide (LPS) interaction [1 ,9]. Activated microglia also have a characteristic 
morphology where ramified processes shorten and enlargement of the soma, referred to 
as "amoeboid" phenotype [9]. Further, activated microglia significantly increase their 
phagocytic capability and secrete pro-inflammatory innate cytokines including: tumor 
necrosis factor-alpha (TNF-a), interleukin-1-beta (IL-l~) and interleukin-6 (IL-6) [9]. 
Inflammation's Involvement in Neurovathology 
Collectively, neurodegenerative diseases such as Alzheimer's disease (AD), 
Parkinson ' s disease (PD), and Amyotrophic Lateral Sclerosis (ALS) are clinically 
disparate in etiology, but all share a common trait in their pathology: sustained activation 
of CNS inflammatory processes [2,10,11]. Further, a recent review by Czirr et al. has 
summarized over 36 different genetic modifications to genes associated with the 
inflammatory response that when dysregulated have been shown to demonstrated either 
beneficial or detrimental effects on the progression of neurodegenerative disease in 
various mouse models [11]. Interestingly, genetic modifications to six genes: 
complement component 3 (C3), chemokine (C-C motif) ligand 2 (CCL2), fractalkine 
receptor (CX3CR1) , IL-l~, transforming growth factor-beta 1 (TGF-~1), and 
transforming growth factor-beta receptor 2 (TGFBR2) actually demonstrated either 
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beneficial or detrimental effects depending not on the gene itself, but rather on the actual 
neurodegenerative disease model [11]. 
AD is the most common neurodegenerative disease and has two hallmark 
pathologies: 1) extracellular plaques composed of cleaved fragments of Amyloid 
precursor protein (APP) leading to deposition of amyloid-beta (A~ 1-42 or A~ 1-40) and 
2) intracellular neurofibrillary tangles (NFTs) composed of hyper-phosphorylated 
microtubule binding protein tau [2,10] . In AD mouse models, microglia have been 
shown to elaborate pro-inflammatory cytokines IL-l~' TNF-a, IL-6, and have 
upregulated MHC-II expression, all markers of activated microglia, as well increased 
production of ROS/RNS and astrocyte activation [10,12]. Activation of microglia by A~ 
plaques is thought to occur through interactions with either TLR receptors and/or 
scavenger receptor for advanced glycosolation end-products receptors [10,13]. 
Stroke is the third leading cause of death and most common cause of permanent 
disability worldwide [2,14]. The ensuing inflammatory response has been demonstrated 
to correlate to the severity of the infarct and subsequent neurological deficits [14] . 
Microglia activation initiates the inflammatory response to stroke, occurring within 
minutes of the ischemic event [14]. This triggers a period of microglia proliferation, 
peaking at 2-3 days post event, and the elaboration of ROS , cytokines (IL-l~, TNF-a, 
and IL-6) , and chemokines [14,15]. Neutrophil invasion is a hallmark of stroke, perhaps 
due to breakdown of BBB, and the severity of damage in a stroke has been directly 
attributable to the number of invading neutophils [14]. 
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Multiple Sclerosis (MS) is an inflammatory demyelination disease of the CNS , 
targeting the oligodendrocyte specifically [2,16]. Currently, the most accepted etiology 
of MS is that it is driven by the adaptive immune response, in the form ofT -cell mediated 
(CD4+, CD8+ and y/o T cells) immunity against antigens found uniquely on 
oligodendrocytes [2,16]. 
Inflammation has also been linked to neuropsychiatric disorders, such as 
Depression, independent of the sickness response [2,17 ,18]. A potential mechanism 
mediating cytokine-induced depression is indolearnine-2.3-dioxygenase enzyme, which is 
up-regulated during pro-inflammatory states either centrally or peripherally [17]. IDO 
degrades the amino-acid tryptophan, the limiting factor in the synthesis of serotonin 
[17,18]. 
Macrophage Plasticitv: Ml and M2 phenotypes defined 
Current research is suggesting that peripheral macrophages display much more 
plasticity in their phenotypic response to pathogenic stimuli , ranging from a "classically 
activated" (Ml) pro-inflammatory state characterize by both pro-recruitment and 
formation of cytotoxic ROS/RNS species to "alternatively activated" (M2) 
macrophages exhibit anti-inflammatory, pro-phagocytosis of apoptotic bodies , and 
wound healing properties [19-28]. The M1 phenotype appears as the default response to 
LPS , a prototypical TLR-4ligand, and other pro-inflammatory stimuli in macrophages 
[19,20]. However, pre-treatment of macrophages with various M2-promoting cytokines 
can influence the responsiveness to either an pro-cleanup with enhanced phagocytosis 
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capability, M2a (via IL-4/IL-13), or wound-healing, M2c (via TGF-~ or corticosteroids), 
phenotype as depicted and annotated in Figure 1 [19,20,29,30]. It should be clarified, 
that while these the terms M1/M2 are used to denote a specifically phenotype, these are 
quite dynamic and better thought to be though of as a continuum [19-28] . The 
understanding how peripheral macrophages regulate these phenotypes and 
guide/influence the innate immune response is a very active area of investigation. 
Adaptive immunity's role in macrophage activation 
In additional to pathogenic stimuli the adaptive immune system can also activate 
macrophages either to the M1-classically activated or to the M2-alternatively activated 
through the secretion of Intelferon-gamma (IFN-y) or Interleukin-4 (IL-4) respectively 
from CD4+ helper T -cells [31-33]. In fact, the Ml/M2 nomenclature was derived in part 
to match the T H 1/T H2 nomenclature ascribe to different phenotypes observed in CD4+ 
helper T-cells [24,32,34]. Research as demonstrated that there are many flavors of helper 
CD4+ T -cells and simplifying them down to only T H1 or T H2 does not do justice to the 
field [35]. The TH1/TH2 nomenclature actually describes a phenotype for the adaptive 
response that coordinates the immune response in a more focused and optimized response 
to a specific class of pathogens [35]. The TH1 phenotype in helper CD4+ T-cells is known 
for the response to intracellular pathogens, viruses, and tumors [35]. On the other hand, 
T H2 cells induce the removal of intestinal helminths (worms) and other parasites [35]. 
Other subclasses of helper T -cells exist, e.g. Regulatory T -cells (T Reg) that work to 
suppress the immune response and prevent autoimmune responses or T H 17 that work to 
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enhance the response to extracellular bacteria, and fungi [35]. Taken, together, it is 
almost inescapable not to link M1 and M2 macrophage activation of the innate immune 
system to that ofT Hl and T H2 activation in CD4+ T -cells of the adaptive immune system. 
The larger question is how applicable of a model of activation is this in microglial given 
the reduced adaptive immune response in the CNS [9]. 
Microglia Plasticity 
Microglia are generally accepted as the resident member of the mononuclear 
phagocytic system in the CNS , similar to peripheral macrophages, have emerged as the 
driver of the neuroinflammatory response and a critical mediator in CNS wound healing 
[8] . Originally described by Pio Del Rio-Hortega in 1932, microglia were initially 
thought to exist in two states: a "Resting" state with a ramified, branched morphology or 
an "Activated" state with an amoeboid morphology, transitioning upon detection of 
pathogenic stimulation [8,9,36,37]. Current research is suggesting that microglia display 
a similar dynamic phenotypic response to either pathogenic or cytokine stimulation much 
as peripheral macrophages exhibit, ranging from the M1 pro-inflammatory phenotype to 
the M2 anti-inflammatory/pro-wound healing phenotype [19-24,26,27,38] . Colton et al., 
validated that application of IL-4/IL-13 can equally skew microglia into a M2 
alternatively activated state [22]. Further, Fenn et al., demonstrated specifically impaired 
M2a and M2c skewing and enhanced M1 skewing in aged versus adult microglia in an 
LPS challenge paradigm [38]. Currently, this is a very active area of microglial research 
that lags considerably further behind than that in peripheral macrophages . 
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MicroRNAs 
Early studies of gene regulation using Escherichia coli (E. coli) and the classical 
lactose (Lac) operon clearly demonstrated how proteins, coupled with environmental 
cues can feedback on DNA and either activate or prevent gene transcription [39 ,40]. 
However , Mattick and Gagen demonstrated that regulatory networks scale up 
exponentially rather than linearly , and hence concluded a protein-only based regulatory 
network would ultimately limit the complexity of organisms well below that of 
mammalian systems [41]. As a result , Mattick and Gagen reasoned that scalability drove 
the need for an alternative regulatory control mechanism initially not observed in simpler 
prokaryotic organisms (e.g. E. coli) [41]. Further they concluded that an RNA-based 
control architecture, specifically pointing to small non-coding RNAs (ncRNAs), which 
include microRNAs (miRNAs), silencing RNAs (siRNAs), and Piwi-interacting RNAs 
(piRNAs), were necessary in the evolution and development of sophisticated multi-
cellular organisms [39,41-43]. Interestingly, Heimberg, et al. have recently hypothesized 
that underlying the vertebrate complexity is dramatic "expansion of the non-coding RNA 
inventory including miRNAs", rather than an increase in the number of gnomically coded 
proteins [ 44]. Specifically, Heimberg, et al. have identified 41 unique miRNA families 
that appear to have evolved right at the base of vertebrata, which they believe helped 
separate them from non-vertebra chordata [44]. 
miRNAs are one class of non-coding RNAs that are now known to regulate gene 
expression post-transcriptionally and play critical roles in embryogenesis, phenotypic 
cellular differentiation , viral infections , and carcinogensis [39 ,45,46]. miRNAs are 
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derived from double-stranded RNA precursors that are cleaved and processed into ~22 
nucleotide single-stranded RNA molecules [39,45]. Biogenesis of miRNA involves 
genomic transcription of primary miRNA , which then complexs with both Drosha/Pasha 
for further processing to form pre-miRNA [45]. Pre-miRNA is exported to the cytosol 
where it complexes with Argonaut 1 (AGOl) and the RNA-induced silence complex for 
final processing into a mature active single-stranded miRNA [39,45]. There are multiple 
AGO proteins with AGO 1 is associated with miRNA functionality, AG02 is associated 
with siRNA, and AG03 is associated with piRNA [43]. The combined mature RISC 
complex with the loaded miRNA partially binds to the target messenger RNA (mRNA) in 
the 3'- untranslated region (UTR) through Watson-Crick complementary base pairing to 
a conserved seed region, about 6-7 nucleotides [39,43,45,47]. Typically , when a miRNA 
binds to a target mRNA the effect on the mRNA results in either steric inhibition of 
translational machinery or enhanced degradation of the targeted mRNA [39 ,43 ,45 ,47]. 
Taken together, miRNA represents an entirely new control point in the regulation of 
genes , and may represent a ' last-ditch' effort to prevent unwanted translation. 
rniRNAs have been implicated in many physiological and pathological processes 
and as such opens the door to the development of novel therapeutics in their management 
[48]. Specifically, miRNA based-gene regulation has been implicated in many 
physiological processes including general developmental processes, cell-cycle regulation, 
immune cell maturation, and the acute inflammatory response [48,49]. However, 
dysregulated miRNA expression and subsequent dysregulated gene regulation has been 
linked to several pathological states of cancer including various lymphomas, pancreatic, 
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lung , breast, cervical, and prostate cancers [49]. Further, miRNAs are implicated in a 
number of non-cancer related diseases including cardiovascular disease, viral infections, 
and neurological disorders [49] . 
miRNA Involvement in the Inflammatorv Response 
Recently , the role of miRNAs in regulation of the acute inflammatory response 
has acquired significant attention with the demonstration that a number of miRNAs are 
upregulated upon TLR stimulation in peripheral macrophages including: miR-155 along 
with others [50-52] . In 2006, Taganov et al. were the first to uncover yet an additional 
layer of regulation by demonstrating that upon induction of LPS, various miRNAs were 
upregulated during the acute inflammatory response [50] . They speculated that since 
miRNAs had been shown in plants to be involved in the response to many different 
stressors , including viral , they hypothesized that there would be involvement of miRNAs 
in the regulation of the innate immune system upon LPS challenge, i.e. activation of an 
acute inflammatory response [50] . After testing over 200 known miRNAs in LPS 
stimulated monocytes they consistently found three key miRNAs upregulated: mir-
146a/b, miR-132, and miR-155 [50]. Further, Paulely et al. demonstrated the clinical 
significance of this suite of miRNAs ( -146a, -132, and -155) and found that all three are 
upregulated in samples of human peripheral blood monocytes from patients suffering 
from Rheumatoid Arthritis (RA) with some patients suffering other concomitant 
autoimmune disorders [53]. In addition, Tili et al. , observed a yin-yang relationship 
between miR-155 , up-regulated , and miR-125b, down-regulated, during activation of the 
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acute inflammatory response [54]. Taken together, alterations in specific microRNAs do 
indeed appear to be associated with activation of the acute inflammatory response in a 
very specific manner. 
miRNA Involvement in Microglial Functionality 
Ail previous studies linking miRNA functionality to the functionality of the acute 
immune response had been performed using in peripheral macrophages, monocytes or 
monocytic/macrophage cell lines [50-54] . Far less is known about miRNA involvement 
in microglial functionality, though much effort is converging on three critical miRNAs: 
miR-124, miR-146a and miR-155 [55-59]. In 2011, Ponomarev et al. demonstrated a key 
role for miR-124 in the overall microglial phenotype by demonstrating the ability to 
convert infiltrating macrophages into microglia and inhibiting their overaii activation 
ability in a mouse model of MS [56] . In early 2012, Cardoso et al. demonstrated that 
miR-155 was upregulated in response to an LPS challenge and targets Suppressor of 
Cytokine Signaling 1 (SOCSl) leading in increased production of both pro-inflammatory 
cytokines and increased reactive Nitric Oxide Synthase (NOS) production [55]. As 
mentioned above, miR-146a has been implicated in the both the pathologies of prion 
disease and AD [58] . While much focus has been drawn to these three miRNAs, Zhang, 
et al. has recently has demonstrated a role for both miR-21 and mir-181c in microglial 
biology [60]. Specifically , he demonstrated that miR-21 can represses FAS Ligand 
thereby preventing microglial mediated neuronal cell death in response to hypoxic 
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challenge [ 60]. Further, he also demonstrated that miR -181 c direct) y targets TN F-a, 
which miR-181c is commonly down regulated during an inflammatory challenge [61]. 
miRNA involvement in Neuropathology 
Within the last decade an explosion published reports have linked or 
demonstrated dysregulation of miRNAs in the pathogenesis of many psychiatric, 
neurodegenerative and other neuropathologies [62-64]. For the purposes of this report, 
the focus here will be on miRNAs connected with both neuroimmune functionality and 
neuropathology. Recently, in a study of short-interval post mortem AD brains versus 
aged matched control brains Lukiw and Alexandrov demonstrated significant 
upregulation of both miR-146a and miR-125b and went on to posit a role for both 
miRNAs in the regulation of complement factor H [65]. In the Experimental 
Autoimmune Encephalomyelitis (EAE) mouse model of Multiple Sclerosis (MS), 
silencing of miR-155 was demonstrated to significantly improve mean EAE clinical 
scores [66]. However, more striking results were obtained by exogenously giving miR-
124, which either completely blocked detection or reverse course of the normal disease 
progression due to the EAE as measure by mean clinical score when compared to control 
miRNA EAE challenged mice [56]. Recently, using the Superoxide Dismutase-1 
(SODl) mouse model of ALS , Butovkskey et al. demonstrated that mir-155 is strongly 
upregulated in microglia isolated from the spinal column of SOD1 mice compared to WT 
control mice [59]. 
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miR-155: Innate Immune and Microglial Functionalitv 
miR-155 is found on chromosome 21 and is part of the B-cell integration cluster 
(Bic) gene, a non coding gene where miR-155 is embedded within exon 3 [51 ,67 ,68]. 
miR-155 is perhaps the first miRNA tied to immune cell dysregulation with the Bic gene 
region identified as early as the late 80's, dating back long before miRNA was even 
identified [69,70]. Initially, miR-155 was identified by its over-expression associated 
with various B-celllymphomas and solid organ tumors e.g. breast, lung, prostrate, colon 
and pancreatic tumors [69-73]. As a result, miR-155 was initially dubbed an onco-miR 
due this oncogenic relationship [72]. miR-155 has been implicated in the differentiation 
of both innate and adaptive immune cells [74-77] and classic autoimmune diseases such 
as MS [66,78,79], RA [80], and Systemic Lupus Erythematosus (SLE) [81]. 
Interestingly, miR-155 has been found to be evolutionarily conserved, at lest 78% 
commonality, with almost every species from human down to ascidian Ciona intestinalis 
(solitary tunicate) at the base of the chordata phyla [44,68]. 
miR-155's role in acute inflammation is now well appreciated such that complete 
knockout of bic gene in CD4+ T -cells resulted immunodeficiency and displayed increased 
tissue remodeling, particularly in the pulmonary system, and expression alterations in 
many cytokines, chemokines and transcription factors [82]. Fmther, Rodriguez et al. 
demonstrated that adaptive immunity is impair though Salmonella typhimurim 
vaccination model and subsequent challenge where unvaccinated animals, wild-type 
(WT) or miR-155_,_ died with in a week, and WT vaccinated survived the challenge, but 
miR-155_,_ survived only about a month [82]. Rodriguez et al. also demonstrated that 
15 
there is a reduced B-cell response , since lgG 1 levels were significantly reduced in LPS 
challenged miR-155_,_ and found impaired activation of adaptive immunity from dendritic 
cells, a class of professional APC cells [82]. Lastly, through systems biological analysis 
the c-Musculoaponeurotic fibrosarcoma gene was identified as valid target of miR-155, 
which in miR-15s-'-is upregulated, which Rodriguez et al. speculates that mir-15s-'-
predisposed one to enhanced T 112 skewing in CD4+ T-cells [82]. 
O'Connel, et al. first demonstrated miR-155's role in the acute inflammatory 
response in peripheral monocytes by showing miR-155's upregulation upon LPS 
stimulated [50,51]. Further, O'Connel , et al. later demonstrated that a typical viral 
pattern or host antiviral stimulation, Poly(I:C) and Interferon-~ (IFN-~) respectively, 
would also upregulate miR-155 [51]. However, IFN-~ induced upregulation of miR-155 
was significantly weaker than Poly(I:C) and did further require autocrine stimulation of 
TNF-a [51]. Taken together, this demonstrated that miR-155 is specifically upregulated 
during stimulation by typical bacterial and viral pathogens during the acute inflammatory 
response in peripheral monocytes [50 ,51]. 
Analysis of the promoter region of the Bic gene reveals an interesting suite of 
putative activators. Specifically, the Bic gene appears to be regulated by both NF-KB and 
AP-1 [51 ,83]. O'Connel et al., has identified two Activating Protein- I (AP-1) sites 
through promoter sequence analysis [51]. However, Yin et al. only identify a single AP-
I site, which they found had the greatest effect on modulating the expression of miR-155 
[83] . Further, the Nuclear Factor- Kappa B (NF-KB) site is a far distant enhancer, 
>1000 ki\obase pairs (kbp), from transcription start site and had little effect in mutagenic 
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testing [83]. Interestingly , both AP-1 and NF-KB were strongly activated during Ml 
skewing as shown in Chapter 4. 
As with most miRNAs all the targets that miR-155 actually regulates are poorly 
understood and to date only a few bona-fide targets have been elucidated. However, 
many of known targets have unique ramifications on regulation of the acute immune 
response [82] . O'Conell et al. demonstrated that Inositol polyphosphate-5-phosphatase D 
(INPP5D) is one of the first validated targets of miR-155 and specifically through 
interactions with the 3'UTR if INPP5D [84]. Further, when either miR-155 or INPP5D 
were inhibited similar myeloproliferative disorders in the hematopoietic compartment 
were observed [84] . 
Neurogenesis 
It has now been well established that adult neurogenesis, lasting throughout the 
entire life of the host, occurs in both the Sub-Granular Zone (SGZ) of the dentate gyrus 
and the Sub-Ventricular Zone providing a supply of new neurons for the hippocampal 
region and the olfactory regions, respectively [85,86]. The SGZ lies along the border of 
the hilus and the granluar cell layer of the Dentate Gyrus [87]. This report focuses solely 
on neurogenesis in the Dentate Gyrus SGZ of the Hippocampus. Neurogenesis can be 
thought of having three distinct processes: proliferation, differentiation and survival 
[88 ,89]. Proliferation relates to the rate of production of new cells via mitosis of NSC in 
the SGZ [88,89]. Differentiation is the maturation of the newly divided daughter cells 
into either new neurons, about 80-90% under normal conditions , or glial cells about 
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~10% under normal conditions. Lastly, survival is the long-term incorporation of the 
newly differentiated cell into the dentate gyrus, many newly dividing cells undergo 
apoptosi s [88-90]. 
Functionally, the dentate gyrus has been implicated in the encoding of episodic 
memory and more specifically it aids in the temporal separation of events versus the 
details within an event [91 ,92] . Without neurogenesis Aimone, et al. speculates that 
there is a loss of temporal relationships in writing new memories and further a loss of old 
information as new information is interferes with older coded information [91]. This is 
an important aspect to keep in mind since, this suggests dysfunctional neurogenesis will 
phenotypically present it self as impairments in creating new episodic memories. In other 
words, an individual might be able to recall doing events A, Band C, but details of events 
A, B and C would be mixed up between the three events temporally . 
A loss of the ability to form new memories is a hallmark of AD and has been 
extensively characterized in both humans and mouse models of AD [93]. Interestingly, 
in AD, alterations in SGZ neurogenesis is mixed, with reports of it being both enhanced 
in some and impaired in other studies [94,95]. However, a recent study has demonstrated 
impaired neurogenesis is an early feature, detectable as early as 2 months of age , in a 
double transgenic, APPswe/PS1dE9, mouse model of familial AD [96]. 
Neurogenesis and Behavioral Disorders 
There are also strong linkages of reduced neurogenesis observed in the multiple 
behavioral disorders including Depression and Anxiety . Revest et al. demonstrated that 
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reduced neurogenesis, through induction of selective apoptosis in newly differentiated 
neurons, led to increased anxiety-like behavior as measured with elevated plus-maze 
[97] 0 Impaired neurogenesis has even been posited to be an etiological cause of 
Depressiono[88,98] This hypothesis is supported by observations that treatment with 
anti -depressants has been down to increase neurogenesis [99]0 Drugs of addiction are 
also know to suppresses neurogenesis [100]0 Interestingly, there is a supposition by 
many that normal neurogenesis is required for normal mood function termed the 
"neurogenic hypothesis of depression" , which is supported by the finding that chronic 
application of anti-depressants actually increased neurogenesis in the SGZ region 
[99,101]0 Specifically, Fluoxetine treatment demonstrated about a 17% increase in NSC 
proliferation , as measured by an increase in the number of newly labeled BrdU positive 
cells, of which 75% of these were differentiating into new neurons [99] 0 
Queues that alter Neurogenesis 
Many studies have demonstrated one over-riding principal of neurogenesis, 
particularly in the SGZ, it that it ' s a very dynamic process that is highly sensitive to the 
experiences of the individual [1 02] 0 Simply put, experiences that are detrimental to the 
individual inhibit or suppress neurogenesis, where as rewarding experiences increase 
neurogenesis [88,102] 0 Rewarding experiences that have been demonstrated to enhance 
the rate of neurongenesis include: running , learning, enriched environments , and sex 
[102-106]0 Stress , either acute or chronic, from social defeat models, electric shock or 
physical restraint all have demonstrated to impair neurogenesis [88 ,107-110]0 Current 
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research has not yet elucidated a rationale as to why neurogenesis is so sensitive to 
environmental queues. However, some have posited that, during survival situations, e.g. 
fighting off a virus or bacterial infection, energy can be diverted to other 
systems/processes that may be more useful for survival [102]. 
Impact Inflammation has on Neurogenesis 
The neuro-immune system has been shown to play a key role in regulating 
neurogenesis [111-114]. Ekdahl et al., first demonstrated that active neurogenic 
inflammation can alter neurogenesis with an ~65% reduction in production of new 
neurons after 28 days of continuous LPS infusion into the CNS [112]. This finding was 
quickly followed up with Monje et al. demonstrating that merely peripheral LPS 
stimulation resulted in a ~35% decrease in neurogenesis and a corresponding 240% 
increase in the density of activated microglia in the SGZ [113]. More importantly , anti-
inflammatory therapeutics , Indomethacin or Minocycline , both restored neurogenesis 
during LPS stimulation back to pre-LPS exposure levels [112,113]. Using cultured 
neurospheres , Rolls et al. showed that LPS also inhibited neurosphere formation and 
blocking TLR-4, the pattern recognition receptor for LPS, actually increased neurosphere 
formation in vitro [114]. Taken together , there is strong evidence suggesting the process 
of neurogenesis is very responsive to both local and systemic inflammatory states. 
However, the exact mechanisms as to how or even why remains unclear. 
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Neuropoietic Cvtokines 
Neuropoietic cytokines are a class of neurotrophic factors that were initially 
identified through the immune response, but now have been shown to have key roles in 
both CNS development and CNS injury response in adults [115,116]. IL-6 is the 
founding member of the Neuropoietic cytokines whose functions in the CNS range from 
CNS development to injury response [115,117]. In addition to IL-6, the neuropoietin 
family includes the following cytokines: B-cell stimulating factor 3 (BSF3), Ciliary 
Neurotrophic Factor (CNTF), Cardiotrophin-like cytokine (CLC) , Cardiotrophin 1 (CT-
1), Interleukin-11 (IL-11), Interleukin-27 (IL-27), Leukemia inhibitory factor (LIF), and 
Oncostatin M (OSM) [115 ,117]. Two common signature features unify the neuropoietin 
family. First, all neuropoietic cytokines will complex with a common receptor element, 
Glycoprotein-130 (GP130), and form a heterodimer with a specific secondary receptor 
upon ligand binding [115 ,116]. Secondly, all neuropoietic cytokines signal through a 
combination of the Signal Transducer and Activator of Transcription (ST AT3) and the 
Mitogen-activated protein kinase (MAPK) intracellular signaling pathways [115,117-
121]. 
In a very elegant study , Rosell et al . demonstrated basal level mRNA expression 
levels in rats of many neuropoietic cytokines, including IL-6, IL-11, CNTF, and OSM, in 
the hippocampus using in-situ hybridization techniques [122]. More importantly, Rosell 
et al. also demonstrated expression of the corresponding receptors for the neuropoietic 
family in the hippocampus at rest including GP130 (most intense), LIF-R, IL-6R, and IL-
11R [122]. Interestingly, using the status epilepticus model in rats Rosell, et al . track the 
21 
time course of expression and up-regulation and found that only ll-6 , IL-11, and LIF were 
induced in response to the seizure [122]. 
There is a growing body of evidence supporting a role for the neruopoietin family 
of cytokines mediating a switch between neuronal cell fates to astrocytic cells fates. 
Specifically, multiple members of the neuropoientin family, LIF, CT-1 and CNTF, have 
been linked to the developmental switch from neurogenesis to gliogenesis [119,123-126]. 
Further, its been demonstrated that the Glial fibrillary acidic protein (GFAP) gene, a 
canonical marker of astrocytes when active, has a STAT3 recognition sequence at its 
promoter region, suggestion that this feature is common to all neuropoietic cyokines 
[127]. 
Regulation ofll-6 Exvression 
IL-6 expression is regulated by a number of transcription factors at the IL-6 
promoter inc! uding: NF-KB, Interferon Regulatory Factor-1 (IRF-1) , CCAA T /enhancer-
Binding Protein Beta/Delta (C/EBP-~/o), Specificity Protein-1 (SP1), and AP-1 [128-
131]. Four of the six transcription factors: AP-1, NF-KB and both C/EBP-~/o, are not 
active in resting microglia, but are activated upon TLR-4 signaling by LPS stimulation, 
see Figure 2 [128]. Many studies suggest that it's the coordinated effort of all these 
transcription factors combined to induce maximal expression levels ofiL-6 [128-131]. 
C/EBP-~ has been discovered in many different tissues many times over and 
subsequently has many different names ascribed to it including both Nuclear Factor-IL-6 
(NF-IL6) and Liver-enriched transcriptional activator protein (LAP) [132]. The C/EBP-~ 
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gene actually translates three different isoforms, which have been termed LAP1 and 
LAP2 and an inhibitory isoform termed Liver-enriched transcriptional inhibitory protein 
(LIP), which acts as a dominant negative [133]. Interestingly, expression levels of 
C/EBP-~ responsive genes have been tied to the LAP-to-LIP ratio levels, suggesting that 
inhibition of the LIP form can lead to up-regulation ofiL-6 [133,134]. Further, C/EBP-o, 
also called NF-IL6~ (not to be confused with C/EBP-~/NF-IL6), which is also induced 
upon LPS stimulation has been showed to form heterodimers with C/EBP-~ and has been 
shown to have synergistic effect on IL-6 expression as well [132]. 
Signaling Mechanisms for IL-6 at Target Cells 
IL-6 has been shown to signal through two separate signaling pathways to target 
cells. First, the classical pathway where membrane bound Interleukin-6 Receptor (IL-
6R) binds with its ligand IL-6 then complexes with GP130 will activate the STAT3 and 
MAPK pathways [135,136]. Secondly, a trans-signaling mechanism involving the 
shedding of the IL-6R, through proteolytic cleavage by A disintegrin and 
metalloproteinase-17 (ADAM17), from one cell and once solublized the sll-6R can bind 
to its ligand IL-6 and then on the surface of a different cell complex with GP130, which 
then leads to activation of the STAT3 and MAPK pathways in that cell, see Figure 2 
[135 ,136]. Interestingly, the trans signaling pathways is more associated with the 
deleterious affects of inflammation and has specifically been implicated in the 
maintenance of T11 17 phenotype, RA, intestinal inflammation [135,137-143]. The soluble 
form of the IL-6R is generated primarily form ectodomain shedding through cleavage by 
23 
ADAM17 and also by an alternative splicing variant [137,144,145]. ADAM17 is known 
to be a key player in an M1-pro-inflammatory phenotype, since ADAM 17 is also know 
as Tumor Necrosis Factor-a converting enzyme (TACE), the same enzyme that cleaves 
TNF-a during active inflammation.[135,137,146] Taken together, its clear that trans-
signaling maybe the more dominate form if IL-6 signaling during pro-inflammatory 
states. 
The role of!L-6 in the CNS 
IL-6, or interferon beta-2 (IFN-~2), is the founding member of the neuropoietic 
cytokine family and has the ability to penetrate the BBB [147]. Interestingly, a 
MacArthur study has associated high levels of serum IL-6 with an increased risk of 
cognitive deficits in humans [148]. Further, Major Depressive Disorder (MDD) in 
humans has been shown to correlate with high levels IL-6 coupled with low 
Hippocampus volume [149]. Polymorphism in the IL-6 gene has been associated with 
some AD studies, but not all [150]. Sadly, activation of maternal inflammation alters 
fetal brain development through the action of IL-6 leading to abnormalities in behaviors 
and transcriptional alterations that are similar to schizophrenia and autism in fetal pups 
[151]. The abnormalities triggered by the maternal inflammation can be ameliorated by 
treatment with anti-IL-6 monoclonal antibody (mAb) or prevented in IL-6 knockout (KO) 
mice [151]. 
There is strong evidence that IL-6 directly can alter the neurogenic niches within 
the brain. Vallieres, et al. demonstrated a 63% reduction in neurogenesis in the 
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hippocampus dentate gyrus in a transgenic mouse model over expressing IL-6 when 
compared to aged-match WT controls [126] . Interestingly , this value corresponds nicely 
with the level of reduction observed by Ekdal, et al. utilizing a chronic inflammatory 
stimuli challenge, i.e. LPS [112]. Bonni et al., demonstrated that IL-6 combined with 
siL-6 receptor increased the astrocytic differentiation in primary cortical cells from E17 
rat embryos [125]. Nakanishi et al. demonstrated that as little as two hours of exposure to 
microglial cultures NSC media conditioned from primary microglia cultures could 
increase the percentage of astrocytes and reduce the percentage of neurons , which could 
be ablated if the condition media were treated with a neutralizing IL-6 mAb or a STA T3 
inhibitor [119]. Further, the astrocytic skewing of differentiation could be achieved with 
the exogenous application of recombinant IL-6 [119] . 
Specific Rationale, Objectives, and Hypothesis 
Neurogeneic processes in the SGZ of the hippocampus display a remarkable 
degree of sensitivity to many different factors including inflammatory challenges to 
either the CNS directly or peripherally [88,112,113]. One consequence of inflammation 
is cytokine release, acting as chemical messengers locally or systemically, as mediators 
of the inflammatory response. Neuropoietic cytokines, e.g. IL-6, are a class of cytokines 
released during inflammation that poses key functional roles for the immune system as 
well as function as neurotrophic factors, including possessing the ability to alter the 
neurogenic niches within the CNS [115 ,116]. This research has identified IL-6 is the 
most up-regulated pro-inflammatory mediator in primary microglia during an 
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inflammatory challenge from LPS, see chapter 3. miRNA based gene-regulation has 
been implicated in many physiological processes including general developmental 
processes, cell-cycle regulation, immune cell maturation, and recently the acute 
inflammatory response [48 ,49]. This research has identified miR-155 as the most up-
regulated miRNA in primary microglia during an inflammatory challenge from LPS, see 
chapter 3, which has since been identified in two other labs [55,59]. 
This research also demonstrates that miR-155levels corresponded with IL-6 
levels, such that when miR-155 was up-regulated, e.g. upon LPS stimulation, IL-6levels 
rose , see chapter 5. Conversely , when miR-155 was knocked out or knocked down, IL-6 
levels subsequently were reduced when compared to untreated or wildtype microglia 
during the same LPS stimulation, see chapter 5. Since this is opposite of the canonical 
regulation of an mRNA by miRNA and no apparent miR-155 binding site(s) has been 
identified in the 3' -UTR of the IL-6 mRNA transcript, suggesting that miR-155 does not 
directly target IL-6 itself [39,43,45,47]. 
However, this type of behavior strongly suggests that miR-155 dis-inhibits IL-6 
expression through the targeting of a transcriptional repressor of IL-6 expression. 
Recently, Yin et al. has demonstrated that miR-155 targets the transcription factor 
C/EBP-~, a key driver in the expression of IL-6, see Figure 2 , which is known to have 
two activating forms , LAP1/LAP2, and a dominant negative inhibitory form, LIP, see 
above [134,152]. Expression levels of C/EBP-~ responsive genes , e.g. IL-6, have been 
tied to the LAP-to-LIP ratio levels [133,134]. Interestingly, multiple miRNAs encoded 
by Kaposi's sarcoma-associated herpesvirus (KSHV) have been shown to preferentiaJly 
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reduce expression of C/EBP-~ p20, the dominant negative LIP form only , thereby 
enhancing the LAP-to-LIP ratio levels and thereby actually enhancing expression of 
C/EBP-~ responsive genes , e.g. IL-6 [153]. Further, Skalsky eta/. has shown KSHV 
encodes multiple miRNAs, which miR-K12-11 has been demonstrated to be a viral 
ortholog to miR-155 with full homology to the critical seed region of miR-155 and close 
to 60% homology between the full form of miR-155 [154]. Taken together, this suggests 
that miR-155 has the ability interact with the C/EBP-~ mRNA transcript and 
preferentially inhibit the LIP form, thereby altering the LAP-to-LIP ratio and enhancing 
IL-6 expression. 
The overarching hypothesis of this research is that miR-155 suppresses neurogenesis 
during inflammation. The hypothesized mediator of this indirect regulation is the 
neuropoietic cytokine IL-6 (Chapter 4) , presumable though miR-.155 ' s direct interaction 
with C/EBP-b as described above. As primary microglia are skewed to the M1-
proinflammatory state, miR-155 is up-regulated putatively targeting the LIP form of 
C/EBP-~ thereby increasing the active LAP form and increasing expression and secretion 
of IL-6. IL-6 in the extracellular compartment then complexes with the siL-6R, also shed 
during the pro-inflammatory response, and dimerizes with GP130 on NSCs. Upon 
binding to GP130 on NSCs the STAT3 signaling pathway is activated, which has been 
shown to alter neurogenesis away from neuronal differentiation to that of astrocytic 
differentiation (Chapter 5). Interestingly, miR-155 may also regulate IL-6 signaling 
within the NSC though dis-inhibition of its intracellular signaling pathways. At potential 
recipient cells for IL-6 signaling, NSCs or even microglia, rniR-155 is also known to 
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target the SOCS 1, leading to higher levels of activation of the STAT3 signaling pathway 
[55]. Thus fmtherfacilitating alterations in nem·ogenesis away from neuronal 
differentiation to that of astrocytic differentiation. Taken together, there are two potential 
mechanisms whereby miR-155 can suppress neurogenesis during an inflammatory 
response. An overall schema is depicted in Figure 2. 
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Figure 1 Conceptual state-transition diagram of the inflammatory response in miroglia 
A conceptualized state-transition diagram of the innate immune response that has a 
working goal to maintain tissue homeostasis of the local microenvironment. However, 
upon a disruption of the tissue homeostasis , e.g. due to detection of a viral, bacterial or 
cytokine, the MO states transitions into a pro-inflammatory response, termed "M 1", that 
releases a number of cytokines/chemokines to recruit neutrophils (PMNs) and later 
monocytes/macrophages as these cells arrive at the foci of inflammation, the release ROS 
and RNS species to attack the pathogen at hand and with higher phagocytic capacity seen 
focused on antibody pathogen clearance, termed "M2B" characterized by high levels of 
IL-10 combined with a release of canonical pro-inflammatory mediators. As the 
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pathogen is cleared other mediators, e.g . resolvins/lipoxins or IL-4/IL-13, trigger a state 
change in to that of more of an anti-inflammatory mode, termed "M2a", that reduces the 
influx of immune cells (moncytes and PMNs) to the region and resident immune cells 
activate with a higher phagocytic capacity shifted towards scavenging of debris and 
removal of apoptotic bodies. As the affected region is cleared other mediators (TGF-~, I-
1 0) signal state transition into a tissue remodeling/wound healing state, "termed M2c", to 
reconstruct the tissue matrix or lay scar tissue. Lastly, once the region has been 
remodeled the resident immune cells return to a resting quiescent state, termed "MO", and 
homeostasis is restored. 
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Figure 2 Proposed mechanism ofmiR-155's indirect regulation ofNeurogenesis during 
acute inflammation 
During an acute inflammatory response , such as one triggered from LPS binding to TLR4 
on microglia , miR-155 is up-regulated along with IL-6 and many other cytokines through 
the actions of NF-KB and AP-1. miR-155 facilitates strong up-regulation in IL-6 through 
dis-inhibition potentially by the selective targeting of a dominate negative form of CEBP-
B (LIP) thereby enhancing the active form of CEBP-B (LAP). In addition, microglial 
sheds portions of its IL-6 receptor, this creating siL-6. The dimmer of IL-6 and siL-6R 
then complexes with GP130 on the NSC, which activates the STAT3 pathway triggering 
a differentiation switch from neurogenesis to astrogliogenesis in the NSC. ··• 
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Chapter 2: GENERAL METHODS 
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Animals 
Timed-pregnant female CD-1 mice were purchased from Charles River 
(Wilmington, MA) for primary microglial cultures. B6.Cg-MirlSStmllRsk/J, herein 
referred too either as miR-lSs-1- or miR-ISSKO mice, and control CS7BL/6J mice were 
purchased from Jackson Laboratory (Bar Harbor, ME) and bread in house for either 
intracranial surgeries or primary microglial cultures. All procedures were performed in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals and approved by the Boston University's School of Medicine 
IACUC. 
Primarv Microglia Isolation & Culture 
Primary Microglia were isolated from PO or Pl pups from CD-1, miR -Iss-!-, or 
CS7BL/6J mice and cultured as previously published [1SS]. Briefly, Each pup was 
euthanized and the brain isolated from the surrounding tissue was placed in Hank's 
Balanced Salt Solution (HBSS) (Life Technologies Corporation/Invitrogen, Carlsbad, 
CA). Meninges were removed by rolling the excised brain on 201-grade filter paper 
(Reeve Angel, S201-090, Kempenhout, Belgium). The remaining CNS tissue for the 
entire litter was pooled together and then minced for lS minutes sterile razor blades. The 
minced tissues was subjected to two serial trypsin digestions and tituration using 0.2S% 
trypsin (Invitrogen, 2S200) and O.S% deoxyribonuclease I from bovine pancreas (Sigma-
Alderich, DN2S, St. Louis, MO) and incubated for 9 minutes at 37 deg C. Fetal Bovine 
Serum (FBS) (Life Technologies Corporation, 10082147, Carlsbad, CA) was then added 
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to quench the trypsin reaction and the cellular suspension was filtered through a 70 mm 
nylon cell strainer (BD-falcon, 352350, San Jose, CA). The filtered suspension was then 
centrifuged at 500x g's for 6 minutes, re-suspended in 10 milliliters (ml) of HBSS. The 
HBSS cellular suspension was centrifuged at 500x g for 6 minutes, and re-suspended in 
four ml of 37% isotonic Percoll™ (GE Healthcare, 17-0891-01, Fai1field, CT) solution. 
To complete the Percoll™ gradient, four ml of a 70% isotonic Percoll™ solution was 
layered underneath the 37% layer with the cellular suspension. Then an additional four 
ml of 30% layer of isotonic Percoll™ solution was added above the original 37% layer. 
Lastly, a two mllayer of HBSS was added above the 30% layer of isotonic Percoll™, for 
a total of four separate and distinct layers. The cellular suspension in the Percoll™ 
gradient was then centrifuged at 200x g's for 40 minutes without braking. Microglia 
primarily aggregated between the 70%- 37% layers was extracted, mixed with HBSS in 
a 2:1 ratio (HBSS:isolated Percoll™), then centrifuged for an additional 7 minutes at 
500x g. The cell pellet was washed twice in total with HBSS in the same procedure. Cells 
were plated at a concentration of 2 x 106 cells/well of 6 well plates in Dulbecco's 
modified essential media high glucose, 10% fetal bovine serum, 100 U/ml penicillin and 
10 mg/ml streptomycin (all from Life Technologies Corporation/Invitrogen). The isolated 
primary microglia is incubated for 1 hour at 37 oc in 5% C02, and the tissue culture 
media was replaced with fresh media to remove non-adherent cells, potentially non-
microglial cells. The adherent cells on the original plate are the enriched primary 
microglia. Non-adherent cells were kept and considered a mixed glial culture. The 
isolated Primary Microglia are then stimulated with 10 ng/ml recombinant murine 
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granulocyte macrophage-colony stimulating factor (GM-CSF) (Abazyme, CTK-222, 
Cambridge, MA) and 10 ng/ml murine M-CSF (Abazyme, CTK-308) and incubated for 
5-7 days prior to stimulation. We have observed a >85% enrichment of microglia (Figure 
3) with minimal neuronal or astrocytic contamination in our cultures using this approach. 
Stimulation ofPrimary Microglia and RNA Isolation 
After 5-7 days, the primary cultured microglia were placed in serum free media 
overnight and then stimulated with purified 055:B5 E. coli LPS (Sigma, L2880) at 100 
ng/ml , recombinant murine IL-4 (Abazyme, CTK282) at 20 ng/ml, or equal volume of 
Phosphate buffered solution (PBS) for 4 hours at 37°C with 5% C02 • 
To extract combined mRNA and miRNA, the cells are washed once with PBS and 
then lysed using QIAzol® Lysis Reagent (Qiagen, 79306, Germantown, MD) and then 
isolated using the miRNeasy® Mini Kit (Qiagen, 217004) and the QIAcube® (Qiagen, 
9001292) automated RNA purification instrument. The isolated RNA is checked for 
quality by RNA agarose gel electrophoresis, having a minimum 260/280 ratio of 1.80 or 
greater, and then quantified using NanoDrop 1000 (Thermo Scientific, Waltham, MA) . 
mRNA Gene Expression and miRNA Exvression Profiling Microarrays 
For total mRNA gene expression profiling, we utilized the Affymetrix GeneChip 
Mouse Exon 1.0 ST Array (Affymetrix, 900818 , Santa Clara, CA) which targets more 
than 28,000 annotated genes with over 835,897 distinct probes , approximately 40 probes 
per gene. For total miRNA expression profiling, we utilized the Affymetrix Mouse 
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GeneChip miRNA 2.0 Array (Affymetrix, 901754) that interrogates 690 murine pre-
miRNAs and 722 murine mature miRNAs and providing complete coverage of miRBase 
v15, including both mature and hairpin stem loops. Both mRNA and miRNA expression 
profiling was pe1formed through the Boston University School of Medicine' s Microarray 
Core facility. 
Microarray Data Analysis 
To identify canonical pathways and functions previously ascribed to the 
significantly differentially expressed mRNAs and miRNAs were uploaded and analyzed 
using Ingenuity® Pathway Analysis (IPA) tool, a commercially available web-delivered 
bioinformatics tool, December 18, 2011 release (Ingenuity Systems, Redwood City, CA, 
USA- http://www .ingenuity .com) [156,157]. Ingenuity functional analysis, canonical 
pathway analysis, and transcriptional factor analysis were identified by pe1forming 
Ingenuity® Pathway Analysis (IPA) core analysis of log2 fold change for LPS or IL-4 
stimulated versus un-stimulated primary microglia microarray data sets. The Functional 
Analysis of the observed LPS or IL-4 data sets identified the biological functions that 
were most significant to the data set. Molecules from the dataset that were associated 
biological functions in the Ingenuity Knowledge Base were considered for the analysis. 
Right-tailed Fisher's exact test was used to calculate a p-value determining the 
probability that each biological function assigned to the data set is due to chance alone. 
Further, A regulation Z-score is calculated according to the fit of our significantly 
differentially regulated genes, where a Z-score > 2 or a Z-score <2 indicates a 99% 
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confidence of not being generated by random chance alone for up-regulated functions or 
down regulated functions respectively. Canonical pathway analysis identified the 
pathways from the IPA library of canonical pathways that were most significant enriched 
in either LPS or IL-4 stimulated primary microglia. Molecules from either data set that 
were associated with a canonical pathway in the Ingenuity Knowledge Base were 
considered for the analysis. The significance of the association between the data set and 
the pathway was measured in 2 ways: 1) a ratio of the number of molecules from the data 
set that map to the pathway divided by the total number of molecules that map to the 
canonical pathways is displayed. 2) Fisher's exact test was used to calculate a p-value 
determining the probability that the association between the genes in the observed values 
and the canonical pathway is explained by chance alone. Transcriptional factor analysis 
identifies activated or inhibited transcription factors based on the enrichment and 
direction of change of known target genes in the Ingenuity Knowledge Base and their 
association to transcription factors that were most significant enriched in either LPS or 
IL-4 stimulated primary microglia. The regulation Z-score is used to identify 
transcriptional regulators and infer their activation state. The significance of the 
association between the data set and the transcription factors was measured Fisher's exact 
test was used to calculate an overlap p-value determining the probability that the 
association between the genes in the observed values and the genes known to be 
regulated by a specific transcription factor is explained by chance alone. 
All differentially regulated miRNA with a power of (P<0.05) were uploaded for 
both the LPS or IL-4 treated group, identified by standard miRBase number [158] 
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(release 16) along with fold change relative to control PBS treated group and power were 
also uploaded for Functional analysis, transcriptional factor analysis, canonical pathway 
analysis pathway and network analysis as previously described. 
miRNA Correlation Analysis 
To identify potential miRNA-mRNA interactions we combined publically 
available miRNA prediction target databases, including miRanda database 
(http: //www .microrna.org) and Ingenuity Systems which combines TargetS can 
(http: //www .targetscan.org) and Tar Base (http: //diana.cslab.ece.ntua.gr/tarbase/) [ 159-
161]. Key differentially regulated miRNAs were correlated with observed gene 
expression differences and then compared with predicted targets of the miRNA using 
publically available Gene List Venn Diagram software [162] 
(http: I I simbioinf .com/me be/ applications/ genevenn/ genevenn .htm). 
Real-Time Reverse Transcription PCR 
To validate gene expression alterations in both the mRNA gene expression and 
miRNA expression microarrays, as well as general gene expression alterations in primary 
microglial cultures stimulated in various conditions RT-PCR was petformed. mRNA 
RT-PCR was performed using QuantiTect Reverse transcription kit (Qiagen, 205311) for 
eDNA synthesis and QuantiFast SYBR Green RT-PCR Kit (Qiagen , 204154) and custom 
designed primers (Invitrogen). Table 1 provides a list of the specific mRNA primer 
sequences used for all experiments . miRNA RT -PCR was performed using miRCURY 
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Lock Nucleic Acid (LNA)™ Universal eDNA Synthesis Kit (Exiqon, 203300, Vedbaek, 
Denmark) and miRCURY LNA™ SYBR Green master mix RT-PCR Kit (Exiqon, 
203450) and specific Exiqon primers to mmu-miR-155, mmu-miR-124 and mmu-miR-
146a (Exiqon #205080, #204319, and #204688 respectively). All RT-PCR reactions 
were conducted using the Mastercycler® ep realplex, and real-time thermal cycler 
(Eppendorf) . 
Table 1 Primer List used in mRNA RT-PCR 
Gene Direction Primer 
IL-6 Forward 5 '-CCAGTTCCTTCTTGGGACTG-3' 
Reverse 5' -CAGGTCTGTTGGGAGTGGTATCC-3' 
IL-l~ Forward 5'-CTGGGATCCTCTCCAGCCAAGCT-3' Reverse 5'-GGAAGCAGCCCTTCATCTTTTGGGG-3' 
TNF-a Forward 5' -GCCCAGACCCTCACACTCAGATCA-3' Reverse 5' -CCCATCGGCTGGCACCACTAGT -3 ' 
NOS2 Forward 5' -CCCTTCCGAAGTTTCTGGCAGCAGCG-3' Reverse 5' -GGCTGTCAGAGCCTCGTGGCTTTGG-3' 
IL-10 Forward 5' -GGCTGAGGCGCTGTCA TCGATTT -3 ' 
Reverse 5' -GGCCTTGTAGACACCTTGGTCTTGG-3 ' 
PAI-l Forward 5' -GGGACACCCTCAGCATGTTC-3' Reverse 5'-TGTTGGTGAGGGCGGAGA-3' 
CHI3L3 Forward 5'-CCAGCAGAAGCTCTCCAGAAGCAAT-3' Reverse 5' -GGAAGATCCCAGCTGTCGTTCAGA-3' 
Argl Forward 5'-IT AGGGTT ACGGCCGGTGGAGAG-3' Reverse 5 '-CCCCTCCTCGAGGCTGTCCTTTTG-3' 
INPPSD Forward 5'-TGAGGCTGAGGAGGACACTGTAGA-3' Reverse 5'-GGGGCTCGGGGGTTCTCTGT-3' 
GAPDH Forward 5' -ACGGCCGCATCTTTCTTGTGCA-3' 
Reverse 5' -CCAGGCGCCCAA TACGGCC-3' 
miR -155 Inhibition "Knockdown" Assays 
To perform functional assessment of miR-155 we employed to methodologies of 
miRNA inhibition. First we employed LNA-based anti-miR-155 and later we were 
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generously given a gift of AA V9-TuD-155 from Dr. Guangping Gao, Ph.D. from the 
University of Massachusetts Medical School. To assess miR-155 's functional affect on 
primary microglia during active inflammation we employed both LNA-based anti-miR 
transfection and AA V9-Tud-155 transduction as described below. 
LNA-based Anti-miR-155 Transfection 
To inhibit mir-155 we purchased mmu-miR-155 miRCURY LNA™ microRNA 
inhibitor with 5' -fluorescein label (Exiqon, 411222-04) or "scramble" negative anti-sense 
control with 5' -fluorescein label (Exiqon, 199004-04). The miR-155 inhibitor is a 20 nt 
oligonucleotide that binds complementary and with high affinity to the active form of 
miR-155. Primary microglia were isolated from CD-1 mice PO or P1 pups as described 
above and cultured for 5 to 7 days. In one tube miR-155 inhibitor (100 pmol) or 
Scramble anti-miR (100 pmol) was mixed with OptiMem I (Gibco, 31985-062) and in a 
second tube Lipofectamoe® 2000 (5 ul) (Invitrogen 11668-027) was also mixed with 
OptiMem I allowed to incubate for 5 minutes at room temperature. Volumes of 
Lipofectamoe® 2000 and amount of miR-155 inhibitor/scramble depended on well size 
and cell density. After 5 minutes, transfection media was created by combining the 
OptiMem 1-Lipofectamine 2000 mixture with the OptiMem 1-anti-miR mixture, briefly 
vortexting and then allowed to incubate for 30 minutes at room temperature. Media was 
removed from wells to be transfected and cells were washed 3 times with PBS. 
Tranfection media was then added to the appropriate wells and allowed to incubate for 4-
6 hours at 37 degrees C and 5% C02. After that time, the transfection media was 
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removed and cells were washed again three times in PBS and normal microglia media 
was replaced and cells were allowed to recover for 24 to 48 hours prior to stimulation. 
The night before stimulation occurred microglia media was removed and washed 3x and 
replaced with serum free media. Cells were stimulated for 4 hours with 1 OOng/ml of 
LPS or equivalent volume of PBS. Total RNA was isolated and RT-PCR was pe1formed 
as described above to assess both the impact and effectiveness of the miR-155 
knockdown. 
Tud-miR-155 AA V9 Transduction 
A second method used to inhibit the functionality of miRNAs is a relatively 
newer technology called "Tough-decoy" or "Tud". Tuds are expression vectors that are 
driven by a constitutive U6 mouse promoter that make a hairpin loop and stem that are 
embedded with miRNA binding sites [163]. In this case, with two miR-155 binding sites 
fully complementary that are actively being expressed at relatively high expression levels 
provides a rich environment of "decoy" targets that easily outcompete endogens miR-155 
binding sites in the 3' UTRs of target mRNAs [163,164] . With the AA V9 viral vector 
MOis of a minimum of 10,000 and ideally of 100,000 were used for each experiment, i.e. 
the number of viral particles to the number of cells targeting undergoing transduction 
[165,166]. Cells were infected with either the tough-decoy for mir-155, termed "Tud-
155", or a scramble control Tough decoy, termed "Tud-Scram", AA V9 viral vector in 
normal tissue culture media for 24-48 hours prior to and stimulation or co-culture. Prior 
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to stimulation or co-culture cells would be washed three times with PBS and then new 
media provided appropriate to the experimental conditions required. 
Peripheral Induction oflnflammation 
To induce peripheral inflammation we injected purified 055:B5 Escherichia coli 
LPS (Sigma, L2880) (1 mg/kg) IP or equivalent volume of Saline IP into 4 week-old WT 
C57BL/6J mice [113]. 
Intracerebroventricular ICV Microinjections 
To assess the effect of miR-155 knockout has on neurogenesis we used 3 to 4 
week old miR-155_,_ and C57BL/6J (WT) mice and performed ICV surgery to microinject 
either 1 ~-tl of purified 055:B5 Escherichia coli LPS (Sigma, L2880) (1~-tgl~-tl) or 1 ~-tl of 
Saline. A total of 28 mice were divided into four groups as follows: 
1. mir-155_,_ Saline n=7 (4 females/3 males) 
2. miR-155_,_ LPS n=7 (4 females/3 males) 
3. WT Saline n=8 (4 females/4 males) 
4. WTLPS n=6 (3 females/3 males) 
Briefly, the animals were allowed to adapt to the new facility,~ 1 hr, before the 
procedure started and weighed. All animals were anesthetized with Isoflurane (11695-
6776-2, Butler Schein Animal Health, Dublin, OH) and then placed/attached to a small 
animal Stereotaxic instrument (Model 900, KopfiY, Tujunga, CA). Both Saline (0.024 
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mil g) (APP Pharmecuticals, Schaumberg, IL) and Rimadyl (Carprofen) (4.5 mg/kg) 
(Pfizer New York, New York) analgesic were given subcutaneously prior to the start of 
the surgery. Microinjection of LPS or Saline was targeted to the Left or right lateral 
ventricle with the following coordinates relative to Bregma: AP = +0.1 mm, ML = +1-
0.85 mm and DV of -2.5 mm. One microliter (1 f!l) microinjection was performed using 
a programmable Stereotaxic injector and a 10f!l Hamilton syringe (Reno, NV) with a 23-
Gauge needle into the lateral ventricle at a rate of 0.5 f!l/minute . After the injection was 
completed a period of 5 minutes was provided to allow for fluid dissemination prior to 
withdrawal of the needle from the injection site. After this period the wound would be 
closed with two 4-0-nylon sutures and the animal was allowed to recover back in its 
home cage. One-day post surgery the animal was giving additional injection of analgesic 
Rimadyl (Carprofen) ( 4.5 mg/kg) given subcutaneously. 
BrdU Injections 
To label newly dividing cells within the SGZ a series of 5 injections of 
Bromodeoxyuridine (BrdU) (50 mg/kg) (Sigma-Aldrich, StLouis MO, 858811-SG) were 
performed on days+ 1' +2 and +3 relative from the day of rev microinjection surgery or 
Peripheral induction of inflammation, t=O. Two (2) BrdU injections per day were 
administered IP, with a minimum of 12 hours between each injection and one injection 
on day 3. On day four ( +4) the animals were allowed to rest and animals were 
monitored for any signs of distress or morbidity . 
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Perfusion and Tissue Processing 
On Day +5 , the animals were euthanized and the brain extracted for 
Immunohistochemistry (IHC). Briefly, animals were deeply anesthetized with Isoflurane 
(11695-6776-2, Butler Schein Animal Health) and the thoracic cavity was opened up to 
expose the heart. A 21G butterfly needle was inserted into the left ventricle with tubes 
connecting to a 60 ml syringe filled with PBS. The right atrial chamber was lacerated 
and 30 ml of PBS were slowly injected into the left ventricle and throughout the body to 
exsanguinate the mouse. Then the syringe was changed to a second 60 ml syringe filled 
4% paraformaldehyde and 30 ml was slowly injected into the left ventricle and 
throughout the body to fix the tissue. The brain was then excised and placed in 5 ml of 
ice cold 4% paraformaldehyde. Once the brain sunk to the bottom of the tube , about 1 
day later, the brain was transferred to a 15% sucrose solution. Once the brain sunk to the 
bottom of the 15% sucrose solution, again about 1 day, the brain was transferred to a 30% 
sucrose solution. Once the brain sunk to the bottom of the 30% sucrose solution the brain 
was then fixed in OTC and mounted on a cryostat for slicing 30 1--lm think brain slices in 
the coronal plane. Brain slices were stored as free-floating slices in PBS at 4 degree C 
for future IHC. 
lmmuohistochemistv 
IHC was performed on both free-floating tissue sections or fixed cell culture wells 
with cover slips. Briefly , cells were washed 3x in PBS and permeablized with a 30 min 
incubation in 0.1 % Triton-X PBS (PBS-T) at room temperature on a shaker. Cells were 
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then blocked with a one-hour incubation at room temperature on a shaker in 2% Goat() 
or Donkey Serum() and PBS-T. The cells were then incubated overnight at 4 deg Con a 
shaker in the primary antibody staining mixture, 2% Goat or Donkey Serum and PBS-T 
combined with the appropriate antibody. The following primary antibodies where used 
in this study: Mouse anti-BrdU (University of Illinois, Urbana, IL, G3G4, 1: 100) , Rat 
anti-BrdU (Abeam, Cambridge, MA ab6326, 1:250), goat anti-Doublecortin (DCX) 
(Santa Cruz, Dallas, TX, sc-8066, 1:500), rabbit anti-Ionized calcium-binding adapter 
molecule-1 (IBA1) (Wako, Richmond, VA, 19741, 1:500), Rabbit polyclonal anti-GFAP 
(Dako, Carpinteria, CA, Z0334, 1:500), and mouse anti-~III Tubulin mAb (Promega, 
Madison, WI, G712A, 1:500). The next day, the cells were washed 3x in PBS-T for 10 
minutes at room temperature on a shaker and then incubated for 60 minutes at room 
temperature on a shaker in the appropriate secondary antibody stain. Cells were then 
washed 3x in PBS-T and the stained for 5 min at room temp on a shaker with 1:5000 
Hoechst 33342 (Ana Spec Inc. Fremont, CA 83218) in PBS-T. Cells where then washed 
3x with PBS for 5 minutes at room temperature on a shaker. All tissue sections were then 
mounted on glass slides with Vectashield (Vector Laboratory, Burlingame, CA, H-1000) 
and coverslip placed on top and sealed with clear nail polish. Stained Tissue culture 
coverslips are mounted on slides with Vectashield and sealed with nail polish. All slides 
were then imaged and quantified as described below. 
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BrdU Staining 
IHC was performed on both free-floating tissue sections to label newly divided 
cells that have incorporated BrdU. All steps describe were performed at room 
temperature and on a shaker unless noted otherwise. Briefly , cells were washed 3x in 
PBS for 5. For antigen retrieval tissue sections were incubated for 2 hrs in 50% 
formamide and a 50% 2x sodium citrate buffer at 65 degrees C. After which the tissue 
sections were rinsed in 2x sodium citrate buffer for 10 minutes and then incubated with 
30 minutes in 2M HCl at 37 degrees C. Tissue sections were then rinsed in a 0.1M borate 
buffer solution for 10 minutes and then wasted 3x in PBS . Tissue sections were then 
permeablized with 30 min incubation in 0.1% PBS-Tat room temperature on a shaker 
and the remainder of the staining is as described above. 
Image Capture, Analysis, and Quantification 
All images were captured using an Eclipse TE 2000-S microscope (Nikon, 
Instruments Inc. , Melville, NY) coupled with the X-cite™-120 Fluorescence Illumination 
System (Lumen Dynamics Group Inc., Mississauga, Canada) and the NIS-Elements 
Microscope Imaging SW (Nikon, Instruments Inc, BR ver. 3.22.11). All images were 
analyzed using image analysis software (ImageJ 1.45s, NIH, Bethesda, MD). 
For microglial density counts all images where partitioned into 200f!m x 200f!m 
grids and each cell body was counted grid by grid. Counts of only grids where the 
complete grid covered the target neuroanatomical area were made. Average number of 
46 
microglia per grid for both the hippocampal and cortical regions were made and then 
normalized into the number of microglia per mm2 • 
For all BrdU counts in the Dentate Gyrus, both SGZ length (in mm) and Granular 
Zone (GZ) area (in mm2) were taken along with the number of BrdU positive cells along 
the SGZ, in the GZ and in the Mossy Fiber separately. The number of BrdU positive 
cells along the SGZ was normalized to the per mm length of the SGZ and the number of 
BrdU positive cells in the GZ was normalized to the per mm2 area of the GZ. 
For DCX intensity was obtained using ImageJ 'measure' tool that measure 
average intensity of all pixels in a give area. For each image analyzed a small rectangle 
was created using the "area" tool, approximately the width of the SGZ for each image, 
and a minimum of 10 sample points along the SGZ was taken to calculate the average 
measured DCX intensity. An additional 10 sample points were randomly chosen with the 
same rectangle, though not along the SGZ, to capture the average image background 
intensity. The difference between the Average measured DCX intensity minus the 
average background intensity was determined to be the average DCX intensity for that 
Image. 
Primary NeuroStem Cell Cultures 
Primary NeuroStem Cells (NSC) Cultures were isolated from gestational day 
E13.5 to E14 CD-1 mouse fetuses. Briefly, the entire fetal brain was removed and the 
cortex is separated from the brain and placed on cold PBS with 2% glucose kept on ice. 
Carefully, the meninges are removed from the cortex and the cortex is separated from the 
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remainder of the brain. Once all dissections are completed all the tissue is collect in a 15 
ml falcon tube. Allowing time for the tissue to settle at the bottom of the tube, the 
supernatant is removed. The pooled brain tissue is re-suspended in 1 ml of proliferation 
media. The tissue is then triturated about five times with a 1 ml pipette set to 0 .9 ml to 
make a single cell suspension. Remove supernatant if any tissue chunks persist. Add an 
additional 9 ml of proliferation media, total volume is 10 ml , to the single cells 
suspension. Centrifuge for 5 min at 150 x g ' s. Aspirate the supernatant and re-suspend 
cells in 1 ml of proliferation media with a brief trituration and then add an additional 3 ml 
of proliferation media. Filter the cell suspension through a 40 !-liD filter and than count 
cells. PO neruosphere cultures were started by seeding 1.5xl06 in 50 ml of proliferation 
media in a T150 flask and incubated at 37 degrees C in 5% C02 • Neuosphere cultures 
were passaged once the neurospheres attained a diameter of about 100 !-liD, about every 2-
3 days and were suitable for use though about P7 . 
NSC/Primary Microglial Co-Culture Assay 
To determine the impact that microglia has on neurogenesis in vitro a co-culture 
assay was developed using 24-well Transwell® plates with 0.4 mm pores (3412, Corning 
Life Sciences , Lowell , MA). This assay combines primary NSCs , isolated as described 
above, in the lower compartment of the Transwell® and primary microglia, isolated as 
described above, in the upper compartment of the Transwell® . All primary NSCs are 
plated on coverslips that are poly-D lysine coated over night and incubated at room 
temperature under UV light over night and laminin coated for a minimum of 3 hrs 
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incubated at 37 degrees C. Primary NSCs from PI to P7 were dissociated thought five-
minute Accutase (StemCell Technologies, Vancouver , BC Canada, 07920) incubation at 
37 degress C and 2x volume of differentiation media added to quench the accutase 
reaction. Cells were centrifuged at for 5 min at 150 x g's and supernatant was then 
aspirated off, and re-suspend cells in 1 ml of differentiation or proliferation media as 
needed by the assay . The Cells were then counted and plated to between 50,000 and 
100,000 cells per well in 700 ~--tl of differentiation or proliferation media. 
Primary microglia were trypsinized and re-suspended using appropriate media , 
counted and then stimulated prior being added to the transwell®. Stimulation conditions 
were 4 hours, performed in snap tubes and included the following groups (n=4 for each 
group): 
1. WT primary Microglia with PBS 
2. WT primary Microglia with LPS (1 00 ng/ml) , 
3. WT primary Microglia with IL-6 neutralizing Antibody (200 ng/ml) and PBS 
4. WT primary Microglia with IL-6 neutralizing Antibody (200 ng/ml) and LPS 
(100 ng/ml) 
5. WT primary Microglia with Isotype control Antibody (200 ng/ml) and PBS 
6. WT primary Microglia with Isotype control Antibody (200 ng/ml) and LPS 
(100 ng/ml) 
Stimulated primary microglia were than seeded to a 3:10 ratio of microglia to neuron 
ratio respectively, e.g. 50,000 neurons would require 15,000 microglia, to the upper 
compartment of the Transwell®. 
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Differentiation Assessment using the NSC/Primary Microglial Co-Culture Assay 
To determine the impact that microglia has on cell fate determination in vitro the 
NSC/Primary Microglial Co-Culture Assay was employed with differentiation media for 
a period of 5 days. Differentiation media is a combination of DMEM/F12 (Invitrogen, 
11330) , Penn/Strep, and B27 supplement. At the end of the fifth day the media was 
removed and cells were fixed with 4% paraformaldehyde, washed 3x. Cells were then 
stained by IHC for GFAP, marking astrocytes, (3-111 Tubulin, marking neurons, and 
Hoest33342, as described above to identify all viable cells. Coverslips were mounted on 
slides and a minimum of 10 images were taken and assessed for each group. Counts of 
astrocytes and neurons were made relative to the percentage of viable cells. 
Statistical Analysis 
All data was normally distributed and presented as mean values +1- Data was 
analyzed as mean +1- SEM. In the case of single mean comparisons, the data was 
analyzed by Students t-test. In the case of multiple mean comparisons , data was analyzed 
by one-way analysis of variance and Tukey 's post hoc or to-way repeated measures 
analysis of variance. (Prism 4.0c, GraphPad Software, San Diego, CA, USA). p-values < 
0.05 were regarded as a significant difference. Statistical analysis on microarray data 
was performed with the aid of Boston University School of Medicine 's Microarray Core 
facility performing Students t-tests on miRNA and gene expression arrays , as well as 
Pearson's correlation coefficient between select miRNAs and gene expression. 
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Figure 3 Demonstration of Microglial Purity from Percoll® Isolation 
Candidate image demonstrating >85% enrichment for microglia form the 
Percoll® isolation protocol coupled with 5-7 days of culturing in M-CSF. Image 
stained for Microglia: CD-llb (green), Astrocytes: GFAP (blue), and Neurons: 
Microtubule-Associated Protein-2 (MAP2) (red). 
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Chapter 3: IDENTIFICATION OF miRNAs THAT INFLUENCE THE 
INFLAMMATORY RESPONSE IN MICROGLIA 
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RESULTS 
Primary Microglia were isolated from CD-1 PO mouse pups, as described above , 
and stimulated for four-hours with LPS (100 ng/ml) to induce an M1-classical activation 
state in primary microglia. After the four-hour incubation, cells were lysed and total 
RNA was isolated. RNA samples were subjected to quality examination and eDNA 
microarray expression profiling of both mRNAs and miRNAs using Affymetrix Mouse 
Exon 1.0 ST Array and Mouse GeneChip miRNA 2.0 Array, respectively. Fmther, 
manual mRNA RT-PCR and LNA-based miRNA RT-PCR was performed to validate key 
differentially regulated genes and miRNAs identified from the microarray findings . 
mRNA Microarray Assessment and Validation ofMJ-Classically Activated State 
M1-skewed primary microglia differentially regulated a total of 7892 genes out of 
total 28,853 genes to a significantly, (p<0.05 using the Student T-Test when compared to 
the resting state), Table 2. A differential mRNA expression profile is characterized in 
heat-map form highlighting 63 genes that were differentially regulated to a significance 
determined by a moderated FDR q < 1x10-7 as compared against resting microglia, Figure 
4. Consistent with previous reports in both microglia and macrophages, we found the IL-
6 gene to be the most up-regulated gene upon LPS stimulation, 425-fold increase (8.73 
log2 fold change) relative to control, Figure 5-A [167,168]. In addition, M1-skewing of 
primary microglia also significantly (p < 0.05) up regulated 3375, which besides IL-6 
included the following top 15 genes: IL-12~, CD69, NOS2, Serpineb2, IL-l~ , CXCL9, 
GBP5, TNFSF15, CXCL1, CXCL3, PTGS2, CXCL11, CD40, and Serpinea3a, Figure 5-
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A. Each of the identified top 15 genes demonstrated a greater than a 32-fold increase (>5 
log2 fold change) relative to control and all are well characterized as LPS responsive 
genes in either microglia or peripheral macrophages, Figure 5-A [167,168]. 
Further , the microarray analysis identified RasGRP3 as the most down regulated, 
12-fold decrease (-3.54log2 fold change), relative to control under Ml-skewing of 
primary microglia, Figure 5-B. In addition, Ml-skewing of primary microglia also 
significantly (p < 0.001) down regulated 1798 genes, Table 2, which includes RasGRP3 
and the following top 15 genes: SESNl, NFAM1, MTSSl, GCNTl. CD300LB, 
TMEM154, BIN2, CNR2, RAB3IL1, LPINl , CXCR4, FBX032, INPP5D AND CHEK2, 
Figure 5-B. Interestingly, only CNR2 and CXCR4 have any previously association with 
microgilal functionality, all other down regulated genes identified are novel findings 
[169,170]. 
To validate the microarray results, manual RT -PCR was performed on select up 
regulated genes and confirmed that IL-6, IL-l~, and NOS2 that were significantly up-
regulated upon LPS stimulated primary microglia Figure 6-A. Further, we also 
demonstrated a strong up-regulation of TNF-a, Figure 6-A, which correspondingly was 
up regulated in the mRNA microarray data by 28-fold increase (4.8log2 fold change), 
data not shown. These findings are consistent with Martinez, et al. findings of Ml-
skewed peripheral macrophage transcriptional profiles [171]. Taken together, this 
demonstrates successful Ml-skewed classical activation of primary mouse microglia. 
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Table 2 The number of d~fferentially regulated genes and miRNAs in Primary Microglia 
by both Ml-Classical Activation and M2-Alterntaive Activation 
Ml-Classical Activation M2-Alternative Activation 
mRNA 7892 (37%) UP 3375 4139 (20%) Up 2255 
Down 4517 Down 1884 
miRNA 47 (6.5%) UP 12 44 (6.1 %) UP 16 
Down 35 Down 28 
mRNA Microarray Assessment and Validation ofM2-Alternatively Activation State 
M2-skewed primary microglia by IL-4 stimulation differentially regulated a total 
of 1606 genes to a significantly, (p<0.05 using the Student T-Test when compared to the 
resting state) where 2255 genes (54%) were up regulated and 1884 genes (46%) were 
down regulated, Table 2. The Chitinase-3 Like 3 (CHI3L3) gene was the most up-
regulated gene, 38.85-fold increase, in IL-4 stimulated primary microglia , Figure 7-A. 
CHI3L3 is considered an M2a-skewing marker in both microglia and peripheral 
macrophages [22,172]. Up-regulation of other known markers ofM2a-skewing in either 
peripheral macrophages/microglia or allergic disorders (e.g. asthma or allergic airways 
response) includes: RETNLA (FIZZl), EARll, ARG 1, CXCL13, MMP9, OLRl, 
TMEM26, FLTl, GPR84, MGL2, CXCR2, FCRLS, and PDCDllG2 genes, Figure 7-A 
[22,172-174]. 
Further, the microarray analysis identified Interferon Induced Transmembrane 
Protein 6 (IFITM6) as the most down regulated, 6-fold decrease ( -2.59log2 fold change), 
relative to control under M2a-skewing of primary microglia, Figure 7-B. In addition, 
55 
M2a-skewing of primary microglia also significantly (p < 0.05) down regulated 1884 
genes , Table 2, which includes IFITM6 and the following top 15 genes: H28 , CD28 , 
SLFN5, LRRC14B , OAS2, CD93, FCGR1, SLC40A1, ADA, HPGD, SP100, KLRA17, 
TRIM30d , and IGHM, Figure 7-B. Interestingly , only CD93 and FCGR1 have any direct 
previously association with microgilal functionality [175,176]. 
To validate the microarray results RT -PCR was performed on select genes and 
confirmed that gene expression of both CHI3L3 and ARG 1 were significantly increased 
upon IL-4 stimulation Figure 6-A. These findings are consistent with M2a-skewed 
peripheral macrophage transcriptional profiles [177] . Taken together, this data 
demonstrates successful M2-skewing of primary microglia, presumably to the M2a 
phenotype [24,178]. 
Identification ofmiRNAs Associated with the Ml-Classically Activated State 
M1-skewed primary microglia differentially regulated 47 out of a total 722 
rniRNAs (p < 0.05) , Table 2. Among them, we found that 12 (25%) miRNAs were up-
regulated and 35 (75 %) were down-regulated, Table 2 . A differential rniRNA expression 
profile was characterized in heat-map form highlighting the top 50 miRNAs to a 
significance p < 0.05 as determine by Student t-test compared against resting microglia 
Figure 8. 
As a convention, miRNA nomenclature defines a three or four letter abbreviation 
denoting the species and a numerical reference identifying that miRNA itself in the 
miRBase Registry [158 ,179]. For the purposes of this report , the full miRNA name is 
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e.g. mmu-miR-155 with 'mmu' denoting the species: mouse (Mus musculus) and miR-
155 denoting the specific miRNA, will be simplified to only miR-155 , since all the work 
in the report relates to mouse miRNAs only. 
Under the LPS-stimulating conditions , mmu-miR-155 was the most significantly 
(P < 0.01) up-regulated miRNA demonstrating a 9.69-fold increase (3.28 log2 fold 
change) relative to the PBS control , Figure 9-A. In addition to miR-155, other identified 
miRNAs that were all significantly (p < 0.05) , up regulated in the top 15 include: miRs-
297b-5p, -302c, -191 *,-lOb, -105, -495, -7a, -670, -1934, -201, -200c*, -214*, -673, and 
-141 * were all significantly (p < 0.05), up regulated Figure 9-A. Further, there was 
significant down regulation, only the top-15 are listed here, in the expression of miRs-
1928, -3474,-383,-192,-1939, -466b-3p, -2134,-1901,-762,-689, -128*, -542, -700,-
219, and -705 (p < 0.05), Figure 9-B. To validate the miRNA microarray result miRNA 
LNA-based RT-PCR was performed using the same samples as those that the microarray 
analysis used. In primary microglia LNA-based RT-PCR confirmed miR-155's 
expression is significantly (p < 0.01) increased upon LPS stimulation by 43-fold (5.42 
delta delta CT value) relative to the PBS control, Figure 9-C. 
Identification ofmiRNAs Associated with the M2-Alternatively Activated State 
Interestingly , IL-4 stimulating conditions differentially regulated 44 miRNAs 
(p<0.05), where 16 (36%) miRNAs were up regulated and 28 (64%) were down-
regulated, Table 2. In the IL-4 stimulated primary microglia we observed miR-145 as 
having the largest fold increase (2.66) along with miR-297b-5p and miR-214 (all greater 
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than 2.0-fold increase, p < 0.05), Figure 10-A. Further, there was significant down 
regulation , only the top-15 are listed here, in miRs-1939, -711, -1224, -200a*, -762, -
2138, -2861 , -1971 , -133a, -2132, - 2135 , -2133, -124,-2137, and -325 (p < 0.05), Figure 
10-A. 
We next pe1formed scatter plots analysis in our miRNA data relative to the fold 
change over PBS control group for the LPS and IL-4 stimulated groups separately and 
then between the LPS and IL-4 groups, Figure 11. In the M1-skewed primary microglia 
we observed miR-155 as the most differentially regulated miRNA, but surprisingly we 
also identified miR-449a (4.75 fold increase) and miR-1939 (-4.00 fold decrease) as the 
most up and down regulated respectively in the M2a skewed primary microglia. 
According to miRBase (http://www.mirbase.org) , mmu-miR-1939 sequence may only be 
a part of the mouse Gly-tRNA and therefore is not a likely to be a "bona fide miRNA". 
Therefore, we decided not to pursue miR-1939 in this study . Taken together we have 
identified that rniRNA's miR-155 and miR-449a are the most up-regulated miRNAs in 
the M1 (LPS) or M2a (IL-4) skewed primary microglia respectively , and potentially 
plays key role in shaping both phenotypic responses. 
miRNA expression profile comparison o(MO-resting state versus Ml-Classically 
Activated State 
To further identify unique miRNAs that potentially regulate phenotypic 
alterations of microglia versus common miRNAs that likely confer core differentiation 
states in microglia, miRNA percent expression analysis was performed. Since the 
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microarray data did not provide a sound reference ncRNAs e.g. U1 or U6 of the 
splicosome that is commonly used. miR-709 was used as a reference miRNA, since it is 
the most abundant miRNA found in either the LPS stimulated or the PBS control groups 
with very little variance between the two groups, 14.14 +/- 0.04 combined average 
intensity level. 
To determine relative abundance of miRNAs percent expression level was 
calculated, relative to miR-709, and averaged together for all three samples from each 
group separately. miRNAs for both the PBS and the LPS groups were then divided into 
quartiles separately where the 1st quartile = 75-100% (highest abundance), 2nd quartile= 
50-75%, 3rd quartile= 25-50% and 41h quartile= 0-25% (lowest abundance) as shown 
Table 3. Interestingly, the number ofmiRNAs comprising each quartile didn 't vary 
much between the two groups suggesting that the number of miRNAs up regulated was 
close to the number ofmiRNAs down regulated, Table 3. 
Focusing on the first and second quartiles, presumable these miRNAs would have 
the greatest influence over cellular functionality. We observed a 94% overlap, 16 
common miRNAs, between LPS and PBS in the first, i.e. most abundant, quartile. 
Further, only a single miRNA was identified as unique to the LPS signature profile 
versus the PBS resting profile: miR-222. In the second quartile (50-75% expression) 
there was much more variation in the miRNA distribution with both groups comprising 
roughly 50 miRNAs, ~7-8% ofthe total number ofmiRNAs. 38 miRNAs were common 
between both the LPS and PBS groups in the second quartile and 12 miRNAs, including 
miR-155 , were unique to the LPS signature, Table 3. As Table 3 demonstrates the vast 
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majority, close to 90%, of all the miRNAs have expression levels within the third and 
fourth quartiles. Note, common miRNA are only those miRNAs found in the same 
quartile common to both the PBS and LPS groupings and do not reflect a total miRNAs 
profile. 
As a final refinement of this methodology and to incorporate fold change into this 
analysis, non-significantly changing miRNAs and viral miRNAs were filtered out as 
shown on Table 3. A total47 miRNAS, 6% of the total number ofmiRNAs screened, 
were significantly altered under LPS stimulation. Provides a list broken down by both 
expression level quartile and of the significantly (p<0.05) altered miRNAs between LPS 
and PBS groups. Balded miRNAs denote miRNAs specifics to that group in that 
quartiles of expression level, either PBS or LPS. Interestingly, in the highest two 
quartiles every miRNA identified is down regulated by some degree except mir-155. 
Under LPS stimulation there was no differentially regulated miRNAs that were neither in 
the highest expression quartile at rest, nor post-stimulation condition, xxx. Further, a 
27% increase was observed n number of miRNAs comprising the third quartile as 
compared to the PBS control group. In fact, 5 miRNAs were up-regulated from the 4th 
quartile of the PBS group and 4 miRNAs were down regulated from the 2nd quartile 
account for the 27% increase, Table 4 and Figure 12-A and B. All other quartiles were 
reduced in the number ofmiRNAs comprising them under LPS simulation of primary 
microglia, Table 4. Down regulated miRNAs after LPS stimulation predominantly came 
from the 2nd quartile and either stayed within that quartile or reduced into the 3rd quartile, 
Figure 12-B. These data indicates that differentially up-regulated miRNAs after Ml-
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skewing are mostly inducible miRNAs, whereas differentially down regulated miRNAs 
are relatively abundant miRNAs, which account for about 6% population of total 
miRNAs. 
Table 3: Comparison of the number ofMl-Classically Activated versus MO-Resting 
miRNAs grouped by expression level quartiles (All miRNAs inclusive) 
1st Quartile 2"d Quartile 
Group #of %of #of %of 
miRNAs miRNAs miRNAs miRNAs 
PBS 25 3.26 53 6.93 
LPS 17 2.22 50 6.54 
Common 16 2.09 38 4.97 
3rd Quartile 4111 Quartile 
Group #of %of #of %of 
miRNAs miRNAs miRNAs miRNAs 
PBS 321 41.96 366 47.84 
LPS 296 38.69 402 52.55 
Common 257 33.59 340 44.44 
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Table 4: Significantly (p< 0.05) altered miRNAs by LPS stimulation segregated by 
expression level quartiles 
PBS (MO) Resting LPS (M1-Classically) Activated 
miRNA Fold Power miRNA Fold Power Change Change 
1st quartile 1st quartile 
mmu-miR-762 -1.21 0.0128 mmu-miR-2137 -0.75 0.0268 
mmu-miR-2137 -0.75 0.0268 mmu-let-7b -0.26 0.0307 
mmu-let-7b -0.26 0.0307 mmu-miR-2861 -0.93 0.0399 
mmu-miR-103 -0.36 0.0388 mmu-miR-2132 -0.96 0.0442 
mmu-miR-2861 -0.93 0.0399 mmu-miR-24 -0.36 0.0478 
mmu-miR-2132 -0.96 0.0442 
mmu-miR-24 -0.36 0.0478 
2nd quartile 2nd quartile 
mmu-miR-2135 -0.81 0.0057 mmu-miR-155 3.28 0.0040 
mmu-miR-705 -1.13 0.0153 mmu-miR-2135 -0.81 0.0057 
mmu-miR-2133 -1.07 0.0237 mmu-miR-762 -1.21 0.0128 
mmu-miR-423-5p -0.54 0.0290 mmu-miR-2133 -1.07 0.0237 
mmu-miR-689 -1.19 0.0372 mmu-miR-423-5p -0.54 0.0290 
mmu-miR-1224 -0.92 0.0391 mmu-miR-103 -0.36 0.0388 
mmu-miR-93 -0.40 0.0403 mmu-miR-1224 -0.92 0.0391 
mmu-miR-574-3p -0.75 0.0411 mmu-miR-93 -0.40 0.0403 
mmu-miR-1937a -0.78 0.0431 mmu-miR-1937a -0.78 0.0431 
mmu-miR-181b -0.62 0.0439 mmu-miR-181b -0.62 0.0439 
mmu-miR-124 -0.85 0.0460 mmu-miR-2146 -0.71 0.0493 
mmu-miR-2146 -0 .71 0.0493 
3rd quartile 3rd quartile 
mmu-miR-1901 -1.29 0.0002 mmu-miR-670 1.15 0.0034 
mmu-miR-3474 -2.08 0.0106 mmu-miR-297b-5p 1.59 0.0066 
mmu-miR-1937c -0.84 0.0109 mmu-miR-1937c -0.84 0.0109 
mmu-miR-1939 -1.54 0.0147 mmu-miR-lOb 1.31 0.0121 
mmu-miR-1906 -0.75 0.0158 mmu-miR-141 * 1.06 0.0125 
mmu-miR-466b-3p -1.32 0.0167 mmu-miR-200c* 1.10 0.0136 
mmu-miR-1928 -2.11 0.0168 mmu-miR-1939 -1.54 0.0147 
mmu-miR-324-3p -0.47 0.0227 mmu-miR-705 -1.13 0.0153 
mmu-miR-376a 1.06 0.0243 mmu-miR-1906 -0.75 0.0158 
mmu-miR-669c 0.80 0.0308 mmu-miR-466b-3p -1.32 0.0167 
mmu-miR-700 -1.13 0.0316 mmu-miR-324-3p -0.47 0.0227 
mmu-miR-1894-3p -0.88 0.0375 mmu-miR-376a 1.06 0.0243 
62 
mmu-miR-24-2* -0.77 0.0383 mmu-miR-669c 0.80 0.0308 
mmu-miR-1962 -0.35 0.0454 mmu-miR-700 -1.13 0.0316 
mmu-miR-711 -0.99 0.0457 mmu-miR-689 -1.19 0.0372 
mmu-miR-1196 -0.78 0.0461 mmu-miR-1894-3p -0.88 0.0375 
mmu-miR-24-2* -0.77 0.0383 
mmu-miR-574-3p -0.75 0.0411 
mmu-miR-1962 -0.35 0.0454 
mmu-miR-711 -0.99 0.0457 
mmu-miR-124 -0.85 0.0460 
mmu-miR-1196 -0.78 0.0461 
4th Quartile 4th Quartile 
mmu-miR-670 1.15 0.0034 mmu-miR-1901 -1.29 0.0002 
mmu-miR-155 3.28 0.0040 mmu-miR-2136 0.66 0.0046 
mmu-miR-2136 0.66 0.0046 mmu-miR-3474 -2.08 0.0106 
mmu-miR-297b-5p 1.59 0.0066 mmu-miR-1928 -2.11 0.0168 
mmu-miR-10b 1.31 0.0121 mmu-miR-1982.2 0.91 0.0216 
mmu-miR-141 * 1.06 0.0125 mmu-miR-191 * 1.37 0.0300 
mmu-miR-200c* 1.10 0.0136 mmu-miR-220 -0.50 0.0320 
mmu-miR-1982.2 0.91 0.0216 mmu-miR-710 0.75 0.0371 
mmu-miR-191 * 1.37 0.0300 mmu-miR-410 -0.75 0.0381 
mmu-miR-220 -0.50 0.0320 
mmu-miR-710 0.75 0.0371 
mmu-miR-410 -0.75 0.0381 
miRNA expression profile comparison ofMO-Resting State versus M2-Alternative 
Activation State 
Similar to M1-associated miRNAs, most up-regulated miRNAs after M2a-
skewing initially have very low expression levels, falling within either the 3rd or 41h 
expression qumiiles. IL-4 stimulation up-regulated their expression levels to the next 
quartile, -A. mRNAs miR-449a, -214, and -145 were both the most up-reglated and 
highest expressing miRNAs observed under IL-4 treatment, Figure 13-A. Down-
regulated miRNAs after IL-4 stimulation were more widely distributed across all 
quartiles, including both miRNAs miR-711 and miR-124, Figure 13-B. These data 
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indicates that differentially up-regulated miRNAs after M2a-skewing are mostly 
inducible miRNAs, whereas the expression level of differentially down-regulated 
miRNAs are spread out among all the quartiles. 
Combining fold change results with expression level analysis allowed us to focus 
on critical miRNAs. Our data indicate that for LPS-stimulated murine microglia miR-
155 is the primary miRNA, while other up-regulated miRNAs may play a role in fine-
tuning the response, as their expression levels are still relatively low by comparison (Fig 
3B). We also identified a number ofmiRNAs including: miR-762, miR-2133, miR-689, 
and miR-705 that are all down regulated upon LPS stimulation and may play a role in 
enabling the M1 classically activated state in primary microglia. In IL-4 treated 
microglia miR-449a, -214, and -145 collectively represent miRNAs that aid in shaping 
the M2a phenotype. Further, miRNAs miR -711, miR -7 62 and miR -124 are both down 
regulated under IL-4 stimulating conditions and may play a role in enabling the M2a 
alternatively activated state in primary microglia. 
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Table 5 Comparison of the number of M2-Alternatively Activated versus MO-Resting 
miRNAs grouped by expression level quartiles (All miRNAs inclusive) 
1st Quartile 2"d Quartile 
Group #of % of #of %of 
miRNAs miRNAs miRNAs miRNAs 
PBS 25 3.26 53 6.93 
IL-4 23 3.00 61 7.97 
Common 22 2.88 45 5.88 
3rd Quartile 41h Quartile 
Group #of %of #of %of 
miRNAs miRNAs miRNAs miRNAs 
PBS 321 41.96 366 47.84 
IL-4 300 39.21 381 49.80 
Common 265 34.25 335 43.79 
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Table 6 Significantly (p< 0.05) altered miRNAs by /L-4 Stimulation segregated by 
expression level quarti/es 
PBS (MO Resting) IL-4 (M2a-Aiteratively) Activated 
miRNA Fold Power miRNA Fold Power Change Change 
1st quartile 1st quartile 
mmu-miR-2137 -0.96 0.0106 mmu-miR-2137 -0.96 0.0106 
mmu-miR-2132 -1.13 0.0009 mmu-miR-125b-5p 0.13 0.0235 
mmu -miR-2138 -1.34 0.0011 mmu-miR-22 0.29 0.0139 
mmu -miR-2861 -1.31 0.0000 mmu-miR-2132 -1.13 0.0009 
mmu-miR-125b-5p 0.13 0.0235 mmu-miR-2138 -1.34 0.0011 
mmu-miR-2145 -0.83 0.0059 mmu-miR-2861 -1.31 0.0000 
mmu-miR-762 -1.39 0.0004 mmu-miR-222 0.18 0.0340 
mmu-miR-22 0.29 0.0139 
mmu-miR-2134 -0.71 0.0104 
.2nd quartile 2nd quartile 
mmu-miR-222 0.18 0.0340 mmu-miR-2145 -0.83 0.0059 
mmu-miR- 2133 -1.05 0.0007 mmu -miR-2134 -0.71 0.0104 
mmu-miR-1224 -1.62 0.0015 mmu-miR-762 -1.39 0.0004 
mmu-miR-2135 -1.07 0.0027 mmu-miR-2133 -1.05 0.0007 
mmu-miR-2146 -0.34 0.0268 mmu-miR-2135 -1.07 0.0027 
mmu-miR- 705 -0.91 0.0288 mmu-miR-214 1.01 0.0197 
mmu-miR-689 -0.55 0.0002 mmu-miR-2146 -0.34 0.0268 
mmu-miR-124 -0.96 0.0109 mmu-miR-1224 -1.62 0.0015 
mmu-miR-705 -0.91 0.0288 
mmu-miR-145 1.41 0.0035 
3rd quartile 3rd quartile 
mmu-miR-214 1.01 0.0197 mmu-miR-689 -0.55 0.0002 
mmu-miR-1939 -2.00 0.0493 mmu-miR-31 0.95 0.0307 
mmu-miR-711 -1.69 0.0022 mmu-miR-124 -0.96 0.0109 
mmu-miR-145 1.41 0.0035 mmu -miR-376a 0.92 0.0255 
mmu-miR-31 0.95 0.0307 mmu-miR-199a-5p 0.73 0.0371 
mmu-miR-200a* -1.50 0.0342 mmu-miR-324-3p -0 .52 0.0237 
mmu-miR-335-5p -0.78 0.0030 mmu-miR-335-5p -0.78 0.0030 
mmu-miR-324-3p -0.52 0.0237 mmu-miR-297b- 1.37 0.0055 5p 
mmu-miR-376a 0.92 0.0255 
mmu-miR-199a-5p 0.73 0.0371 
mmu-miR-1971 -1.16 0.0358 
mmu-miR-883a-3p -0.25 0.0475 
mmu-miR-133a -1.16 0.0399 
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4th quartile 4th quartile 
mmu-miR-220 -0.62 0 .0471 mmu-miR-883a- -0.25 0.0475 3p 
mmu-miR-410 -0.61 0.0321 mmu-miR-711 - 1.69 0.0022 
mmu-miR-467c -0.72 0.0468 mmu-miR-199a -3p 0.58 0.0274 
mmu-miR-199a-3p 0.58 0.0274 mmu-miR-1939 -2.00 0.0493 
mmu-miR-10a * -0.42 0.0089 mmu-miR-200a* -1.50 0.0342 
mmu-miR-325 -0.93 0.0323 mmu-miR- 200b 0.68 0 .0280 
mmu-miR-376c -0.53 0.0451 mmu-miR- 26b* 0 .89 0.0211 
mmu-m iR-200b 0.68 0.0280 mmu -miR-220 -0.62 0.0471 
mmu-miR-297b- 1.37 0.0055 mmu-miR- 214* 1.01 0.0072 Sp 
mmu-miR-26b* 0.89 0 .0211 mmu-miR-410 -0.61 0.0321 
mmu-miR-466a-5p 0.87 0.0177 mmu-miR-1971 - 1.16 0.0358 
mmu-miR-879 0.60 0.0158 mmu-miR-466a-5p 0 .87 0.0177 
mmu-miR-653 0.61 0.0316 mmu-miR-133a -1.16 0.0399 
mmu-miR-214* 1.01 0.0072 mmu -miR-467c -0.72 0.0468 
mmu-miR-879 0 .60 0.0158 
mmu-miR-10a * -0.42 0.0089 
mmu-miR-653 0 .61 0.0316 
mmu -miR-376c -0.53 0.0451 
mmu-m iR-325 -0.93 0.0323 
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Figure 4: mRNA Microarray Cluster Analysis- Heatmap of PBS, LPS, and /L-4 mRNA 
Expression Profiles of Primary Microglia 
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(A) Heatmap of expression (cluster analysis) of 63 differentially regulated genes between 
the Ml-skewed (LPS), M2a-skewed (IL-4) versus MO resting primary microglia from 
mRNA microarray analysis. (Moderated FDR q < lxl0-7) Color scheme: Blue= below 
average, white= average and red= above average. 1, 2, and 3 are replicates for each 
individual microarray of the LPS, IL-4 and PBS stimulating conditions. 
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Figure 5: Microarray Analysis - Top 15 differentially regulated genes under Ml-skewing 
of Primary Microglia 
(A) Microarray expression profile of the top 15 up regulated genes under Ml-skewing 
conditions, 4-hour LPS stimulation (1 00 ng/ml) in primary microglia (n=3, all anal yates 
have p < lxl0·5 determined by Student T-Test relative to the MO state). (B) Microanay 
expression profile of the top 15 down regulated genes under Ml-skewing conditions in 
primary microglia (n=3, all analyates have p < 0.001 determined by Student T-Test 
relative to the MO state). 
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Figure 6: Normalized confirmatory mRNA RT-PCR of select genes in Ml-Skewed and 
M2a-skewed primary microglia normalized to the MO resting state 
(A) Confirmatory mRNA RT-PCR of the gene expression of select genes . Canonical Ml-
skewing markers (IL-6, IL-l~ , TNF-a and NOS2), M2b-skewing markers (IL-10 and 
PAI-l) and M2a-skewing markers (Chi3 l3 and Argl) delta CT values presented 
normalized to resting state MO (n=4, *** = p<O.OOl and ** = p<O.Ol) 
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Figure 7: Microarray Analysis- Top 15 differentially regulated genes under M2a-
skewing of Primary Microglia 
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(A) Microarray expression profile of the top 15 up regulated genes under M2a-skewing 
conditions, 4-hour IL-4 stimulation (20 ng/ml) in primary microglia (n=3 , all analyates 
have p < 1x10·5 determined by Student T-Test relative to the MO state). (B) Microarray 
expression profile of the top 15 down regulated genes under M2a-skewing conditions in 
primary microglia (n=3, all anal yates have p < 0.001 determined by Student T -Test 
relative to the MO state). 
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Figure 8: miRNA Microarray Cluster Analysis- Heatmap of PBS, LPS, and IL-4 1niRNA 
Expression Profiles of Primary Microglia 
(A) Heat map of top 50 differentially regulated miRNAs expression clusters from 
mi RNA microarray analysis (p<0.05 for all miRNAs identified) . Color scheme: Blue = 
below average, white = average and red = above average. lA , 2A, and 3A are replicates 
for each individual microarray of the LPS , IL-4 and PBS stimulating conditions . 
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Figure 9: miRNA Differential Expression Analysis of Ml-skewed Primary Microglia 
(A) Top 15 differentially expressed miRNAs up-regulated (n=3, p < 0.05) from miRNA 
microarray expression data, as compared to the MO-resting state, under M 1-skewing 
conditions. (B) Top 15 differentially expressed miRNAs down regulated (n=3, p < 0.05) 
from miRNA microarray expression data, as compared to the MO-resting state, under 
both M 1-skewing conditions . (C) Confirmatory LNA-based RT-PCR of the miRNA 
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expression microarrays demonstrating strong up-regualtion, ~~CT value calculated 
relative to PBS control, miR-155 under LPS stimulation (n=4, ***= p<0.001), as well as 
miR-146a, and miR-124 under M1-Skewing conditions. 
75 
A 
M2a Stimulated (IL-4) Microglia: 
1.75 
1.50 Q) 
Cl(f.) Iii al 1.25 
..c:c.. 
u 0 1.00 
-c-
-Q) ~ ~ 0.75 
N<ll 
g>~ 0.50 
...J 0.25 
Top 15 miRNAs Up-regualted 
O.OO...,.'""'i"'"T'-'""""~I'L'+'""'i"'"i"-LfLit'-'i~o.&f'.,.. 
n 
M2a Stimulated (IL-4) Microglia: 
Top 15 miRNAs Down-regualted 
Q) 
g'(f.) .. 
~~ -1- >:· 
Uo 
-c-
o ~ .,. 
U..; l 
N ~ -2· 
C)Q) 
0 .... 
....1 
Figure 10: miRNA Differential Expression Analysis of M2a-skewed Primary Microglia 
(A) Top 15 differentially expressed miRNAs up-regulated (n=3 , p < 0.05) from miRNA 
rnicroarray expression data, as compared to the MO-resting state, under M2-skewing 
conditions. (B) Top 15 differentially expressed miRNAs down regulated (n=3 , p < 0.05) 
from miRNA microarray expression data, as compared to the MO-resting state, under 
both M2-skewing conditions . 
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Figure 11: Scatter plot of Ml-skewed versus M2a-skewed Log2 fold change miRNA 
(A) Scatter plot of LPS vs. IL-4 differentially expression miRNAs identifying miR-155 
and miR-499a as the most up regulated miRNAs under Ml and M2a skewing conditions 
respectively . 
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Figure 12: miRNA Average percent expression vs.fold change of key miRNAs in Ml-
skewed Primary Microglia. 
Combining highly differentially regulated miRNAs with percent average expression level 
under Ml-skwing conditions. (A) Most Up-regulated (Log2 fold change) miRNAs 
identified in the lowest quartile 4th , 3'd, and 2"d (highest quartile) . (B) Down regulated 
miRNAs identified in the 1st (highest quartile), 2"d, and 3'd (lowest quartile) that are the 
highest up-regulated (Log2 fold change) miRNAs. 
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Figure 13: miRNA Average percent expression vs . fold change of key miRNAs in M2a-
skewed Primary Microglia. 
Combining highly differentially regulated miRNAs with percent average expression level 
under M2-skwing conditions. (A) Most Up-regulated (Log2 fold change) miRNAs 
identified in the lowest quartile 4th, 3'ct, and 2"d (highest quartile). (B) Down regulated 
miRNAs identified in the 1st (highest quartile), 2"ct, 3'ct, and 4th (lowest quartile) that are 
the highest up-regulated (Log2 fold change) rniRNAs. 
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DISCUSSION 
The goal of this study was to identify key miRNAs associated with the Ml-
classically activated phenotype. During the course of this study we skewed primary 
microglia to the M1-classically activated or M2-alternatively activated phenotypes, 
isolated total RNA , and ran microarray expression profiles for both mRNA and miRNA. 
To identify key miRNAs associated with either stimulating condition comparisons of fold 
change and average expression, abundance , analysis were made relative to the MO-resting 
state. 
Ml-Classical Activation o{Primary Microglia 
Many canonical pro-inflammatory cytokines and chemokines were up-regulated 
in primary microglia upon LPS stimulation, For example: IL-6, TNF-a, IL-1{3, NOS2, 
CXCL9 and CXCLll to name a few were all strongly up-regulated, greater than 5 Log2 
fold change relative to resting. These genes are well characterized and known to be up-
regulated upon LPS stimulation in either microglia or peripheral macrophages and this 
data supported that we had successfully skewed primary microglia to the M1-like 
phenotype [ 167, 168]. Further, These fmdings are consistent with Martinez, et al. findings 
of M 1-skewed peripheral macrophage transcriptional profiles [ 171]. Taken together, we 
believe that we successfully skewed primary murine microglia to the Ml-classically 
activated phenotype. 
Characterizing the most down regulated mRNAs under LPS stimulation fell into 
three primary groups that all seemed to work together in enabling the Ml -skewing 
82 
phenotype. First, a number of genes are suppressed that are associated with T H2-skewing 
of the inflammatory response, such that suppression of TH2 promotes T 1-11 and 
correspondingly the M1-phenotype. A second grouping of genes appear to be associated 
with inhibition of specific cellular functions that would compete for cellular resources 
necessary for key aspects of the M1-phenotype. The third grouping of genes significantly 
down regulated are associated with the promotion of anti-inflammatory pathways that 
compete with the M1-phenotype. 
The Ml!M2-skewing nomenclature for peripheral macrophages has been adopted 
from the Tl-11/T H2 skewing demonstrated in T -cells and the adaptive immune response 
[25]. RasGRP3, the most down regulated gene observed under M1-skewing, is known to 
link the RAS, MEK/ERK pathway to the DAG/PKC pathway [180]. RAS signaling 
pathways are know to selectively enhanced proliferation in B cells and plays a key role in 
downstream signaling of the BCR (B-cell receptor) [181,182]. NFAM1 is involved in B 
and T cell activation of NFAT, cytokine expression and overall has been shown to 
modulate B-cell signaling and regulate B-Cell development [183]. Further, NFAM1 is up 
regulated in excessive T H2 (IL-4) canine atopic dermatitis and human esoinophilic 
allergic disease [184]. CD300LB, also down regulated under M1-skewing is a non-
classical activating receptor of the lg superfamily expressed on myeloid cells has been 
shown to lead to Mast cell degranulation, a key immune mediator ofT 1-12 response 
[185,186]. 
A number of the down-regulated genes are associated with cytoskeleton re-
organization including MTSS 1, BIN2, and RAB3IL1. MTSS 1 was initially identified 
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since it is strongly up regulated in metastatic cancerous states and has later been shown to 
regulate changes in the cytoskeleton [ 187]. Knockdown of BIN2 has shown reduced cell 
migration, increased phagocytosis and fewer podosome density [188]. RAB3IL1 is a 
GEF that is known to interact with Rab3a and Inosital INSP6K1 and function in vesicle 
transport [189]. Specifically, RAB3Il1 has been shown to regulated synaptic vesicle 
exocytosis in neuronal cell lines and in macrophage has been shown to aid in the 
development of the ruffled board in osteoclast differentiation [189,190]. Taken together 
these gene alterations suggest cytoskelatal reorganization away from processes favoring 
movement and exocytosis to those favoring endocytic processes, e .g. phagocytosis. 
SESN1 has been shown to protect cells from oxidative stress by degrading Keap1, 
a key inhibitor of the Nrf2 antioxidant response pathway [191]. Thus, under normal 
conditions SESN1 dis-inhibits the Nrf2 pathway that generated anti-oxidants. Therefore , 
under M1-skewing conditions with SESN1 down regulated enables the formation of 
reactive oxygen species, a key feature of M1 classically activated pro-inflammatory 
response. 
CHEK2 is a DNA Damage repair gene and tumor suppressor gene [192,193]. 
Interestingly, BRAC1 is regulated by CHK2[194], which has recently been shown to be 
an epigenetical regulator of miR-155 [195,196]. Potentially, this could release one 
potential competing regulatory for BRAC1, which then would be free to activate miR-
155 eipigenetically. 
Both LPIN1 and CNR2 appear to enable anti-inflammatory pathways directly. 
First, LPIN1 is both known to be down regulated during LPS stimulation of adipocytes 
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and is a validated target of miR-155 [197,198]. Reducing levels of Lipin decreases DAG 
and decrease levels of Protein Kinase C and therefore increases Akt signaling [199]. 
Cannabinoid type-2 agonists demonstrate potent anti-inflammatory properties potentially 
though its blockade of the MAPK pathway during LPS stimulation [169]. 
Identification o{miR- I 55 
It has been a little over five years since Taganov, et al . first demonstrated the 
involvement of miRNA(s) in peripheral macrophage biology and only two years since 
Ponomarev, et al. demonstrated a role for miRNAs in microglial biology [50,56]. In the 
present study, we sought to systematically identify key miRNAs and their role in 
regulating murine microglial M1 or M2 polarization, this is the first genome-wide study 
of both mRNA and miRNA expression profile of primary cultured murine microglia. 
We identified mmu-miR-155 as the primary miRNA induced upon M1-skewing 
LPS stimulation of primary murine microglia. Interestingly, miR-155 plays a key role in 
regulating the acute innate immune response in peripheral macrophages [50,51 ,66,80]. In 
addition, in peripheral macrophages miR-155 is strongly induced upon TLR-mediated 
signaling, e.g LPS and polyriboinosinic-polyribocytidylic acid (poly I:C), as well as 
stimulation with Helicobacter pylori, Kaposi's sarcoma-associated herpesvirus, Epstein-
Barr virus, oxidized LDL, TNF-a, and interferon-beta (IFN-B) (for review, see O'Neill et 
al., 2011 [52]). Further, our finding corroborates Cardosa, A, et al. 2011 study that also 
demonstrated rniR-155 is strongly up-regulated upon LPS stimulation to similar levels for 
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corresponding time points and LPS concentration in both primary microglia and in the 
N9 microglial cell line [55]. 
However, what was an unexpected and novel finding in our study was that 
miRNA regulation of the classically activated phenotype in primary microglia is 
primarily limited to miR-155 with only relatively modest alterations, ~2-4 fold increase, 
in any other miRNAs, e.g. miR-10b and miR-297b-5p based on the genome-wide 
miRNA expression profile. Taken together, miR-155 is likely to be the key miRNA that 
mediates an acute pro-inflammatory state in primary microglia suggesting that inhibition 
of miR-155 would be a viable therapeutic anti-inflammatory strategy. 
M2-Alternative Activation ofPrimary Microglia 
IL-4 stimulation is known to induce alternative activation in primary microglia, 
we observed no miRNA strongly up-regulated, like that observed with miR-155 in LPS 
stimulation, during alternative activation of primary microglia [22]. However, we did 
observed several miRNAs that are significantly dysregulated including miR-145, miR-
297b-5p, and mir-214. To our knowledge this is the first time miRNAs miR-145 , -297b-
5p, -214, and -449a have been associated with the IL-4/STAT6 signaling pathway and 
microglial biology. Interestingly, miR-449a, miR-145 and miR-214 are all tumor 
suppressor miRNAs, where many cancerous states report down regulation in these 
miRNAs either individually or in combination [200-203]. Further, miR-145 over-
expression has been shown specifically to inhibit tumor growth and proliferation [203]. 
Our study suggests a novel role for these miRNAs in mediating the alternative activation 
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state in microglia mediated through the IL-4/STAT6 axis, and perhaps in peripheral 
macrophages . Supporting a role for miR-145 in the IL-4/STAT6 axis Collison A. et al. 
have recently demonstrated that miR-145 inhibition is as efficacious as steroid treatment 
in allergic airway disease, a disease known to be mediated by IL-4 induced Th2 skewing 
disorder [204]. Further, Halappanavar S. et al. also has repmted up regulation of miR-
449a associated with acute phase pulmonary inflammation as a result of exposure to 
nanotitanium dioxide particles, which exposure can induce an allergic reaction in the lung 
[205] . Further, miR-449a is also known to target the Notch signaling pathway directly , 
which has been linked in mediating the Ml to M2 switch in peripheral 
macrophages .[206,207] Lastly, to our knowledge miR-214 has no known roles in either 
microglial or macrophage biology. However, Jindra, PT et al. demonstrated a role for 
miR-214 in the lymphocyte biology by regulating proliferation in T-cell activation [208]. 
Taken together, we believe we did capture core miRNAs that aid in the regulation of IL-
4/STAT6 alternative activation state in microglia. 
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Chapter 4: DETERMINING THE FUNCTIONAL ROLE OF miRNAs 
ASSOCIATED WITH THE INFLAMMATORY RESPONSE IN PRIMARY 
MICROGLIA 
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RESULTS 
In the previous chapter key miRNAs that are differentially regulated in either Ml-
classical activation or M2-alternative activation of primary microglia were identified. 
The overall goal of this chapter is to determine the functionality and role of the identified 
miRNA in skewing primary microglia to either the Ml-classical activation or M2-
alternative activation state. To identify pathways, functions , and transcriptional networks 
altered enrichment analysis using Ingenuity® Pathway Analysis (IPA) tool , as described 
above, was performed on the mRNA gene expression data generated in Chapter 3 for 
both Ml-classical activation or M2-alternative activation of primary microglia. To 
identify key miRNA:mRNA interactions a correlation analysis was performed on select 
key differentially regulated miRNAs, identified in Chapter 3, correlated to both 
differentially regulated mRNA genes and potential miRNA targets identified from public 
databases . Last! y, the key miRNA:mRNA interactions were then used as input for an 
additional enrichment analysis using the IPA tool to determine which functions , 
pathways, and transcriptional networks these miRNAs target, This enabled a comparison 
and identification of key miRNAs regulating the phenotype in primary microglia by 
matching pathways and networks altered in both the mRNA enrichment analysis and the 
miRNA:mRNA correlated targets enrichment analysis . 
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Ml-Classical Activation of Primary Microglia 
Enrichment Analysis ofDitferentially Regulated Genes- Ml-Skewing 
To characterize how classical activation state alters primary microglial 
functionality we performed an enrichment analysis using the IPA tool [156,157] . We 
observed that primary microglia altered 54 key biological functions under M1-skewing 
LPS stimulating conditions. Figure 14-A and B shows the top 10 functions altered both 
up and down regulated respectively under LPS stimulation of primary microglia . 
Consistent with our expectations, the Inflammatory Response/Immune Response function 
was the most significantly enriched function (p < 3.59x10-63) and is associated with over 
280 enriched genes , Figure 14 A . Further, differential regulation in the chemokine 
network altering both cellular movement and immune cell trafficking functionality were 
the next two most significant (p < 5.91x10-37 for both) with over 200+ genes associated 
with each function, Figure 14-A. 
To identify key down-regulated functions we performed similar functional 
analysis only using the most significantly down regulated genes (p<O.OOOl) from the LPS 
stimulated primary microglia data set. Interestingly , the most down-regulated functions 
were cellular growth and proliferation, as well as hematological system development 
(p<6.09xl0-6) with 33 down regulated genes enriched that specifically targeting the 
proliferation of lymphocytes, Figure 14-B. Further we observed significant gene 
enrichments that alter lipid, nucleic acid, and carbohydrate metabolism, as well as other 
core biological functions including molecular transport, DNA replication, and general 
cellular development, Figure 14-B. We also identified key functions that are predicted to 
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be actively inhibited, by Ingenuity's Knowledge Base, which can be classified in three 
critical functions: apoptosis of leukocytes (p < 7.54x10-23), infection by virus (p < 
1.15x10-20), and to a lesser extent functions promoting cancer metastasis (p < 7.54x10-15) , 
(data not shown). Taken together we observed significantly strong up-regulation in many 
genes enriched in canonical pro-inflammatory functionality and observed inhibition or 
down-regulation of cellular growth, proliferation, apoptosis , viral programming and 
cellular metabolic alterations . 
We next looked at the alterations in the transcription networks , based on 
Ingenuity's knowledge Base, which makes predictions based on comparison of the 
transcription factor and its regulation to the regulation of its downstream targets. For 
example, if a transcription factors is up-regulated and down stream targets are 
correspondingly up-regulated, then the transcription factor is identified as "Activated". 
However, if the majority of the downstream targets are differentially regulated from the 
direction that the transcription factor is regulated then the transcription factor is identified 
as "Inhibited" . Under LPS stimulation primary microglia demonstrated many well 
characterized pro-inflammatory transcription factors as the most significantly "Activated" 
including: NF-KB (NfKB 1-RelA), Activating Protein-1 (AP-1), Signal Transducer and 
Activators of Transcriptions (STATs 1-4), and IRFs genes (IRFs 1 ,3,7, and 8), Figure 17-
A (in red). Nine other significantly "activated" transcription factors are also associated 
with the pro-inflammatory state in primary microglia as identified in Figure 17-A and B 
(in red). 
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miRNA Correlation Analysis in M1-skewed Primary Microglia 
Our ultimate goal is to better understand how miRNAs potentially regulate the 
immune response in primary microglia. To better identify potential miRNA-mRNA 
interactions that regulate the transitions between the 'resting state ' (MO) and the M1-
skewed phenotype we performed a correlation analysis between the mRNA and miRNA 
microarray data sets from the same RNA samples to identify the most significant genes 
with the strongest correlations. We next compared the correlated genes to genes 
identified as potential miRNA targets for the particular miRNA, identified through use of 
commercially available target databases, e.g. miRanda and a combined TargetScan (ver 
6.0)ffarBase provided by Ingenuity ' s miRNA target filter application or directly from 
TargetScan only (February 2012) , schema as depicted in Figure 18-A [159-161] . 
Overall, we applied this approach to 22 different miRNAs that represent the most 
up or down regulated miRNAs under Ml-skewing conditions. We applied this 
methodology to the following critical up-regulated miRNAs under LPS stimulation: 
(miR-155 , -297-5p, -302c, -lOb, -495, -7a, -376a, -539, and -876-5p) and the following 
down regulated miRNAs under LPS stimulation: (miR-124, -2132,-2122,-143, -219,-
700,-689, -762,-1901, -466b-3p, -192, -383,-3474 and -1928) . Using miR-155 as an 
example of this methodology to identify potential miRNA targets. We first identified 
4231 genes that were strongly correlated with significantly differentially expressed genes 
under LPS stimulation (p<0.0001) and then compared that data set to the data sets from 
Ingenuity ' s 1081 identified miR-155 targets and miRanda database ' s 3329 predicted 
miR-155 targets, Figure 18-A. The intersection of these three data sets netted a total of 
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112 potential targets. To validate our methodology, we then pelformed literature 
searches on each potential target identified and found that 14.2%, 16 of the 112 genes, 
were already previously validated and therefore known targets of miR-155 (Figure 19-A, 
Table 7, and Table 8). Further we observed, of the 112 potential miR-155 targets 68 
(~61 %) were down regulated and inversely correlated with miR-155 ' s strong up 
regulation, as expected if indeed they are being regulated by miR-155. Interestingly, the 
remaining 44 identified candidate targets (~39%) were actually up regulated and 
positively correlated with miR-155's expression despite the influence of miR-155 
including a number of known targets, e.g. Suppressor of Cytokine Signaling-! (SOCSI), 
hypoxic inducible factor 1-alpha (HIFla) and C/EBP~, Figure 19-A and Table 8. Most 
other predicted targets of specific miRNAs were near evenly split (50/50) between those 
targets inversely correlated to their respective miRNA, as expected, versus those targets 
that were positively correlated with their respective miRNA (data not shown) . This 
observation is consistent with previous miRNA:mRNA correlation observations and 
suggests a more complex schemes of regulation beyond simple down regulation of a 
target or pathway dis-inhibition by down regulating an inhibition [209]. 
In LPS stimulation, we peiformed correlation analysis on a total of 22 
differentially regulated miRNAs, selected based on the criteria of either a +/-1 log2 fold 
increase or decrease respectively. miR-124 was also included, which we observed a 
significant down regulation but only -0.85 log2 fold change, based on its previous 
association with microglial functionality [56]. Collectively, we have identified 1674 
potential miRNA:mRNA interactions, which constitutes ~45% of the average number of 
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correlated genes under LPS stimulation of primary microglia that potentially are 
regulated by miRNA (data not shown). 
Table 7: miR-155 Correlation Analysis - Microglial genes down regulated under LPS 
Stimulation 
c 
0 
·- '"' Log2 "CO.s Symbol Description ~ ~ Fold Power 
~r.. Change 
u 
Faml05a family with sequence similarity 105, member A -0.94 -3.370 7.86E-10 
Inpp5d[84] inositol polyphosphate-5-phosphatase D -0.94 -2.482 3.53E-10 
Arvcf armadillo repeat gene deleted in velo-cardio- -0.92 -2.036 1.32E-07 facial syndrome 
Rapgef5 Rap guanine nucleotide exchange factor (GEF) 5 -0.92 -1.741 1.02E-08 
Ssh2 slingshot homolog 2 (Drosophila) -0.88 -1.661 4.28E-07 
Tspan14 tetraspanin 14 -0.95 -1.537 2 .80E-09 
Myb[210] myeloblastosis oncogene -0.60 -1.434 2.77E-05 
Reck reversion-inducing-cysteine-rich protein with -0 .94 -1.369 1.49E-07 kazal motifs 
Lat2 linker for activation ofT cells family , member 2 -0.91 -1 .270 2.69E-07 
Arhgap18 Rho GTPase activating protein 18 -0.92 -1.219 5 .53E-08 
Card11[211] caspase recruitment domain fami ly, member 11 -0.56 -1.165 5.49E-05 
Mafb v-maf musculoaponeurotic fibrosarcoma -0.78 -1.130 4.54E-08 
oncogene family, protein B (avian) 
Socs6 suppressor of cytokine signaling 6 -0.66 -1.124 2.14E-07 
Tmem144 transmembrane protein 144 -0.83 -1.107 3.68E-06 
Ddo D-aspartate oxidase -0.76 -1.102 3.64E-07 
Entpd1 ectonucleoside triphosphate diphosphohydrolase -0.68 -1.077 1.05E-07 1 
Rcbtb2 regulator of chromosome condensation (RCC1) -0.79 -1.067 1.60E-06 
and BTB (POZ) domain containing protein 2 
Reps2 RALBP1 associated Eps domain containing -0.63 -1.053 7 .89E-07 protein 2 
Arhgap5 Rho GTPase activating protein 5 -0.77 -1.036 1.08E-06 
Tcf712 transcription factor 7-like 2 , T -cell specific , -0 .98 -0.9855 6 .03E-06 HMG-box 
Rreb1[210] ras responsive element binding protein 1 -0.91 -0 .986 1.43E-07 
Agl amylo-1 ,6-glucosidase, 4-alpha- -0.93 -0 .960 2 .82E-07 glucanotransferase 
Add3 adducin 3 (gamma) -0.80 -0 .905 1.83E-07 
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Antxr2 anthrax toxin receptor 2 -0.88 -0.903 1.19E-06 
Satb1[212] special AT-rich sequence binding protein 1 -0.79 -0.873 1.98E-06 
Rnfl66 ring finger protein 166 -0.94 -0.866 5 .91E-06 
Enpp1 ectonucleotide -0.75 -0.849 2.10E-06 pyrophosphatase/phosphodiesterase 1 
Meis1[213] Meis homeobox 1 -0.88 -0 .849 1.52E-05 
Mphosph9 M-phase phosphoprotein 9 -0.84 -0.817 3.11E-06 
Nfia nuclear factor IIA -0.84 -0.809 2.78E-07 
Lcorl ligand dependent nuclear receptor corepressor- -0.93 -0.791 4 .67E-07 like 
Ski[214] ski sarcoma viral oncogene homolog (avian) -0.90 -0.775 2.64E-05 
Dcun1d4 DCN 1, defective in cullin neddylation 1, domain -0.86 -0 .758 5.91E-06 
containing 4 (S. cerevisiae) 
Syne1 synaptic nuclear envelope 1 -0.88 -0.727 4.04E-06 
Sortl sortilin 1 -0.89 -0.722 6.00E-06 
Relll RELT-Iike 1 -0.72 -0.711 8.42E-06 
Dixdcl DIX domain containing 1 -0.73 -0.705 1.40E-05 
Csflr[215] colony stimulating factor 1 receptor -0.80 -0.692 8.23E-06 
Haus3 HAUS augmin-Iike complex , subunit 3 -0.82 -0.680 1.44E-05 
Gabra4 gamma-aminobutyric acid (GABA) A receptor, -0.83 -0.665 2.57E-06 
subunit alpha 4 
Akap10 A kinase (PRKA) anchor protein 10 -0.91 -0.660 1.65E-05 
Cep68 centrosomal protein 68 -0.67 -0.659 8.79E-05 
Rufy2 RUN and FYVE domain-containing 2 -0.96 -0.634 3.60E-06 
MegflO multiple EGF-like-domains 10 -0.90 -0.611 1.75E-05 
Tbck TBC1 domain containing kinase -0.91 -0.600 9.79E-06 
Zc3h12b zinc finger CCCH-type containing 12B -0.79 -0.597 4.85E-05 
Fads1 fatty acid desaturase 1 -0.91 -0.585 4.98E-06 
Zmym2 zinc finger , MYM-type 2 -0.87 -0.581 4.63E-05 
Te1f1 tel om eric repeat binding factor 1 -0.88 -0.574 2.03E-05 
Tnpo1 transportin 1 -0.86 -0.558 8.55E-05 
Igsfl1 immunoglobulin superfamily, member 11 -0.67 -0.540 7.77E-06 
Mbtd1 mbt domain containing 1 -0 .83 -0.533 5.42E-05 
Trim2 tripartite motif-containing 2 -0.76 -0.515 2.27E-05 
Nudt4 nudix (nucleoside diphosphate linked moiety X)- -0.78 -0.510 1.59E-05 type motif 4 
Ogn osteoglycin -0.72 -0.496 9.79E-05 
Ergicl endoplasmic reticulum-golgi intermediate -0.91 -0.480 2.18E-05 
compartment (ERGIC) 1 
Ankrd12 ankyrin repeat domain 12 -0.63 -0.479 1.91E-05 
Csnk1g2 casein kinase 1, gamma 2 -0.94 -0.479 1.96E-05 
Pskh1 protein serine kinase H1 -0.95 -0.467 2.98E-05 
Slc39a10 solute canier family 39 (zinc transporter), -0 .86 -0.448 3.47E-05 
member 10 
Clcn3[216] chloride channel 3 -0 .74 -0.442 7 .51E-05 
Grsfl G-rich RNA sequence binding factor 1 -0 .81 -0.422 4.48E-05 
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Rcorl REST corepressor 1 -0.86 -0.417 3.78E-05 
As ph aspartate-beta-hydroxylase -0.85 -0.414 3 .94E-05 
Ikbip IKBKB interacting protein -0.86 -0.411 9.88E-05 
Dclre1a DNA cross-link repair 1A, PS02 homolog (S. -0.90 -0.372 7 .23E-05 
cerevisiae) 
Tram1 translocating chain-associating membrane -0.86 -0.365 7.87E-05 protein 1 
Fbxo22 F-box protein 22 -0 .90 -0.351 7.44E-05 
Table 8: miR-155 Correlation Analysis- Microglial genes up regulated under LPS 
Stimulation 
= 0 
:c 8 Log2 
Symbol Description .!'t Fold Power f: ell sr.. Change 
u 
Socs1 [55,215] suppressor of cytokine signaling 1 0.89 2.744 1.96E-08 
Gpr85 G protein-coupled receptor 85 0.92 2.211 1.67E-07 
Ell2 elongation factor RNA polymerase II 2 0.93 2.094 6.35E-10 
Fam102b family with sequence similarity 102, member 0.93 1.843 2 .05E-08 B 
B3gnt5 UDP-GlcNAc:betaGal beta-1,3-N- 0.95 1.721 1.74E-08 
acetylglucosaminyltransferase 5 
Fgl2 fibrinogen-like protein 2 0.87 1.695 4.13E-07 
Ets1 [213] E26 avian leukemia oncogene 1, 5' domain 0.91 1.523 8.64E-08 
Hivep2[152] human immunodeficiency virus type I 0.95 1.476 5.03E-08 
enhancer binding protein 2 
Mier3 mesoderm induction early response 1, family 0.95 1.403 4.90E-08 
member 3 
C/ebpf3 [152] CCAAT/enhancer binding protein (C/EBP), 0.86 1.386 5.30E-07 beta 
Il13ra1 [217] interleukin 13 receptor, alpha 1 0.88 1.382 1.24E-07 
Rapgef2 Rap guanine nucleotide exchange factor 0 .94 1.310 1.39E-07 (GEF) 2 
Spred1 sprouty protein with EVH-1 domain 1, related 0.96 1.254 1.59E-07 
sequence 
S1pr1 sphingosine-1-phosphate receptor 1 0.89 1.249 9.70E-08 
Ikbke[218] inhibitor of kappaB kinase epsilon 0.94 1.234 4.68E-07 
Sgk3 serum/glucocorticoid regulated kinase 3 0.92 1.035 5 .15E-08 
Samhd1 SAM domain and HD domain, 1 0.92 1.023 9.24E-08 
Gdf6 growth differentiation factor 6 0.85 0.975 4.59E-05 
Morc3 microrchidia 3 0 .87 0 .888 1.66E-06 
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Myold myosin ID 0.80 0.837 3.79E-06 
Rictor RPTOR independent companion of MTOR, 0.92 0.837 2.27E-07 
complex 2 
Tle4 transducin-like enhancer of split 4 , homolog 0.96 0.795 8.86E-07 
of Drosophila E(spl) 
Satb2 special AT-rich sequence binding protein 2 0 .74 0.790 6.62E-05 
Atad2b ATPase family, AAA domain containing 2B 0.93 0 .787 1.19E-06 
Hifla[219] hypoxia inducible factor 1, alpha subunit 0.96 0.760 1.10E-06 
Cd47[220] CD47 antigen (Rh-related antigen, integrin- 0.93 0 .750 7.77E-06 
associated signal transducer) 
Vcpip1 valosin containing protein (p97)/p47 complex 0.92 0.706 1.26E-06 interacting protein 1 
Asfla ASFl anti-silencing function 1 homolog A (S. 0.91 0.694 1.84E-06 
cerevisiae) 
Whscll1 Wolf-Hirschhorn syndrome candidate 1-like 1 0.91 0.663 4.19E-06 (human) 
Cdk14 cyclin-dependent kinase 14 0.91 0.660 6 .07E-05 
Syvn1 synovial apoptosis inhibitor 1, synoviolin 0.82 0.641 3.91E-05 
G3bp2 GTPase activating protein (SH3 domain) 0.91 0.623 4.05E-06 binding protein 2 
Xiap X-linked inhibitor of apoptosis 0.96 0.611 5.02E-06 
Lrrc59 leucine rich repeat containing 59 0.85 0.595 1.41E-05 
Kalrn kalirin, RhoGEF kinase 0.86 0.590 3.97E-06 
Rab22a RAB22A, member RAS oncogene family 0 .86 0 .578 6.59E-06 
Med131 mediator complex subunit 13-like 0.73 0.542 6 .31E-06 
Pkn2 protein kinase N2 0.91 0.528 1.28E-05 
Carhsp1 calcium regulated heat stable protein 1 0 .68 0.514 6.13E-05 
Dmtf1 cyclin D binding myb-like transcription factor 0.86 0.506 1.36E-05 1 
Ar15b ADP-ribosylation factor-like 5B 0.96 0.476 3.89E-05 
Dennd1b DENN/MADD domain containing 1B 0.81 0.476 1.57E-05 
Kbtbd2 kelch repeat and BTB (POZ) domain 0.94 0.451 5 .61E-05 
containing 2 
Ythdc2 YTH domain containing 2 0.89 0.426 9.64E-05 
Enrichment Analysis of miRNA Correlated Target in Ml-skewed Primary Microglia 
We next approached how each miRNA contributes in shaping the Ml activation 
of microglia. To determine the role that each miRNA plays in shaping the Ml phenotype 
we next took our correlated lists of potential targets from each identified miRNA 
individually and performed enrichment analysis on select miRNA's correlated targets 
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using the IPA tool as detailed above. We selected the miRNAs based on a combination of 
significance and having an average LPS expression greater than 50%, referenced to miR-
709 as previously describe above, to perform enrichment analysis. This combination 
yielded four miRNAs that are up-regulated miRNAs: miR-155, -297b-5p, -lOb, and-
376a and six miRNAs that are down regulated miRNAs: miR-124, -2132,-2133,-700,-
689, and -762. By combining data from all of the miRNAs differentially regulated by 
LPS stimulation and sorted based on -log(p-value) score as determined by IPA 
transcriptional factor analysis, we identified over 153 different transcriptional networks 
that potentially may be altered though miRNA-mRNA interactions. Figure 20-A depicts 
the top 15 networks identified under LPS stimulation. Interestingly, down regulation of 
miR-689 and miR-124 appeared to have more of impact on gene transcriptional 
networks, than the upregulation of miR-155 based on -log(p-value) score, Figure 20-A. 
We identified that miR-689 potentially alters the transcriptional networks of many 
canonical pro-inflammatory pathways including NF-KB-RelA, HMGBl, and NFATC2, 
as well as some novel pathways e.g. SREBF1, BCL3, ZFP36, STAT6, SP3, and 
HDAC10, and LIMD1. Further, reductions in miR-124, a miRNA already known to alter 
microglial phenotype, were identified as potentially regulating ELK4, NCOA3, NFE2L2, 
STATl and PAX7 [56] . Interestingly, miR-155 potentially regulated only three 
transcriptional networks, the most significant being STAT3, HOXA9, and CEBP-&/~. 
Down-regulation of miR-2132 potentially contributes to the regulation of the 
transcriptional networks of EPASl, CREB5, BRD8 and RFCl. Lastly, up-regulation of 
miR-376a potentially altered the transcription network of PRDM16. 
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Further, we observed differential regulation in: ATF2, SP3, CEBP-~, and 
NFE2L2 networks have predicted regulation by miRNAs miR-700, miR-689, miR-155 
and miR-124 respectively. Interestingly, our identified transcriptional networks altered 
many of the same transcriptional networks recently identified by Schmeier, S. et al ., 
which regulate peripheral monocyte differentiation into macrophages [221]. Furthermore, 
over 75% of the transcriptional circuits indentified by Schmeier,S. et al . either are 
regulated or have a similar family member's regulated by the 8 miRNAs differentially 
regulated under LPS stimulation in primary murine microglia. 
Collectively, we have observed a signature miRNA pattern for M1 classically 
activated primary microglia through LPS stimulation and demonstrated how miR-155 
dominates the response, while other miRNAs potentially contribute to shaping this 
dynamic phenotype. Specifically, our analysis identified a novel miRNA, miR-689, 
playing a key role in enabling the M1 pro-inflammatory phenotype by regulating many 
key pro-inflammatory pathways, e.g. NF-KB-RelA, HMGBl and NFATC3/C2 and has 
corroborated previous findings for a similar role for miR-124. On the other hand, our 
analysis suggests that miR-155 is not as critical for the initial (0-2 hours) [TLR 
stimulation, but is critical for STAT1/STAT3 activation mediating the late phase, post 2-
4 hours , pro-inflammatory response genes 
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M2-Alternative Activation of Primary Microglia 
Enrichment Analysis of Differentially Regulated Genes- M2a-Skewing 
Using a similar approach as described above, we found that primary microglia 
altered 66 key biological functions under IL-4 stimulation. Consistent with our 
expectations , the "Inflammatory Response" was the most significantly enriched function 
(p < 3.70x10-26) and associated with over 84 enriched genes , Figure 15-A. Further, 
differential regulation in the chemokine network altering both 'cellular movement' and 
'Immune cell trafficking ' functionality was the next two most significant (p < 1.75 xl0-16 
for both) with approximately 60 genes associated with each function, Figure 15-A. 
Interestingly, these functional categories matched almost identical to the LPS 
stimulated results and caused us to question if we were really capturing to distinct 
phenotypes. To determine if these functional gene enrichments in the "Inflammatory 
Response-Immune response" function were identical between the LPS and IL-4 
stimulated primary microglia we next compared the two gene sets and found only 33 
common genes out of a total of 292 genes, 11.3% overlap between the two conditions, 
Figure 16. From those observations , we concluded that while the top 10 functions are 
similar between the IL-4 and LPS stimulation, different genes or functionality ultimately 
yield different activation phenotypes . 
To identify key functions down-regulated by IL-4 stimulation we pe1formed 
similar functional analysis only using the most significantly down-regulated genes 
(p<0.0001) from the IL-4 stimulated primary microglia data set. Interestingly , the 
"Inflammatory Response" was also the most significantly , (p < 2.50 xl0-9) , down-
100 
regulated function under IL-4 stimulation, Figure 15-B. The gene list suggests that IL-4 
stimulation differentially alters the immune response. For example, down-regulated 
genes include: CD28, a potential T-cell co-activator, arachidonate 5-Iipoxygenase 
(ALOX5) , which converts arachidonic acid into pro-inflammatory leukotriens, and 
caspase recruitment domain family 11 (CARD11), which plays a key role linking T-cell 
receptor signaling activation to NF-KB activation [222]. Collectively, these alterations 
lead to significant reductions in T -cell proliferation, differentiation, and activation, 
consistent with IL-4s canonical function ofT H2 skewing in the periphery, data not shown. 
Further, we also observed significant down-regulation of lipid metabolism (p < 9.85x10-5) 
and targeted inhibition of 'cellular developmental' factors with down-regulation in T-
cells differentiation, Figure 15-B. 
We next characterized the underlying transcriptional regulators of the IL-4 
stimulated profile observed in primary microglia. As expected with canonical IL-4 
stimulation, STAT6 was the most significantly (p< 6.06x10-16) activated transcription 
factor, Figure 17-A. Further, under IL-4 stimulation, we observed significant reductions 
in STAT1, STAT3, STAT4 and IRF3a genes all playing critical roles in the pro-
inflammatory response to LPS, Figure 17-A. We detected significant but modest up-
regulation of many transcription factors that are also seen by M1 stimulation including: 
NF-kB (NfkBl-RelA), JUN, ERG 1, C/EBP-~, and IRF1, Figure 17-B. Further we 
observed significant inhibition of many of the nuclear receptor family including: PPARy, 
NRlH family, THR~ and RXRa under both LPS and IL-4 stimulation, Figure 17-C. 
Interestingly, There is a growing body of evidence to support altered nuclear receptor 
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family contributes to microglial activation, which has been demonstrated to be clinically 
relevant in MS patients [223 ,224]. We also uncovered GLI Family Zinc-finger 2 (GLI2) 
as a significantly up-regulated transcription factor after IL-4 stimulation (p< 8.71x 10"9), 
which is part of the sonic-hedgehog signaling pathway and can limit differentiation ofT-
cells [225,226]. However , most importantly we identified genes that are actively 
suppressed by LPS stimulation and conversely up-regulated by IL-4 stimulation: STAT6, 
Tripartite motif-containing 24 (TRIM24) , cyclic AMP response element-binding-! 
(CREBI) , IRF2 and PPARa/y genes , Figure 17-D. Taken together, these data identify 
the key transcriptional network and functions altered in Ml-skewing and M2a-skewing 
conditions by the application of systems biological approaches. 
miRNA Correlation Analysis in M2a-skewed Primary Microglia 
We next performed the corresponding correlation analysis on our IL-4 stimulated 
primary microglia to identify key potential miRNA:mRNA interactions that regulate 
switching from a MO to an M2a phenotype. Overall, we applied this approach to 20 
different miRNAs that represent the most up or down regulated miRNAs under M2a 
skewing conditions. To identify critical potential miRNA:mRNA interactions that 
regulate switching from a MO to the m2a phenotype we performed correlation analysis on 
the following critical up-regulated miRNAs: miR-449a,- 295,-145, -297-5p, and -214 
and the following down regulated miRNAs: miR-124, -154*, -2133, -384-5p, -2135 , -
3473, -326, -2132,-133 , -383 , -2861 , -2138 , -762, -1224 and -711. Overall, this process 
identified 724 potential targets , ~66% of average number of correlated gene under IL-4 
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stimulation of primary microglia that potentially are regulated by miRNA:mRNA 
interactions. 
Enrichment Analvsis ofmiRNA Correlated Target in M2a-skewed Primarv Microglia 
We next sought to better understand functionally what each miRNA targets, 
therefore we next took our correlated list of potential targets from each identified miRNA 
by IL-4 stimulation , as performed for LPS stimulated miRNAs . We also performed 
enrichment analysis on select miRNA 's correlated targets using the IPA tool as detailed 
above for IL-4 differentially regulated miRNAs. This combination yielded four miRNAs 
that are up-regulated miRNAs: miR-449a, -145 , -297b-5p, and -214 and eight miRNAs 
that are down regulated miRNAs: miR-711 , -124, -2133,-2135 ,-2132, -2861,- 2138,-
762 , and -1224. Under M2a-skewing conditions we identified over 268 different 
transcriptional networks that can potentially be altered though miR-mRNA interactions. 
Interestingly , down regulation of miR-711 , mir-124 and miR-2133 appeared , based on-
log(p-value) score, as critical as upregulation of both miR-145 and miR-449a in 
establishing the M2a phenotype, Figure 20-B . We identified that miR-711 , appears to 
play a similar role as miR-689 does under LPS stimulation , potentially alters the 
transcriptional networks of many canonical pro-inflammatory pathways including NF-
KB-RelA , IRFl/2, SP1 , IkB, and API, as well as some novel pathways e.g. C/EBPE , 
BCL10, and ZFP36. However, a key difference from miR-689 is that miR-711 
potentially regulates key elements of the PPARy network, a transcription factor that has 
been implicated in the establishment of the M2a phenotype in macrophages [227]. 
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Interestingly, miR-145 potentially altered the transcription networks of ETS 1 and 
HOXB4. miR-449a potentially regulates the transcriptional networks of Aryl-
hydrocarbon receptor (AHR), USF2, EZH2, Notch, and Wnt/~-catenin signaling 
pathways. 
As we did with LPS stimulated miRNAs, the IL-4 stimulated miRNAs were also 
compared to the list of key transcriptional circuitry associated with peripheral monocyte 
differentiation into macrophages as described above [221]. As observed in M1-skewing 
conditions, rniRNAs differentially expressed by IL-4 stimulation regulate many of the 
same transcriptional networks, but primarily through different miRNAs. Specifically, 
ATF2, SP3, and ELK1, all have transcriptional networks potentially regulated by a single 
miRNA, miR-711 . Further, C/EBP~, and NFE2L2 networks have predicted regulation 
by miRNAs miR-449a and miR-124 respectively. 
Collectively, we have observed a signature miRNA pattern for M2a alternatively 
activated primary microglia through IL-4 stimulation and demonstrated how up 
regulation of miR-449a and rniR-145 is critical to the IL-4 response. Further, our 
analysis identified down regulation of both miR-711 and miR-124, playing a key role in 
enabling key alternative activation pathways in microglia, e.g. PPARy and NFE2L2 
respectively. Overall, our data suggests that down regulation of miRNAs is as critical to 
' release' microglia from the MO state, miR-711 and miR-124, as upregulation of miR-145 
and rni R-449a contribute to the establishment of the M2a state. 
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Figure 14 Summary Functional Analysis (Top-10).· Ml-Classically Activated Microglia 
Gene enrichment analysis of differentially regulated mRNA expression data identifying 
the Top 10 highly enriched "Biological Functions" up-regulated (A) and down-regulated 
(B) in Ml-classically activated primary Microglia. The highly enriched functions were 
identified from Ingenuity® Knowledge Base functional analysis and ranked based on-
Log(p-value) score. (p < 0.05 corresponds to -Log(p-value) > 1.30) 
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Figure 15: Summary Functional Analysis (Top-10): M2a-Aleternatively Activated 
Microglia 
Gene enrichment analysis of differentially regulated mRNA expression data identifying 
the Top 10 highly enriched "Biological Functions" up-regulated (A) and down-regulated 
(B) in M2a-alternatively activated primary Microglia. The highly enriched functions were 
identified from Ingenuity® Knowledge Base functional analysis and ranked based on -
Log(p-value) score. (p < 0.05 corresponds to -Log(p-value) > 1.30) 
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Figure 16: Representative comparison of gene enrichment between M I and M2a-skewing 
for a common function: "inflammatory-Immune Response" 
Representative detailed analysis of the "Inflammatory-Immune Response Function" by 
Venn-Diagram analysis demonstrates low (11.3 %) commonality in enriched genes 
comprising the "Inflammatory-Immune Response Function" despite the same function 
being mapped in both Ml-skewing and M2a-skewing phenotype. 
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Figure 17: Transcriptional Network Regulatory Analysis: Comparison between Ml and 
M2a phenotypes in microglia 
Comparison of transcriptional network regulation based on enrichment of targets and 
expression changes in key transcription factors between Ml-classically activated (red) 
and M2a-alternatively activated (blue) conditions in primary microglia (A-D) . (A) 
Comparison of differentially regulated transcriptional networks between Ml and M2a 
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phenotypes, Ml up-regulated/M2a down-regulated (A-Top) and M2a up-regulated/Ml 
down-regulated (A-bottom). Transcriptional networks that are up-regulated in both the 
Ml and M2a phenotype in microglia. (B) Transcriptional networks that are down 
regulated in both the Ml and M2a phenotypes in microglia. (C) A comparison of the 
most significant differentially regulated Transcriptional networks between Ml and M2a 
phenotypes (D). 
109 
A 
t:xperimental 
Ohsen·atjons 
Fold Change 
& Power 
Key 
Up/Down 
regulated 
miRNAs 
II= -2 1.000 
Filler Cril:fria: 
I. p<O.OOO I 
::! . SLrong Correlat ion 
(r >0.5 orr <0.5) 
miRNA Taroet Enrichment Anai \'Sis 
Functions: 
Pathway!\ 
Tra11 sc..·riptional Networks 
Network:" 
II =42) J 
For LPS 
Stimulation 
Potential miRNA Target Sourn-s 
Target ScanffarBasc 
Ingenuity® 
II= 108 1 \ 
1\ 
n = 45 j n= 67 Per unjQUC srl.ill Correla(ed 
Targets 
Figure 18: miRNA Summary Systems Biology Analysis Schema. 
Methodology schema employed for miRNA correlation analysis and miRNA potential 
target enrichment analysis. Briefly, we performed Pearson's correlation analysis to 
identify highly correlated genes with select miRNA expression differences. This gene set 
was then compared with miRNA-mRNA targeting database gene sets for that miRNA. 
Select miRNAs correlated targets were then uploaded to Ingenuity® Systems and 
enrichment analysis was performed to identify functions targeted, pathway analysis, 
transcriptional networks altered and Network analysis that the miRNA targets, Numbers 
denote an example correlation analysis for miR-155. 
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Figure 19: Representative miRNA:mRNA Correlation Analysis for miR-155 
Venn-Diagram analysis of representative miRNA:mRNA correlation analysis for miR-
155 . Comparison of two or more bioinformatical-based target sets publically available 
(e .g. miRanda Database, Ingenuity or TargetScan) were used to generate a list of 
predicted. Correlated genes list was a filtered genes based on two key criteria: First a 
Fold change p < 0.0001 and secondly, were strongly correlation (r > 0.5 orr< -0.5) with 
the specific miRNA. Venn-diagram analysis was used to determine the intersection gene 
set of predicted targets that were correlated with our appropriate skewing condition, e,g, 
112 genes for miR-155. 
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Figure 20: Top-15 Transcriptional Network Regulatory Analysis Altered by miRNA 
correlated Targets 
Enrichment analysis was performed on select miRNA correlated targets using the 
Ingenuity® Systems for Ml and M2a phenotypes separately. For all miRNAs of a 
specific phenotype analyzed regulated transcriptional networks identified as enriched 
where grouped together and sorted by -Log(p-value) . Identified transcriptional networks 
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where further compared to and filtered against the same transcriptional network identified 
regulating the M1 or M2a phenotypes performed as part of the mRNA systems biologic 
analysis identified in figure 15 to better determine the key miRNAs that potentially 
regulate microglial phenotype. The top 15 transcriptional networks that were enriched 
miRNA:mRNA potential interactions are identified in (A) M1-skewing conditions and 
(B) M2a-skewing conditions, ranked based on -Log(p-value) score. (p < 0.05 corresponds 
to -Log(p-value) > 1.30). 
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DISCUSSION 
Performing a system biology analysis yields so much data about different 
networks , pathways , functions that are altered in the various conditions , are both daunting 
and challenging. Modern tools , such as the IPA tool employed here are getting better and 
better every year, but one still has much work to interpret and make sense of all the data. 
After going through all the data from the various different analysis the IPA tool provided, 
perhaps the clearest views of the cellular response to the three different conditions tested 
in this research was best looks at from how the various transcriptional networks were 
altered. Overall , This provided information on transcriptional networks that were 
activated, down regulated and actively suppressed. 
This approach is supported by an emerging view the phenotype is no longer just 
the current suite of genes express, but the combination of the genes and regulatory 
elements , e.g. miRNAs, that control the gene' s expression [228]. Since we probed for 
both gene and miRNA expression levels that primarily left the transcriptional networks to 
gain insight in to these various phenotypes of the microglia. 
Comparison of Key Microglial Regulators in the Ml, M2a and MO phenotypes 
Ml-skewed primary microglia demonstrated activation along many well-
characterized pro-inflammatory transcriptional networks including: NF-KB (NfKBl-
RelA), AP-1, STATs 1-4, and IRFs 1 ,3,7, and 8 [229-231]. Whereas, M2a-skewed 
primary microglia demonstrated a unique activation signature primarily through known 
IL-4 signaling pathway mediators including: STAT6, CREB1 and IRF2 [232-234]. One 
114 
of the most striking observations when comparing the Ml phenotype to the M2a 
phenotype was the strong differential regulation in the JAK/STAT family of transcription 
factors, Figure 17. There was also similar differential regulation observed in the IRF 
family as well, but to a much less extent, Figure 17. This analysis has also identified 
TRIM24 as the most differentially regulated transcriptional network between the Ml and 
M2a phenotypes in primary microglia. In addition , we observed profound suppression of 
many transcriptional networks in the nuclear receptor family under both Ml and M2a 
phenotypes suggesting their activity is necessary in the maintenance of the MO resting 
state of microglia. Interestingly, we did observe a key difference in PPARa/y regulation, 
which appears to be selectively spared under M2a-skewing of primary microglia, which 
has been linked with M2a skewing in peripheral macrophages [227]. 
Differential lAX/STAT Signaling in Microglia Activation 
We observed significant differences in the transcriptional regulation between LPS 
and IL-4 stimulation in primary microglia particularly in the activation patterns of the 
JAX/STATs. At the four-hour time point, STAT3 and STATI signaling dominate the 
active transcriptional network in LPS stimulated primary microglia. This is consistent 
with similar observations in peripheral macrophages stimulated with LPS that 
demonstrate marked reductions in TLR/NF-KB signaling after~ 1-2 hours and strong up 
regulation of STAT1/STAT3 signaling [230,231]. The neuroinflammatory role of 
STAT3 in microglia has been strongly suggested where multiple studies have 
demonstrated inhibition of STAT3 or STAT3 activation mitigates LPS induced 
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inflammation in microglia [235,236]. Further, to underscore the prominence of STAT3 
mediation of the pro-inflammatory state Qin, H. et al. recently demonstrated that 
enhancing STAT3 signaling, through conditional knockout of suppressor of cytokines 3 
(SOCS3), a STAT3 endogenous antagonist, in peripheral macrophages increases the 
severity of EAE mouse model of MS [237]. Interestingly, adoptive transfer of M2-
alternatively activated peripheral macrophages markedly reduced the severity of EAE 
[237] . To our knowledge this is the first time STAT3/STAT1 axis has directly shown to 
be the dominating active signal pathway promoting neuroinflammation in primary 
microglia . 
While Ml-skewed microglia are dominated by STAT3/STAT1, M2a-skewed 
microglia are dominated by STA T6 signaling. Interestingly, we observed strong down 
regulation of STAT6 signaling under LPS stimulation and marked up-regulation of 
STAT6 signaling under IL-4 stimulation, suggesting active repression of the STAT6 
pathway under LPS stimulation. STAT6 is the canonical activated transcription factor in 
the IL-4 signaling pathway so our observations are entirely consistent with IL-4 
stimulation [232,238]. 
Differential IRF Signaling in Microglia Activation 
We also observed very strong induction of IRF3 signaling during LPS 
stimulation. Recently, Tarassishin, L. et al . demonstrated that IRF3 could alter the 
microglial phenotype, mediated through the Phosphatidylinositol 3-kinase (PI-3k)/AkT, 
from Ml to M2 and found strong up-regulation in IL-10 and marked reductions in the IL-
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1b signaling [239]. Interestingly, IRF3 signaling is differentially regulated in peripheral 
macrophages with IRF3 initially up-regula.ted within~ 1-2 hours post LPS stimulation, 
but marked reductions are observed four hours and remain at low levels [230,231]. Taken 
together, this suggests that IRF3 signaling may play a key role in shaping the microglial 
M2b versus a pure M1 phenotype in response to LPS stimulation. Further, this suggests 
that IRF3 signaling my represent a critical difference between CNS resident microglial 
and circulating monocytes/macrophages where therapeutic targeting of the Pl3k/Akt with 
agonist could potentially bock pro-inflammatory conditions. 
Under IL-4 stimulation we observed activation of the IRF2 signaling. Paludan, 
SR. et al. demonstrated that inhibition if iN OS activity upon either viral infected 
macrophages or Interferon-gamma (IFN-y) is mediating through IRF2 [234]. In an IRF2-
,_ microglia mouse model and upon viral stimulation, Schoneboom B. et al. demonstrated 
that IRF2 regulates the Nitric Oxide (NO) pathway both pre & post-transcriptionally 
[240]. However, initial studies in LPS stimulated peripheral macrophage demonstrated a 
more prominent role for IRF1 in NO production, leading to the hypothesis that IRF2 can 
compete with IRF1 [234,241]. 
TRIM24's role in M2-Alternative Activation o{Microglia 
Perhaps the most interesting observation has uncovered is a novel transcription 
factor, Trim24, also known as Transcriptional intermediary factor 1-alpha (TIFla), that 
is strongly differentially regulated between the Ml versus M2a phenotype. Little is know 
about the role Trim24 may play in the inflammatory response and even less is know of its 
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role in microglia. However, we observed strong down regulation of Trim24' s 
transcriptional activity in Ml-skewing conditions, whereas M2a skewing strongly up 
regulated Trim24' s activity. The tripartite motif family is more than 30 members total, 
and Trim24 is one of only four members that include a bromo-domain, which is known to 
act as a chromatic remodeling activity and is a known tumor suppressor gene [242]. 
Further, Trim24 has been shown to interact through yeast-two hybrid studies with many 
nuclear receptors, in particular Trim24 is known to antagonize the RARa signaling 
pathway [243]. Recently, Tisserand, J. et al. demonstrated how Trim24 may potentially 
regulate the inflammatory response through RARa inhibition [244]. Specifically, 
Tisserand, J. et al. demonstrated that in Trim24_,_ mice there is reduced inhibition on the 
RARa pathway , since the loss of Trim24 inhibition, which leads to over activation of 
both the STATl and interferon pathways, whereas when Trim24 is present both pathways 
are repressed [244]. Interestingly, we did observe strong up-regulation of STAT I by LPS 
stimulation, consistent with Trim24's down regulation. However, by IL-4 stimulation we 
saw marked activation of the RXR signaling pathway despite microglial activation. This 
may seem counter-intuitive at first, but we posit that Trim24' s preferential binding to 
RAR versus RXR is enabling microglia to preferentially activate the RXR pathway over 
the RAR pathway. RXR pathway activation may be critical for IL-4 signaling, since 
Grenningloh, R. et al. have demonstrated that RXR inhibition is sufficient to block T H2 
skewing and prevents allergic lung inflammation [245]. Taken together, this suggests 
Trim24 could be novel therapeutic target for agonistic activity as a means of blunting the 
STATl mediated pro-inflammatory phenotype. 
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The Role ofNuclear Receptors in the MO Resting State ofMicroglia 
Under both the M1 or M2 phenotypes we observed marked reductions in the 
transcriptional activity of many nuclear receptors relative to the MO resting phenotype 
including: Proxisome proliferator-activated receptor alpha/gamma/delta (PPARa/y/6), 
Liver X receptor-alpha/beta (LXRa/~), glucocortioid receptor (NR3C1), Thyroid 
hormone receptor alpha/beta (THR-a/~), and the retinoic acid receptor-alpha (RARa). 
There is a growing body of literature linking innate inflammatory processes under M !-
skewing conditions to reduced activation of the various nuclear receptors , e.g. PPARy/6, 
RXR and LXR systems [223,246-251]. The necessity of reduced nuclear receptor 
activity in enabling the M1 phenotype is underscored by the ability of PPARy/6, RXR or 
LXR nuclear receptor agonists to blunt many of the pro-inflammatory mediators under 
LPS stimulation [247-249,251]. Further, these nuclear receptor agonists have all 
demonstrated to exert anti-inflammatory activity in peripheral macrophages and reduce 
macrophage mediated disorders such as atherosclerosis [252-254] . In microglia, 
PPARa/6, RXR and LXR agonists have all demonstrated to inhibit pro-inflammatory 
cytokine levels including: iNOS, IL-6, TNF-a, and IL-l~ under LPS stimulation [255-
257]. Recently , Achiron, A. et al. demonstrated similar dysregulation of the nuclear 
receptor family in human peripheral blood of pre-disease state of MS suggesting this is a 
critical aspect in the progression of MS from pre-clinical to clinical states [223]. 
Based on the strong down regulation of the nuclear receptor family in the Ml 
phenotype and the growing body of evidence linking nuclear receptor activation with 
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anti-inflammatory activity , we originally anticipated that M2a-skewing to up-regulate the 
activity of the nuclear receptor family. Surprisingly, many of the same nuclear receptors 
seen down regulated under LPS stimulation were also down regulated in IL-4 
stimulation, albeit to a much lesser extent. However, we observed two critical 
differences between the Ml and M2a phenotypes where there was more than 3 fold 
increase in the transcriptional activity of both PPARy and RARa upon IL-4 stimulation. 
Interestingly, therapeutic application of the PPARy agonists , pioglitazone, has been 
demonstrated to skew microglia from Ml to the M2 phenotype, reduce amyloid plaque 
burden, and improve cognitive deficits were seen in the APP/PSl mouse model of AD 
[258]. Further, there is a growing body if literature supporting the role of PPARy 
specifically regulating M2a phenotype in peripheral macrophages [227 ,259]. Interesting, 
RARa has been associated with IL-4 mediated T H2 skewing in T -cells as well as a! tering 
T H17/T,eg cell populations both in ulcerative colitis and mouse models of inflammatory 
bowel disease [260]. In primary microglia, we observed up-regulation of the RARa 
network and modest down regulation of the PP ARy transcriptional network, suggesting 
that RARa my play more critical role in M2-skewing. 
The role of PPAR6 in microglia remains unexplored at this time. However, in the 
periphery PPAR6 agonists have been demonstrated to reduce both atherosclerotic lesion 
area, the number of macrophages in the lesion, as well as many pro-inflammatory 
mediators, e.g IL-1~ IL-6, and MCP-1. This data suggests that PPAR6 can potentially be 
a new therapeutic target to skew microglia from the Ml pro-inflammatory to the M2 anti-
inflammatory state [261]. 
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Identifying Functional Roles for miRNAs Associated with Ml-skewing of Microglia 
We are intrigued by the possibility that miRNA can have such a huge impact on 
the phenotypes of cells. miRNA interaction with their target mRNA canonically leads to 
post-transcriptional repression either by blocking translation or enhancing the mRNA's 
degradation, but often overlooked is also the ability to enable/activate key pathways 
through dis-inhibition [158 ,262]. Overall we believe this combined inhibition, activation, 
and target specificity conveys the ability of miRNA to target key gene pathway regulators 
that enable phenotypic switching and facilitating cells to rapidly alter phenotypes that 
require coordination of thousands of genes at once in response to ever changing external 
stimuli [262,263]. 
In the previous chapter we identified miR-155 as the most up-regulated miRNA in 
primary microglial response to LPS. miR-155, an established pro-inflammatory and 
oncogenic miRNA, with targets that include Src homology-2 domain-containing inositol 
5-phosphatase 1 (SHIP) and suppressor of cytokine signaling 1 (SOCS1) that ultimately 
dis-inhibits the JAX/STAT pathway [55 ,72,84,264,265]. The exact means that SHIP1 
negatively regulated LPS-induced inflammation is unclear, but involves negative 
regulation of multiple intra-cellular signaling pathways including: Phosphoinositide 3-
kinease (PI-3K), C-Jun , MAPK and down regulation of IkappaB-alpha [264]. 
Surprisingly , we observed significant down regulation in Breast Cancer 1 
(BRCAl) , data not shown, which is best known as a DNA damage repair coordinator and 
dysregulation is associated with many forms of breast cancer in women [266]. However, 
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a recent study has identified a new role for BRCAl during the classical activation state to 
the epigenetical repression of the miR-155 promoter region in conjunction with Histone 
deacetylase 2 (HDAC2), which the observed BRCAl inhibition can help explain swift 
up-regulation of miR-155 that we observed in out miRNA observations [195 ,196]. 
Interestingly, based on the transcriptional network alterations that miR-155 
potentially regulates it appears miR-155 is less critical for the initial NF-kB mediated 
response to TLR agonists , e.g LPS , but more critical the late phase response enabling and 
regulating STAT3 mediated inflammatory signaling [84,231] . We also identified two 
addition miRNAs that potentially act as enablers of the NF-Kb mediated TLR response to 
LPS in primary microglia, miR-689 and miR-124. miR-124 already is established as a 
microglia regulator, through the work of Ponomarev , E. et al. demonstrating that over 
expression of miR-124 was sufficient to suppress EAE model of MS [56]. Reductions in 
miR-689 can lead to increases in potential effectors , e.g. IL-10 and IL- l~' as well as the 
transcriptional regulation of CEBP-a, the same target of miR-124 as Ponomarev 
identified [56] . 
Further , our analysis shows that mir-689 can potentially regulate the Sterol 
regulatory element-binding transcription factor-1 (SREBFl) transcriptional network that 
can alter genes encoding the inflammasome in addition to directly targeting IL- l~, as 
well as altering Lipogenesis under LPS stimulation [267]. In addition, down regulation 
of miR-689 may allow increases in the Tristetraprolin (TTP) transcriptional network that 
facilitates activation of both bactericidal/permeability-increasing proteins and when 
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combined with AP-1 the activation of CD11 b, a classic marker of microlgial activation 
[268-270]. 
Taken together, while miR-155 is the most up-regulated miRNA in response to 
LPS, its role appears to enable the late phase response mediated by STAT1/STAT3. 
However, reductions in miR-124 and miR-689 both release inhibition on initial response 
mediated through NF-KB , therefore functioning to transition microglia from the resting 
(MO) to the initial Ml-skewed active state. 
Identifying Functional Roles for miRNAs Associated with M2a-skewing of 
Microglia 
Far less is known about miRNAs role in shaping the M2a phenotype in either 
peripheral macrophages let alone primary microglia. We identified upon IL-4 stimulation 
primary microglia up-regulate in miR-449a, -145,-214, and -297b-5p and down regulate 
in miR-711 , -1224, -762, -124,-2132, and -2133. As we observed under LPS stimulation 
down regulates certain miRNAs to facilitate activation, during IL-4 stimulation down 
regulation of miR-711 and miR-124 work in coordination to release microglia from the 
MO resting state. miR-711 potentially regulates targets associated with a number of pro-
inflammatory pathways including API, IRFl/2, NF-kB 1-ReiA, SP3, Krupple-like factor 
2 and PPAR-y. Interestingly, mir-711 targets a combination of canonical Ml 
transcriptional pathways (e.g. API, IRFl/2, and NF-kBl-RelA) and we did observe its 
down regulation under LPS stimulation, though not to the same extent as observed under 
IL-4 stimulation. Uniquely though, miR-711 also potentially regulates SP3, KLF2 and 
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PPAR-y each of which have associations with both allergic airway disease, an IL-4 
mediated disorder, and in the mediation of the M2a phenotype, a hallmark of the M2 
phenotype [227,259,271-273]. Specifically, Odegaard, et al. demonstrated that PPAR-y 
directly regulates alternative activation in macrophages and both Das et al. and Van Tits 
et al., demonstrated that KLF2 directly regulates the pro-inflammatory state in monocytes 
and facilitates the switch to alternative activation to M2 phenotype respectively 
[227 ,271 ,273] . 
M2 skewing conditions also resulted in a up-regulation of mir-145, that potentially 
regulates the ETS 1 transcriptional network which reductions in ETS 1 has been associated 
with increase mucus production in airway inflammation and expression levels of PTSG2 
[274,275]. Perhaps most importantly mir-449a, since it was the most up-regulated upon 
M2a skewing conditions, could potentially regulate the AHR, USF2, EZH2 and RUNX3 
where each of these transcriptional factors has been implicated in inflammation or 
monocyte to macrophage differentiation [276-280] . More importantly RUNX3 knockout 
mice exhibited spontaneous eosinophilic lung inflammation, airway remodeling and 
enhanced allergic airway inflammation, all hallmarks of dysreregulated IL-4 signaling 
[281]. Interesting miR-449a also potentially regulates the PRDM16 transcriptional 
network, which Avagyan,S. et al. has shown that PRDM16 can alter the transcriptional 
activity of PPAR-y specifically and thus potentially could disrupt the MO-M2a switch 
[282]. 
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Proposed Comprehensive Model of the Ml and M2a Phenotypes in primary 
Microglia 
This research sought to elucidate the role miRNAs play in regulating primary 
microglial phenotypes under resting, M1-skewing and M2a-skewing conditions. Initial 
literature searches suggested that microglial function similar to peripheral macrophages. 
This allowed the construction of a working state transition model of the various dynamic 
phenotypes observed in microglial activation states , Figure 1 (Chapter 1 reference). 
Through marrying miRNA expression data and mRNA gene expression data and 
petforming a lengthy system biologic analysis on the data gave much more insight and 
enable a significant revision from initial model, as depicted in Figure 21. 
In short, this research is suggesting the following microglial phenotype (state) 
transition diagram identifying key miRNAs and altered transcription networks mediating 
the transitions between the MO, M1 and M2a phenotypes in Figure 21. To establish the 
M1-Iike classical activation in primary microglia, we have identified a previous unknown 
role for miR-689 in microglial biology and confirmed previous works of both miR-155 
and miR-124. Reductions of both miR-689 and miR-124 increase canonical TLR signal 
pathways and NF-KB-RelaA effector pathways thus enabling the initial pro-inflammatory 
"recruitment" Ml phenotype. We also further demonstrate that swift up-regulation of 
miR-155 during the acute phase of the M1 phenotype, drives the transition from TLR 
signal and NF-kB/RelA effector pathways to that driven by STAT1/STAT3 signaling 
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pathways to facilitate the late-phase response elements of the M1-pro-inflammatory 
response. 
To our knowledge there has never been a comprehensive analysis of IL-4 
stimulated microglia or even peripheral macrophages that attempt to identify key 
miRNAs and the roles they facilitate in shaping the alternatively activated phenotype. 
Like in Ml-skewing conditions , we observed down regulation of key miRNAs , miR-711 
and miR-124, under IL-4 stimulation that both inhibit pro-inflammatory/activation states 
targeting both key transcriptional regulator (e.g. C/EBPa and ETS1) and key effectors 
(e.g. PTSG2 and TNF-a). Interestingly, miR-711 also potentially regulates PPARg 
network, which is known to facilitate the M2a "resolution" phenotype [227]. We also 
observed up-regulation of miR-145 and miR-449a which both appear to play a key role in 
shaping the M2a phenotype. miR-145 potentially alters the transcription networks of 
ETS1and HOXB4. miR-449a potentially regulates the transcriptional networks of known 
pro-inflammatory pathways Notch and Wnt/~-catenin through targeting of Jagl , notch1 , 
and Myc in primary microglia[206,283,284]. However, our analysis also identifies 4 
novel pathways that miR-449a can also potentially regulate, the transcriptional networks 
of AHR, USF2, EZH2, and PRDM16, in primary microglia. Overall, our data suggests 
that down regulation of miRNAs is as critical in 'releasing ' primary microglia from their 
MO-Resting state, through down regulation of miR-711 and miR-124, to establishing the 
M2a-alterantively activated state by up-regulation of miRNAs miR-145 and miR-449a in 
primary microglia. Further studies will be necessary for the validation of our 
observations. 
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Since the Ml-classical activation state is such a strong and reproducible response 
in primary microglia in both altered expression of mRNAs and miRNAs , future work 
focused on the Ml-state. The M2a response appears much more closer to the resting 
stating and differences were not nearly as pronounced as they were for the Ml state. We 
choose to focus on both miR-155 and IL-6, the two most up regulated miRNA and 
mRNA under Ml-classical activation and the affect the Ml -phenotype has on the CNS, 
specifically neurogenesis for future work. 
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Figure 21: Overall Proposed Model of Key regulators for the MO, Ml and M2a 
Microglial Phenotypes 
Based on our observations and analysis made in both Chapter 3 and 4 we propose the 
following model identifying key genes, transcriptional networks, and miRNAs regulating 
the MO, Ml , and M2a phenotypes in primary microglia_ 
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Chapter 5: Inhibition of miR-155 Alters the Acute Inflammatory Response in 
Primary Microglia 
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Results 
To assess the impact miR- 155 has on the immune response in microglia, a series 
of in-vitro experiments where miR-155 was either knocked-out or knocked-down were 
pe1formed with primary microglia stimulated for 4 hours with LPS , an M1-skewing 
stimulant. We chose 4 hours as a standard stimulating time to capture the acute 
inflammatory response in microglia and to match the conditions captured with the 
microarray experiment described in chapter 3 . Primary microglia were isolated from 
miR-155_,_ mice or WT that were treated with either LNA-based anti-miR-155 or Tough 
Decoy miR-155, here in referred to as TuD-155 to inhibit miR-155 . Further, to assess the 
impact of miR-155 has on microglial functionality in vivo, ICV injections of LPS or 
saline were pertormed in miR-155_,_ mice and WT C57BL/6J control mice and 
subsequently brain slices were stained for microglia. 
miR-155_,_ Alters canonical Ml Pro-inflammatory markers 
Primary microglia were isolated from PO pups from either CD-1 or miR-155_,_ 
mice and cultured for 5-7 days , as described above. Media removed, washed once and 
then changed to serum-free media over night prior to the addition of LPS (100 ng/ml) for 
four hours of stimulation. Total RNA was then extracted and RT-PCR was pertormed to 
assess alterations in canonical Ml markers, same as those defined in chapter 3. In every 
Ml marker we looked at we saw significant reductions in expression when compared to 
WT primary microglia stimulated under similar conditions . Interestingly, We observed 
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two levels of alterations . miR-155_1_ primary microglia had significant reductions in 
expression levels that exceeded 60% in both IL-6 (p<0.001 , n=3) and NOS2 (p<0.05, 
n=3) in response to the LPS challenge, Figure 22-A. The second level demonstrated 
only about a 33% reduction in expression levels in IL-l~ (p<0.05 , n=3) and TNF-
a (p<0.001, n=3) , Figure 22-A. To validate miR-155_1_ was functionally was altered we 
probed the INPP5D, a known miR-155 target, expression levels [84]. Under an LPS 
challenge in WT primary microglia INPP5D is down regulated almost 40 fold, 
presumably due to the action of miR-155 , which we observed near complete ablation 
(p<O.OOl , n=3) of this down regulation under similar conditions in miR-155_1_ primary 
microglia, Figure 22-A. Lastly, we looked at the expression level of miR-155 in miR-
155_1_ to validate that it was knocked out and as expected it was undetectable, Figure 22-
B. In addition, miR-124, a miRNA identified as down regulated upon LPS stimulation in 
primary microglia (see chapter 3), was also probed, which was nearly unchanged 
compared to resting state, Figme 22-B. Taken together, this demonstrates that miR-155_1_ 
significantly regulates many canonical M1 markers during the acute inflammation in 
response to a four-hour LPS challenge. 
miR-155 inhibition alters canonical M1 Pro-inflammatory markers 
Next we applied two different methods to knockdown miR-155 ' s activity . First 
we transfected LNA based anti-miR-155 into primary microglia that were isolated from 
CD-1 PO mice pups, as described in chapter 2. The transfection of anti-miR-155 was 
performed 24-48 prior to the LPS challenge. For the LPS challenge, media was removed 
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and washed once, then changed to serum-free media over night prior to the addition of 
LPS (100 ng/ml) for four-hours of stimulation . Total RNA was then extracted and RT-
PCR was performed to assess alterations in canonical M1 markers, defined in chapter 3. 
Through miR-155 knockdown, by treatment with LNA-based anti-miR-155 , IL-6 
expression levels were significantly (p<O.OOl , n=4) reduced by about 50% when 
compared against wildtype CD-1 response to an equivalent LPS challenge. However, 
TNF-a levels were only modestly reduced, still significantly (p<0.05 , n=4), by about 
15% and IL-1~ was unchanged, Figure 23-A. Again, we used INPP5D expression levels 
to validate the functionality of the LNA-based miR-155 inhibition. Under anti-miR-155 
transfection coupled with an LPS challenge, INP55D expression levels in primary 
microglia significantly (p<0.05, n=4) recovered 36% from its resting level as expected, 
Figure 23-A. -
To determine the extend that miR-155 ' s expression was suppressed through 
treatment of LNA-based anti-miR-155, we performed LNA-based RT -PCR and 
demonstrated significantly (p<0.05, n=4) about a 70% reduction in the induction of miR-
155 in response to LPS in anti-miR-155 treated primary microglia, Figure 23-B. This 
suggests about 70% efficiency in our transfection protocol. There was no difference 
observed between scramble treated and LPS stimulated primary microglia and control 
LPS stimulated primary microglia, suggesting the transfection had little impact on the 
immune response to LPS, Figure 23-B. 
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miR-155 regulates IL-6levels during the acute Inflammatory Response 
To explore the possibility that miR-155 regulates IL-6levels specifically we 
compared IL-6 expression levels in LPS stimulated conditions in WT, miR-155_1_, and 
LNA-based anti-miR-155 treatment groups of primary microglia. In either the miR-155_1_ 
or anti-miR-155 treated groups we observed a significant (p<0.001 , n= 3 or 4) reduction 
in the expression level of IL-6 of greater than 60% or near 50% reduction respectively. 
There was also an observed 15% significant (p<0.05, n= 3 or 4) difference between the 
miR-155_1_ and the anti-miR-155 treatment groups, Figure 24-A. Again, this suggests not 
a complete knockdown of miR-155 ' s activity and as reported above only about a 70% 
transfection efficiency was achieved. In comparison, INPP5D is a known target of miR-
155 , which alterations normally observed under LPS stimulation were complete ablated 
in miR-155_1_ primary microglia, (p<0.001 , n= 3 or 4). Transfection of LNA-based anti-
miR-155 only significantly (p<0.05 , n= 3 or 4) rescued INPP5D expression level by 
about 35%, Figme 24-B. Taken together comparing IL-6 expression levels to that of 
INPP5D, a known target in miR-155 , in WT , miR-155-/- or LNA-based anti-miR-155 
treated primary microglia suggests that miR-155 has the ability, presumably though 
interacting with C/EBP-j) . 
miR-155_1_ Mice demonstrate altered microgliosis in response to inflammatory challenge 
We previously have been looking at miR-155 ' s ability to regulate the acute 
immune response in stimulated primary microglia cultures in vitro. To assess miR-155' s 
ability to regulate the acute immune response in an in vivo model we performed ICY 
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stereotactic injection of 1 f!l LPS (1 f!g/f!l) or 1 f!l of saline into either the left or right 
side of the lateral ventricle as described above. Mice were broken into four groups: WT-
Saline, WT-LPS, miR-lss-'--Saline, and miR-155_,_ - LPS. Brain sections, n=3 animals 
per group, were then stained for IBAl, a known marker for micoglia, and imaged, 3-4 
images per animal.[285] Two neuroanatomical areas were analyzed: The entire 
hippocampal area, including the CAl, CA2, CA3 fields and the dentate gyrus, and the 
Cortex. Microglial densities were determined and normalized based on partitioning 
images into 200 f!m x 200 f!m grid sections and counting the number cell bodies within 
each grid. Representative images are shown in figure for each group and the both the 
hippocampus and cortex Figure 25 A-H. 
In the saline treated WT mice we observed that microglial densities in both the 
Hippocampal region and the Cortex are essentially identical, 227.8 +1- 5.9 cells per mm2 
and 227.4 +1- 5.3 cells per rnm2. respectively, suggesting that micorglial densities are 
uniform throughout much of the CNS at rest, Figure 25-I and J. As expected during 
active inflammation in the CNS results in microgliosis, a process in which microglial 
numbers increase and therefore their densities increase [36]. In the hippocampus we saw 
a 40% increase in microglial density from the resting state relative to the inflamed state in 
WT mice , Figure 25-1. However, in the Cortex we observed only about a 25% increase 
in the microglial density due to the active inflammation in WT mice, Figure 25-J. In 
other words, there was a 15% increase in microglial density in the hippocampal region 
when compared to the cortex during active inflammation in the WT mouse. 
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Unexpectedly , in miR-15s-'· mice we observed a 20% increase in the resting 
microglial density , ~290 +1- 6.2 cells per mm2 , which is significantly (p<0.001 , n=3 
animals and 2-4 images per animal) higher than their WT counterpart, Figure 25-I. In 
miR-15s-'- mice cortical and hippocampal microglial densities were essentially the same, 
just as observed in WT mice. Under an LPS inflammatory challenge miR-15s-'· mice 
demonstrated less responsiveness than their WT mice. Specifically , a significant 
increase, of only 10%, was observed in microglial densities when compared to their 
resting values in either hippocampal (p<0.05, n=3) or cortex (p<0.01 , n=3) during active 
inflammation in the miR-15s-'· mouse. Overall this suggests , that the microglial response 
to an LPS challenge in miR-155_,_ mice is impaired by about 30%, particularly in the 
hippocampal region. 
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Figure 22: miR -Iss·'· primary microglia demonstrate deficient Ml-proinfalmmatory 
cytokine expression under LPS challenge . 
mRNA RT-PCR results comparison between primary microglia isolated from either CD-
1 mice or miR- 155·'· mice that were stimulated wi th LPS for 4-hours . (A) mRNA RT-
PCR of M1-canonical markers for WT CD-1 mice (n=4) Black columns and miR-155·'· 
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(n=3) mice Open columns(*= p < 0.05, ** = p < 0.01, and *** = p < 0.001). (B) 
miRNA LNA-based RT -PCR for miR-155 and miR-124 of WT CD-1 mice (n=4) Black 
columns and miR-155_,_ (n=3) mice Open columns(** = p < 0.01) . 
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Figure 23: Inhibition of miR -155 primary microglia demonstrates deficient Ml-
proinfalmmatory cytokine expression under LPS challenge 
mRNA RT-PCR results comparison between primary microglia isolated from CD-1 mice 
that were trasfected with LNA-based anti-miR-155 (100 pmol) and stimulated with LPS 
for 4-hours. (A) mRNA RT-PCR of M1-canonical markers for WT CD-1 mice, black 
columns, and anti-miR-155 treated WT-CD-1 microglia mice, open columns, (n=4, * = p 
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< 0.05 and *** = p < 0.001). (B) miRNA LNA-based RT-PCR for miR-155 in mock 
transfected, black column, and LNA-based anti-miR-155 (100 pmol), open column, 
Scramble (100 pmol), hash column, transfected WT CD-1 mice primary microglia (n=4, 
** = p < 0.05). 
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Figure 24: Comparison of /L-6 and INPP5d levels in WT, miR-155-1- and LNA-based 
anti-miR-155 treated primary microglia. 
mRNA RT-PCR comparison between primary microglia isolated from either CD-1 WT 
mice or miR-155"1- mice. CD-1 WT mice were transfected with LNA-based anti-miR-155 
or scramble (100 pmol) treated (100 pmol) or WT un-transfected and stimulated with 
LPS for 4-hours. (A) mRNA RT-PCR of IL-6 in WT CD-1 mice, black columns, miR-
155"1- mice , open column, and LNA-based anti-miR-155 treated WT-CD-1 mice, hash 
columns , (n=4 and*** = p < 0.001). (B) mRNA RT-PCR of INPP5D in WT Scramble 
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treated , black columns, miR-155_1_ mice, open column, and LNA-based anti-miR-155 
treated WT-CD-1 mice , hash columns, (n=4, * = p <0.05 and***= p < 0.001). 
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Figure 25: Cortex and Hippocampal Microglial density counts 
Representative Images (4x) of the hippocampus (A-D) and Cortex (E-H) in 7-week old 
miR-155_1_ or C57BL/6J (WT) mice 5 days post central inflammatory challenge induced 
by ICY injection of 1 ~-tl of LPS (1 f-lg/ ~-tl) or 1 ~-tl of control saline injected animals . 
Tissue sections were stained with Ibal. (A) WT-saline Hippocampus . (B) WT-LPS 
Hippocampus. (C) miR-155"1--saline Hippocampus. (D) miR-155"1--LPS Hippocampus. 
(E) WT-saline Cortex. (E) WT-LPS Cortex. (G) miR-155·1--saline Cortex. (H) miR-155·1--
LPS Cortex. (I) Normalized Microglial density counts of Hippocampal region (n=3 per 
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group and 2-4 images per animal, *** = p < 0.001). (J) Normalized Microglial density 
counts of the Cortex (n=3 per group, 2-4 images per animal, *** = p < 0.001) . 
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Discussion 
From the research presented in Chapter' s 3 and 4 we identified miR-155 and 
through bioinformatical analysis elucidated its role in microglial biology, which 
suggested it plays a key role in enabling the Ml-classically activated phenotype. In this 
chapter we demonstrated how important miR-155 is to the functionality of the M1 
classically activated phenotype both in vitro and in vivo . We employed three independent 
methods of disrupt miR-155 and then determined the affect based on measuring 
expression levels of canonical M1-markers and observing microgliosis in response to an 
insult directly to the CNS . 
First by using miR-15s-'- deficient mice, we observed that every canonical Ml -
marker probed for demonstrated significant reductions of greater than 30%. 
Interestingly, we observed two levels of inhibition where IL-6 and NOS2 were inhibit 
nearly ~60% or more where as TNF-a and IL-l~ were only inhibited by ~33% in the 
miR-15s-'- mice. This was further corroborated with inhibition studies. When we 
inhibited miR-155 though application of LNA-based miR-155 we observed ~70% 
efficiency and subsequently only 50% reduction in IL-6levels and TNF-a was only 
reduced by 15%. 
Many of these findings have been have been corroborated by the findings of 
Cardoso eta!. in primary microglia [55] . Specifically, Cardoso eta!. showed regulation 
of both TNF-a and IL-6 by miR-155 performing nearly identical experiments [55]. They 
failed to demonstrate miR-155 ability to regulate IL-l~ expression levels [55]. However, 
that most likely was due to incubation period being 18 hours rather than the 4 hours 
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performed in this research [55]. Taken together though, this research does substantiate 
our findings. 
The finding of this research suggest that miR-155 has a greater effect and perhaps 
more closely regulates NOS2 and therefore RNS production coupled with IL-6 
production as opposed to TNF-a or IL-l~ - Recently, Arranz et al. demonstrated that 
levels of IL-6, TNF-a, NOS2 and nitrate levels were all enhanced in Ml-skewing, which 
were dependent on two isoforms of the Akt (Aktl or Akt2) [286]. Intriguingly, Arranz et 
al. demonstrates that in Aktl_,_ mice have enhanced Ml-skewing, with both enhanced IL-
6 and miR-155, whereas Akt2_,_ mice have enhanced M2-skewing and reduced levels of 
both IL-6 and miR-155 [286]. 
More work will be necessary to get a better perspective on the functional role that 
miR-155 pe1forms since we only observed four key Ml-markers. It would be very 
enlightening to perform microarray analysis on miR-15s-'- primary microglia using the 
same paradigm to capture the acute inflammatory response and compare those results to 
resting and LPS challenged WT controls. 
We were very surprised to observe a 20% increase in the numbers of microglial 
observed in the brain parenchyma between the resting state in miR-15s-'- as compared to 
their WT resting counterpart. This suggests some basic role of miR-155 in microglial 
homeostasis, but it is unclear as to what. Further, it is unclear what or how microglial 
density spacing is maintained. In general , one can think of microglia as carving out a 
specific volume of brain parenchyma that is patrols [27,36]. In CNS tissue sections when 
stained for microglial markers, e.g.lbal, a very uniform distribution of microglia with 
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regular spacing separating each cell body one to the next, as seen in Figure 25. Recently, 
Varvel, et al. demonstrated a very elegant method to deplete microglia and within 2 
weeks of depletion microglia-like cells repopulated, but the repopulated cells were much 
more numerous, 2x as many then pre-depletion numbers [287]. This demonstrated that 
altered microglial densities are possible and even at rest, but we do not know what is 
regulates this phenomena. 
In response to an inflammatory challenge, we had anticipated seeing a reduced 
response, which we saw a significant reduction in. Specifically, there was about a loss of 
~30% in the microglial response to the insult. We also observed differences in locations 
within the CNS as to this occurring . In this research we look at both the cortex and the 
hippocampus. We observed much higher numbers of microglila and much more obvious 
staining of lbal in the hippocampal region as opposed to the cortex. In fact , based on our 
observations it appears microglial and perhaps responding peripheral monocytes/ 
macrophages , since lba1 is positive in both cell populations, infiltrate in along the highly 
perfused hippocampal fissure, in particular. Further, in the cortex, with a relative paucity 
of larger vessels number in the WT mouse we observed a 15% reduction when compared 
to the WT hippocampal region under an inflammatory challenge. When compared with 
miR-155"'· mice this intensity within the hippocampus was lost, reduced 30%, during an 
inflammatory challenge. 
There are more questions here than answers. Why are there more microglia at 
rest in the miR-155"'-mice? What is the origin of the cells that respond to the insult? Are 
these migrating and dividing microglia, as posited by canonical microgliosis , or are these 
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peripheral monocytes infiltrating from regions of highly perfused regions of the brain, as 
suggested from the IHC [36] . It would be of great interest to pe1form a similar challenge 
as performed in this experiment and using the same model animal that Varvel , et al. used 
which appears to be able to differentiate between resident microglia and infiltrating 
monocytes [287]. 
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Chapter 6: miR-155 SUPPRESSES NEUROGENESIS DURING THE ACUTE 
INFLAMMATORY RESPONSE IN MICROGLIA 
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Results 
Acute inflammation suppresses nem·ogenesis in vivo 
To test the hypothesis that miR-155 can suppress neurogenesis we first pe1formed 
a pilot study in which 4 week old WT mice were stereotactially injection with 1 fll of 
Anti-miR-155 (800 ng) or anti-miR-Scramble (800 ng) bi-laterally into the hippocampal 
region and one day later were challenge with LPS (50 mg/kg) or saline control injection 
IP, as described above in chapter 2. To label newly dividing cells we injected BrdU (50 
mg/kg) four times over the course of two days, with injections spaced 8 to 12 hours apart 
if on the same day , after the inflammatory challenge. On day four post-microinjection 
the animals were allowed to recover one day and then euthanized the following day. 
Tissue processing and staining for all animals was performed as described in chapter 2. 
Unfortunately, most injections were not deep enough to reach the hippocampus 
and results were mixed. However, since all animals were injected bilaterally into the 
hippocampus equally, we were able to separate the groups into a peripheral inflammation 
LPS challenged or saline control. To ensure there were no effect of the anti-miR-155 we 
ensured that only Scramble control anti-miR injected animals comprised the LPS and 
saline control group. 
However, when comparing LPS challenged animals versus saline controls we 
were able to demonstrate that even peripheral inflammation has the ability to impair 
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neurogenests. To determine alterations in proliferation and differentiation we stained 
brain sections for both BrdU, a maker of newly divided cells, and DCX, a marker for 
newly differentiated neurons, representative images for the LPS and Saline control 
groups are shown in Figure 26 [288]. To assess alterations in proliferation counts of 
BrdU+ cells in the Granular Zone, SGZ, and mossy fiber were made. Specific regions of 
the hippocampus Granular Zone, SGZ and Mossy fiber are outlined in Figure 26-D. 
Overall, we observed that proliferation was significantly reduced in each area 
counted in the LPS challenged group relative to the control saline group. Specifically, 
LPS challenged animals demonstrated a significant (p<O.Ol , n=3 or 4 per group) 20% 
reduction in the number of BrdU+ cells along the SGZ in LPS treated animals (27.8 +1-
0.9 cells per mm) , versus saline control animals (34.8 +1- 2.1 cells per mm), Figure 27-A. 
In the granular zone itself the affect was even more dramatic. LPS challenged animals 
demonstrated a significant (p<0.001 , n=3 or 4 per group) 60% reduction in the number of 
BrdU+ cells in the granular zone in LPS treated animals (74.6 +/-7.4 cells per mm2), 
versus saline control animals (185 .2 +I- 32 cells per mm2), Figure 27-B. In the Mossy 
Fiber region a raw total count of BrdU+ cells was performed rather than normalize since 
the exact area of the Mossy Fiber is hard to determine. In the LPS challenged group there 
was significantly (p<O.Ol , n=3 or 4 per group) fewer BrdU+ cells , 40% reduction 
observed, with 24.2 +1- 2.8 cells in the saline treated group and 14.14 +1- 1.2 cells, Figure 
27-C. 
Just as proliferation was impaired due to a peripheral LPS challenge so too was 
differentiation. In the LPS challenged group (29.27 +/-1.5 arbitrary units) there was a 
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significant (p<O.OOOl, n=3 or 4 per group) 40% reduction in DCX intensity along the 
SGZ when compared to the saline control group (48.16 +1-3.9 arbitrary units), Figure 27-
D. 
Taken together, this demonstrates the sensitivity of the neurogenic niche in the 
SGZ to a peripheral inflammatory challenge. Since an LPS challenge mimics a bacterial 
infection, which is obviously detrimental to host, we anticipated reductions in 
neurogenesis which we observed reductions in both proliferation and differentiation. 
Further, these results mirror results that Monje et al. demonstrated.[l13] However, more 
importantly it suggests that neurogenesis, due to its high sensitivity, can be used as a 
viable readout to the intensity of inflammation an animal is subjected too. 
miR-155_,_ ablates suppression of neurogenesis during the acute inflammatory response in 
To simplify the experimental design mir-15s-'- mice were employed in lieu of 
applying a miRNA inhibitor to miR-155. Another lesson learned from the previous pilot 
study was to utilize older mice due to the extensive proliferation observed still going on 
at 4 weeks of age, which apparently is still developing and was much more extensive than 
originally anticipated, see Figure 26-A. For this study we increase the age of the mice to 
7 weeks to try to move beyond the general CNS maturation process in the mouse brain 
and capture primarily proliferation limited too "adult neurogenesis" in the SGZ. 
Therefore, all mice were age matched to 7 weeks of age. 
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miR-155_,_ mice and WT C57BL/6J control mice were divided into 4 groups: 
WT-Saline, WT-LPS , mir-155-'--Saline, and mir-155-'--LPS as described in chapter 2. All 
mice underwent ICV stereotactic injections of either 1 ~-tl of LPS (1~--tgl ~--tl) or 1 ~-tl of 
Saline . To label newly dividing cells we injected BrdU (50mg/kg) 5 times over the 
course of 3 days starting the following day after ICV injection, with injections spaced 8-
12 hours apart if on the same day . On day four post-challenge the animals rested and the 
following day were euthanized . Tissue processing and staining for all animals was 
performed as described in chapter 2. 
As with the pilot study, both alterations in proliferation and differentiation were 
assessed by staining brain sections of the Dentate gyrus with both BrdU and DCX, as 
described above and representative images for the each group are shown in Figure 28. 
Counts of BrdU+ cells in the Granular Zone, SGZ, and mossy fiber were made to assess 
alterations in proliferation as previously described above. Differentiation was assessed 
by measure the mean intensity of DCX along the SGA as described in Chapter 2. 
Overall , we observed that proliferation was significantly reduced in both a total 
number of BrdU+ cells and along the SGZ due to central inflammation, as observed in the 
WT-LPS group. Specifically, the WT-LPS challenged animals demonstrated a 
significant (p<O.OOl , n=6 or 8 per group) 20% reduction in the total number of BrdU+ 
cells in LPS treated animals (19.67 +1- 0.7 cells), versus WT-Saiine control animals 
(25.17 +1- 0.7 cells), Figure 29-A. Remarkably, the LPS challenged miR-15s-'- animals 
maintained almost exactly the same number of BrdU+ cells (25.09 +1- 0.8 cells, n=7) as 
observed in the WT -Saline control group and there was no differences between the two 
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groups, Figure 29-A. Along the SGZ, WT-LPS challenged animals demonstrated a 
significant (p<O.OOI, n=6 or 8 per group) a 31 % reduction in the total number of BrdU+ 
cells in LPS treated animals (9.73 +1- 0.3 cells per mm) , versus WT -Saline control 
animals (14.17 +/- 0.4 cells per mm), Figure 29-B. Remarkably, the LPS challenged 
miR-155_,_ animals maintained almost exactly the same number of BrdU+ cells (14.32 +1-
0.4 cells, n=7) as observed in the WT-Saline control group and there was no differences 
between the two groups, Figure 29-B. 
Tissue sections were also stained with DCX to assess the impact that 
inflammation and miR-155-'- has on Neurogenic differentiation. In the WT-LPS 
challenged animals demonstrated a significant (p<0.001, n=6 or 8 per group) 29% 
reduction in the DCX intensity observed along the SGZ in the WT-LPS group (34.89 +1-
0.96 arbitrary units), versus WT-Saline control group (48.95 +1- 1.41 arbitrary units), 
Figure 29-C. Remarkably, the LPS challenged miR-155_,_ animals maintained almost 
exactly the same intensity of DCX along the SGZ (50.06 +1- 1.28 cells , n=7) as observed 
in the WT-Saline control group and there was no differences between the two groups, 
Figure 29-C. Taken together, this suggests that blockade of miR -155 would effectively 
restore differentiation levels to near resting states during an inflammatory challenge. 
When we looked at proliferation in the Mossy Fiber and the Granular zone a very 
different picture emerged than was anticipated. In the Mossy Fiber, there were actually 
no differences observed in the number of BrdU+ cells entering that region , there was a 
slight reduction seen in the miR-155KO-saline group, Figure 30-A. Interestingly, There 
were very few newly dividing cells over the 4 days from initial BrdU treatment that 
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entered into this region, on average across all groups 3.15 +1- 0.1 cells combining all 
groups, data not show. However, this suggests that Mossy Fiber is still getting the same 
number of new neurons despite the apparent reductions in the number of newly dividing 
pool in the SGZ, the 30% reduction as a result of the LPS challenge, as noted above. 
This prompted us compare the ratio of the normalized SGZ counts to the Mossy fiber 
counts as shown in Figure 30-C. Surprisingly, The WT-LPS group significantly 
(p<O.OOl, n=6 or 8 per group) increased the ratio by ~60% of newly divided cells 
entering the mossy fiber during the LPS challenge (37.11% +/-2.4%) as compared to the 
WT-saline control group (23.17% +/-1.8%) maintained the number of newly divided cells 
entering the Mossy fibers. This affect was consistent for the two miR-155_,_ groups either 
the saline or LPS treated when compared with the WT-LPS group, perhaps since 
proliferation was unaffected by these groups. 
We next looked at proliferation within the Granular zone, as with in the Mossy 
fiber, a very different picture emerged than was anticipated. In the Granular zone, there 
were actually significant alterations in the number of BrdU+ cells observed in every 
group, Figure 30-B. We observed the lowest level of migration of newly divided cells 
into the Granular zone in the WT-saline group (8.45 +1-0.6 cells per mm2). Under LPS 
stimulation, we had expected this to be reduced, but it actually significantly (p<O.OOl, 
n=6 or 8 per group) increased by 60% relative to WT-LPS groups (13.51 +1- 0.8 cells per 
mm2), Figure 30-D. Surprisingly, even in the miR-155-'--saline treated group groups 
(11.93 +1- 0.8 cells per mm2) demonstrated at significant (p<0.05, n=8 or 7 per group) 
41% increase relative to the resting WT-Saline control group, albeit to a lesser extent that 
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was observed under inflammatory states, Figure 30-B. However, the most significant 
(p<0.001, n=8 or 7 per group) increase was observed in the miR-155-'--LPS treated group 
where an over 110% increase was observed relative to the resting WT-Saline control 
group , Figure 30-B. Lastly, we did look to see if the proportional increase observed 
between the two Saline groups versus the two LPS challenged groups were similar. As 
noted above there was a 60% increase between the WT-Saline and WT-LPS group, where 
as a ~50% increase was observed between the miR-155-'--Saline group versus the miR-
15s-'--LPS group, Figure 30-B. 
To gain a better appreciation of the rate cells are entering the Granular zone 
relative to the rate of production of new cells along the SGZ we determined the ratio of 
the normalized Granular zone count to the normalize SGZ count. There were no 
differences observed between either the WT-Saline group, the miR-155-'--Saline group, as 
well as between the WT-LPS group or the miR-15s-'--LPS group. However there was a 
significant (p<0.001, n=6 or 8 per group) increase, 154%, between the WT-Saline and the 
WT-LPS groups , which also mirrored a 122% significant (p<O.OOl , n=7 per group) 
increase between the miR-155-'--Saline group and the miR-15s-'--LPS group, Figure 30-D. 
Effectively suggesting that miR-155 has little impact on the rate that newly diving cells 
enter the Granular zone layer in the dentate gyrus of the hippocampus. 
Lastly, we compared the results from our pilot study from the 4-week old WT 
mice peripheral inflammatory challenge, presented above, and those from this ICV 
injected LPS challenge model using 7-week old mice. In this comparison only the age 
and method of LPS challenge were the two key parameters altered, all other parameters 
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were either similar or the same, e.g. animal handling, stereotactic injection(s), tissue 
processing, and staining/quantification analysis . First, looking at the affect on 
proliferation we observed a dramatic drop across all locations in the hippocampus 
independent of the LPS challenge. The SGZ had the lowest reduction with about a ~60% 
reduction observed between the 7 week old mice in comparison to the 4 week old mice 
see Figure 31-A. In the Granular Zone or the Mossy Fiber the reductions observed in 
cellular proliferation as even greater and as in the SGZ independent of the LPS challenge 
with about ~87% or ~80% reduction respectively , Figure 31-B and C. Interestingly, the 
rate in differentiation as measured by quantifying DCX intensity across the SGZ 
remained unchanged between the two studies and therefore age independent, Figure 31-
D. However, the DCX intensity, i.e. neuronal differentiation, was equally as sensitive to 
LPS either peripherally induced, demonstrating a ~40% reduction in intensity , or to an 
LPS challenge induced directly into the CNS , which induced ~30% reduction and was 
not statistically significant. Overall, this suggests that there is a precipitous drop in 
proliferation rates that occurs sometime between week 4 and week 7 of age in the mouse. 
However, more importantly though this suggestions that neuronal differentiation rates are 
not different between weeks 4 and 7 of age in mice. 
IL-6 neutralization blocks alterations in neuronal!astrocytic cell fate determination during 
the acute inflammatory response in vitro 
Many members of the neuropoietin family have been demonstrated to alter NSC 
cell fates , i.e. differentiation of NSCs away from neurogenesis and skewed towards 
156 
gliogenesis [119,123-126]. We reasoned that since IL-6 was the most up-regulated gene 
under LPS stimulation to primary microglia, Figure 5-A, IL-6likely candidate cytokine 
mediator that plays a role in the reduced neuronal differentiation we have observed in the 
neugenic niche of the SGZ in response to an inflammatory challenge. To test this 
hypothesis we pe1formed a 5-day co-culture experiment in which stimulated primary 
microglia were co-cultured with NSCs for 5 days under an LPS challenge with or without 
an IL-6 neutralizing antibody . 
To simulate the neurogenic region in the brain we utilized a transwell 
configuration with primary microglia from WT mice in the upper well and dissociated 
NSCs from E14 WT mice in the lower chamber in a ratio of 3:10 respectively, as 
described in Chapter 2. We then separated the wells into the following groups and did 
n=4 replicates per group: WT-PBS, WT-LPS, Anti-IL-6 mAb-PBS, Anti-IL-6 mAb-LPS, 
Isotype control-PBS and Isotype control-LPS. Primary microglia were isolated, as 
described in chapter2, and cultured for 5-7 days for enrichment. After that time, we 
harvested the microglia and counted the cells and separated the necessary cells into 
various treatment groups for a 4-hour pre-stimulation with LPS (100 ng/ml) or equivalent 
volume of PBS combined with anti-IL-6 neutralizing antibody (200 ng/ml) , isotype 
control antibody (200 ng/ml) or equivalent volumn of PBS . After the 4-hr stimulation 
period primary microglia were added to the top compartment of the transwell to 
previously plated dissociated NSCs on poly-D lysine/laminin coated coverslips in the 
bottom well of the transwell and placed in the incubator for 5 days. Note, to control for 
IL-6 production form astrocytes both anti-IL-6 antibody (200 ng/ml), isotype control 
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antibody (200ng/ml) and equivalent volumes of PBS were added to lower chamber as 
well . After 5 days the insert with the primary microglia was discarded and cells were 
fixed with 4% paraformaldehyde and stained for Neuronal marker B-III tubulin or 
astrocytes using GFAP. 
Overall , we observed that normal NSC differentiation was significantly altered 
under inflammatory challenge, which could be nearly ameliorated with the application of 
an IL-6 neutralizing antibody. Representative images demonstrating B-Ill tubulin, GFAP 
and DAPI staining for each group are shown in Figure 32. We observed a significant (p< 
0.001 n=4) 20% increase in the percentage of cells differentiating to astrocytes only in 
the WT-LPS (55% +1- 2.7%) and isotype control-LPS (61 % +/- 3.1 %) groups with all 
other groups, including the Anti-II-6 -LPS treated group remaining about 45 % +1- 2.45% 
an average of all the other groups , Figure 33-B. Correspondingly we also observed a 
more dramatic 50% reduction in both the WT -LPS and Isotype-LPS treatment groups, 
(p<0.05 , n=4) or (p<O.Ol n=4) respectively, in neuronal cell fates, Figure 33-C. Neuronal 
cell differentiation levels where much less than astrocytic overall. In the control groups , 
WT-PBS and Isotype-PBS we observed only about 27% +/-2% neuronal cell 
differentiation normalized to total number of cells Figure 33-C. However, in an LPS 
challenge, WT-LPS or Isotype-LPS the average number of neuronal differentiation 
plummeted to 13.5% +1- 2%, Figure 33-C. This was nearly recovered back to the non-
challenged levels by treatment with the neutralizing IL-6 antibody (25% +/-3%), Figure 
33-C. However , this was not a complete recovery and there was still a 7.7% reduction 
unaccounted for, though this did not reach statistical significance. We next compared the 
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ratio of Neurons to Astrocytes and saw that in either the WT-LPS group or the Isotype-
LPS group this ratio dropped significantly (p<O.OOl ,n=4) either 56% or 64% 
respectively, Figure 33-A. Again, the neutralizing Anti-IL-6 LPS group also 
demonstrated an insignificant 4% reduction, but compared to the other two control 
groups, which actually demonstrated increases Figure 33-A. This further suggests that 
the recovery by adding neutralizing Anti-IL-6 was not complete. 
Taken together we have demonstrated that during and inflammatory challenge 
NSCs skew to astrocytic cell fate at the expense of the neuronal cell fate. Further, 
treatment with a neutralizing anti-IL-6 antibody can reverse upwards of 90% of that 
skewing cell fates during and inflammatory challenge, but likely its not 100% recovery. 
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Figure 26: Representative images demonstrating that Peripheral Inflammation can 
reduce both neurogenic proliferation and differentiation 
Images (20x) of the Dentate Gyrus in 4-week old C57BL/6J mice 4 days post peripheral 
inflammatory challenge (E-H) induced by LPS ( 1 mg/kg) injected IP compared with 
control saline (A-D) injected animals. Tissue sections were triple stained with BrdU, 
DCX and DAPI (Hoechst 33342) (A) BrdU stained of control saline Dentate gyrus, (B) 
DCX image of control saline Dentate gyrus, (C) DAPI (Hoechst 33342) and (D) Merged 
image of saline treated control animal. (E) BrdU stained of control LPS treated Dentate 
gyrus, (F) DCX image of Dentate Gyrus in LPS treated (G) DAPI (Hoechst 33342) and 
(H) Merged image of LPS treated animal. 
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Figure 27: Quantification results demonstrating that Peripheral Inflammation can 
reduce both neurogenic proliferation and differentiation 
Counts of BrdU+ cells in 4-week old C57BL/6J mice of various hippocampal regions 4 
days post peripheral inflammatory challenge induced by LPS (1 mg/kg) injected IP 
compared with control Saline injected animals. (A) Normalized number of BrdU+ cells as 
counted along the length of the SGZ (in mm , n=3-4 per group,**= p<O.Ol). (B) , 
Normalized number of BrdU+ cells as counted within the Granular Zone layer (in mm2) 
of the Hippocampus (n=3-4 per group,***= p<O.OOl). (C) Number of BrdU+ cells as 
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counted within the Mossy Fiber (n=3-4 per group,**= p<O.Ol). (D) DCX intensity 
measurement made along the SGZ to determine neuronal cell differentiation (n=3-4 per 
group,**** = p<O.OOOl). 
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Figure 28: Representative images demonstrating that miR-1 ss-t- can prevent the 
suppression of the neurogenic region as a result of central inflammation. 
Images (20x) of the Dentate Gyrus in 7-week old miR-155_,_ or C57BL/6J (WT) mice 5 
days post central inflammatory challenge induced by ICV injection of 1 !-1-1 of LPS (I 
!-1-gl !-1-1) or 1 !-1-1 of control saline injected animals. Tissue sections were triple stained with 
DAPI (Hoechst 33342) (A, E, I, and M) , BrdU (B, F, 1, and N) , DCX (C, G, K, and 0) 
and merge of all the images (0, H, Land P). (A-D) Images from the WT saline group, 
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(E-H) Images of the miR-155-1--Saline group, (I-L) Images from the WT-LPS group, and 
(M-P) Images of the miR-155-1--LPS group. 
164 
A 
!!! 
Q; 
0 
+ 
=> 
"E 
CD 
-0 
t 1 
.c 
E 
:::1 
z 
Total Number of BrdU+ cells: 
ICV miR-155KO 
*** *** 
" I ,, ., ~ 
f/) 
a. 
iii 
"' 
_J 
f/) f/) . 
. 1- 0 
1- 0 $: ::.:: $: ::.:: It) 
It) It) 
It) 
B Normal ized Number of BrdU+ cells 
~ E 15. 
<ll E ~ t 12, 
::sa. 
z 1/) 10. 
-o= Q) Q) 
N 0 
=+ 
"'=> E-o 
... ... 
o CD 2 
z 
in SGZ: ICV miR-155KO 
*** Ill 
f/) 
a. 
iii iii ..J 
f/) f/) . 
1- 0 
~ 0 $: ::.:: ::.:: It) It) It) 
It) 
C DCX Intensity Measurement: 
~ 
z-. "C: 
·- :::J ~c:-
Q) "' 
- ... c~
-.o 
:;; 1 
~1 
ICV miR-155KO 
*** 
Figure 29: Quantification results demonstrating that that miR-155·1· can prevent the 
suppression of the neurogenic region as a result of centra/ Inflammation. 
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Counts of BrdU+ cells in 7-week old miR-155_1_ or C57BL/6J (WT) mice 5 days post 
central inflammatory challenge induced by ICV injection of 1 !ll of LPS (1 !lg/!ll) or 1 !ll 
of control saline injected animals. (A), Total count of BrdU+ cells within the 
hippocampus (n=6-8 per group,***= p<O.OOl). (B) Normalized number of BrdU+ cells 
as counted along the length of the SGZ (in mm, n=6-8 per group,***= p<O.OOl). (C) 
DCX intensity measurement made along the SGZ to determine neuronal cell 
differentiation (n=6-8 per group,***= p<O.OOl). 
166 
A 
Mossy fiber BrdU Counts: ICV miR-155KO 
.!!!. 
Qj 
u 
+ 
:::1 
"0 
m 
0 
.. 
QJ 
.a 1 
E 
"' z 
"' 
·= ... 
(/) 
~ 
"' 
(/) (/) 
·= 
0.. 0.. 
... 
..J ..J 
(/) ' ~ 0 0 ::.:: 
"' ::.:: 
"' "' 
"' 
~ 
~ 
C Normalized Mossy Fiber to SGZ 
N 
(!) 
(/) 0 
0 ·-
-<a Q;C:: 
.a + 
U:::::> 
>-"E ~Ill 0 1 0 . 
:::0 
Q) 
·= ... 
"' 
1-
~ 
BrdU+ Count Ratio 
*** 
Q) (/) (/) 
·= 
0.. 0.. 
... 
..J ..J 
(/) 
1- 0 
0 ~ ::.:: 
::.:: "' 
"' 
"' 
..... 
"' ..... 
B 
- N 0< 
20 
~ ~ 15 
E .. 
"' QJ za. 
"0 ..!!!. 10 
w-N QJ 
·- u 
co+ 
E::> 
.. "0 0 .. 
Zlll 
D 
1.75 
Normalized GZ BrdU+ counts : 
ICV miR-155KO 
' 1- 0 ~ ::.:: 
"' 
"' ~
Normalized GZ to SGZ 
BrdU+ Count Ratio 
·= ... 
(/) 
0 
::.:: 
"' 
"' ..... 
*** 
*** 
' 0 
::.:: 
"' 
"' ~
' ~ 
"' 
"' 
Figure 30: Quantification results of miR-155·1- ICV inflammatory challenge in both 
Mossy Fiber and Granular Zone. 
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Counts of BrdU+ cells in 7-week old miR-155_1_ or C57BL/6J (WT) mice 5 days post 
central inflammatory challenge induced by ICY injection of 1 !J.l of LPS (1 f.,lg/f.,ll) or 1 f.,ll 
of control saline injected animals. (A), Number of BrdU+ cells as counted within the 
Mossy Fiber (n=6-8 per group, Non Significant). (B) Normalized number of BrdU+ 
cells as counted within the Granular Zone layer (in mm2) of the Hippocampus (n=6-8 per 
group, * = p<O.OS and *** = p<O.OOl). (C) Ratio of the number of BrdU+ cells in the 
Mossy fiber to the number of BrdU+ cell in the SGZ (n=6-8 per group, ***= p<O.OOl). 
(D) Ratio of the number of BrdU+ cells in the Granular Zone to the number of BrdU+ cell 
in the SGZ (n=6-8 per group,***= p<O.OOl). 
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Figure 31: Comparison of neurogenic proliferation and differentiation levels between 4-
week old Periphery Challenged animals versus 7-week old centrally challenged animals. 
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Counts of BrdU+ cells and DCX intensity measurements in 4-week old C57BL/6J mice of 
various hippocampal regions 4 days post peripheral inflammatory challenge induced by 
LPS (1 mg/kg) or saline injected IP compared with 7-week old miR-15s-'- or C57BL/6J 
(WT) mice 5 days post central inflammatory challenge induced by ICV injection of 1 11-l 
of LPS (1 f-Lg/f-Ll) or 1 11-l of control saline injected animals_ (A) Normalized number of 
BrdU+ cells as counted along the SGZ layer (in mm) of the Hippocampus (n=6-8 and 3-4 
and per group,***= p<0.001). (B) Normalized number of BrdU+ cells as counted within 
the granular zone layer (in mm2) of the Hippocampus (n=6-8 and 3-4 and per group, *** 
= p<0.001). (C) Number of BrdU+ cells as counted within the Mossy Fiber (n=6-8 and 
3-4 and per group, *** = p<0.001). (D) DCX intensity measurement made along the 
SGZ to determine neuronal cell differentiation (n=6-8 and 3-4 and per group,***= 
p<0.001 and NS =non significant). 
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Figure 32: Representative images demonstrating that neutralization of /L-6 can prevent 
the skewing of Neural Stemcells to Astrocytic differentiation during an inflammatory 
challenge . 
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Representative images (20x) of 5-day old NSCs that were co-cultured with primary 
microglia isolated from C57BL/6J WT mice. Primary microglia under went a 4-hour pre-
treatment with either LPS (lOOng/ml) or PBS control, Anti-IL-6 antibody (200 ng/ml) 
combined with LPS or Anti-IL-6 antibody with PBS, or control Isotpye IgG antibody 
(200 ng/ml) combined with LPS or control Isotpye IgG antibody PBS. After 4-hours 
primary microglial were added to the upper compartment of the transwell® and 
equivalent concentrations were added to the lower wells of the transwell® containing the 
Pl-P5 NSCs . After a 5-day incubation period, to allow for differentiation, the NSCs were 
then fixed and triple stained with DAPI (Hoechst 33342) (A, E, I, M, 0 and U), ~-III 
Tubulin to identify neurons (B, F, J, N, Rand V), GFAP to identify Astrocytes (C, G, K, 
0, Sand W) and merge (D, H, L, P, T and X) of all the images. (A-D) Images of WT-
PBS group. (E-H) Images of the WT-LPS group. (I-L) Images of the neutralizing anti-
IL-6 antibody plus WT-PBS group. (M-P) Images of the neutralizing anti-IL-6 antibody 
plus WT-LPS group. (Q-T) Images of the isotype control IgG antibody plus WT-PBS 
group . (U-X) Images of the isotype control IgG antibody plus WT-LPS group. 
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Figure 33: Quantification demonstrating that neutralization of /L-6 can prevent the 
skewing of Neural Stemcells to Astrocytic differentiation during an inflammatory 
challenge. 
Quantification of 5-day old NSCs that were co-cultured with primary microgli a isolated 
from C57BL/6J WT mice. Primary microglia under went a 4-hour pre-treatment with 
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either LPS (100ng/ml) or PBS control, Anti-IL-6 antibody (200 ng/ml) combined with 
LPS or Anti-IL-6 antibody with PBS, or control Isotpye IgG antibody (200 ng/ml) 
combined with LPS or control Isotpye IgG antibody PBS. After 4-hours primary 
microglial were added to the upper compartment of the transwell® and equivalent 
concentrations were added to the lower wells of the transwell® containing the P1-P5 
NSCs. After a 5-day incubation period, to allow for differentiation, the NSCs were then 
fixed and triple stained, imaged and counted for quantification. (A) Ratio of neurons (~­
III tubulin+ cells) to Astrocytes (GFAP+ cells) (n = 4 per group at least 10 images per 
group, *** = p< 0.001). (B) Percentage of Astrocytes (GFAP+ cells) relative all cells 
(DAPI) (n = 4 per group at least 10 images per group,***= p< 0.001). (C) Percentage of 
Neruons (~-III tubulin+ cells) relative all cells (DAPI) (n = 4 per group at least 10 images 
per group,*= p< 0.05 and *** = p< 0.001). 
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Discussion 
From the research presented in previous chapters we identified miR-155 and 
demonstrated experimentally it plays a key role in M1-skewing as suggested by the 
bioinformatical analysis pe1formed. To further test this hypothesis we looked at a CNS 
phenomenon that is known to be highly responsive to inflammatory insults-
Neurogenesis. Regardless if the inflammatory insult was made directly on the brain 
parenchyma or peripherally Neurogenesis wthin the SGZ of the dentate gyrus is 
inhibited, which can be rescued with treatment of anti-inflammatory therapeutics 
[112,113]. We posited that since miR-155 is a regulator of the Ml-classical activation in 
microglial and under inflammatory states would suppress Neurogensis, which if inhibited 
under a similar challenge should prevent the suppression. 
The initial attempt at this experiment applying LNA-based anti-miR-155 was not 
as successful as expected. Most injection were well above the targeted dentate gyrus. 
Further, there did not appear to be as much penetration as hoped of the LNA-based miR-
155. However, we were still able to demonstrate the responsive of the neurogenic region 
to an inflammatory challenge. We were able to suppress proliferation and differentiation 
process, two of the three key elements that comprise neurogenesis. Over all, we observed 
a 20% reduction in SGZ proliferation rates and a 40% reduction in differentiation of new 
neurons in the SGZ. This effectively replicated Monje et al. work where they observed a 
near 35% reduction in proliferation rates at the SGZ to peripheral inflammatory insults 
[113]. 
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Next we turn to miR-155-/- mice to complete ablate miR-155's function and 
performed an inflammatory insult directly to the CNS via ICY microinjection. We were 
surprised to observe that ablation of miR-155 completely abolished the normal 
suppression in neurgenesis that would occur in response to an inflammatory insult. As 
expected, we observed a 31 % reduction in proliferation along the SGZ in the WT 
inflammatory challenged group. This is much less reduction than Ekdal , et al. 
demonstrated , 65 % reduced levels of proliferation [112] . This can be accounted for by 
the fact that they continuously infused LPS into the ICV for 28 days versus the single 
injection if LPS we performed [112] . As with proliferation along the SGZ ablation of 
miR-155 completely abolished the normal suppression in differentiation as well. We 
observed a 29% reduction in neuronal cell fate determination. The miR-15s-'· 
inflammatory challenged group demonstrated differentiation levels that were equal with 
control saline treated levels. 
One area of difference we did not anticipate seeing was that in Mossy fibers and 
the Granular zone. Our initial study demonstrated dramatic reductions , 60% in the 
granular zone and 40% reduction in the Mossy fiber, in the numbers of newly divided 
cells entering these regions. In the miR-155-/- mice newly divide cells that migrated into 
the mossy fiber was extremely only about 3 cells per image across every group was 
observed . However , in the Granular zone a slightly different picture emerged. We had 
anticipated to observe a reduction of new neurons entering the granular zone during 
inflammation, but we observed a 60% increase in our WT control groups. Further , with 
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the abolishment of miR-155 at rest lead to an increase of 40% and a staggering 110% 
increase when challenged with LPS. 
To try to understand this data better we normalized these results to the production 
of new cells along the SGZ. Normalizing the data seems to suggest that in the rate of 
migration into the mossy fiber in 7-week old animals was maintained despite the reduced 
pool of available new cells due to the suppressed state observed in the WT -LPS group. 
Further, this affect was dependent of miR-155 since the mossy fiber counts increased 
with LPS and returned to normal control levels in the miR-155-/- LPS group. However, 
in the Granular zone higher rates of newly dividing cells entering were observed in both 
LPS challenged groups , suggesting a miR-155 independent pathway that is enhanced 
under LPS challenge. There are many questions left unanswered here and would be very 
interesting to pursue at a future time. 
One last observation made in this study was that despite being older, 7-week old, 
used in this study compared to the 4-week old mice used in the initial study the rates of 
proliferation were reduced by a staggering amount, approaching 90% in the granular zone 
and mossy fiber in just a 3 week difference. The SGZ reduced proliferation rates by only 
60%, but still very sharply reduced in a real short time. However, what is intriguing was 
that intensity of DCX was unchanged between the 4-week old mice versus the 7-week 
old, but levels at rest for all saline treated as well as the 15s-'-LPS challenged animal and 
the two WT-LPS were suppressed by near equal amount. This suggests the rate of 
differentiation of new neurons is unchanged in this brief 3-week period. That lends an 
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interesting question are these excess cells being produced entering astrocytic or 
oligodendrocytic cell fates since the rate of new neuronal production appears to be 
constant? 
178 
Chapter 7: GENERAL DISCUSSION 
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DISCUSSION 
The overall goal of this research was to demonstrate that blockade of miR-155 
could prevent the detrimental effects that inflammation exerts on Nem·ogenesis. We were 
surprised to observe that ablation of miR-155 completely abolished the normal 
suppression in neurgenesis that would occur in response to an inflammatory insult. As 
expected, we observed a 31% reduction in proliferation along the SGZ in the WT 
inflammatory challenged group. This is much less reduction than Ekdal, et al. 
demonstrated , 65 % reduced levels of proliferation [112]. This can be accounted for by 
the fact that they continuously infused LPS into the ICV for 28 days versus the single 
injection if LPS we peiformed [112]. As with proliferation along the SGZ ablation of 
miR-155 completely abolished the normal suppression in differentiation as well . We 
observed a 29% reduction in neuronal cell fate determination. The miR-155"'· 
inflammatory challenged group demonstrated differentiation levels that were equal with 
control saline treated levels. 
However, first this research needed to take a few steps back to determine which 
miRNAs are critical to microglial functionality and potentially can regulate tell cell that 
is considered the driver of the neuro-immune response, presented in chapters 3 and 4 [8]. 
The overall results point to miR-155 being perhaps the sole miRNA regulator of the M1 
classically activated phenotype in conjunction with reductions in miR-124 and miR-689 
that seem to help maintain the resting MO state. 
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Dynamic Microglial Phenotvves: State Transitions 
This research sought to elucidate the role miRNAs play in regulating primary 
microglial phenotypes under resting, Ml -skewing and M2a-skewing conditions . Initial 
literature searches suggested that microglial function similar to peripheral macrophages. 
This allowed the construction of a working state transition model of the various dynamic 
phenotypes observed in microglial activation states, Figure 1. Through marrying miRNA 
expression data and mRNA gene expression data and performing a lengthy system 
biologic analysis on the data gave much more insight and enable a significant revision 
from initial model, as depicted in Figure 34. 
In short, this research is suggesting the following microglial phenotype (state) 
transition diagram identifying key miRNAs and altered transcription networks mediating 
the transitions between the resting state, recruitment, attack, resolution and repair, 
depicted in Figure 34. To establish the M1-like classical activation in primary microglia, 
we have identified a previous unknown role for miR-689 in microglial biology and 
confirmed previous works of both miR-155 and miR-124. Reductions of both miR-689 
and rniR-124 increase canonical TLR signal pathways and NF-KB-RelaA effector 
pathways thus enabling the initial pro-inflammatory "recruitment" M1 phenotype. We 
also further demonstrate that swift up-regulation of miR-155 during the acute phase of 
the Ml phenotype, drives the transition from TLR signal and NF-kB/RelA effector 
pathways to that driven by STAT1/STAT3 signaling pathways to facilitate the late-phase 
response elements of the Ml-pro-inflammatory response. To our knowledge there has 
never been a comprehensive analysis of IL-4 stimulated microglia or even peripheral 
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macrophages that attempt to identify key miRNAs and the roles they facilitate in shaping 
the alternatively activated phenotype. Like in M1-skewing conditions, we observed 
down regulation of key miRNAs, miR-711 and miR-124, under IL-4 stimulation that 
both inhibit pro-inflammatory/activation states targeting both key transcriptional 
regulator (e.g . C/EBPa and ETSl) and key effectors (e.g. PTSG2 and TNF-a). 
Interestingly , miR-711 also potentially regulates PPARg network, which is known to 
facilitate the M2a "resolution" phenotype [227] . We also observed up-regulation of miR-
145 and miR-449a which both appear to play a key role in shaping the M2a phenotype. 
miR-145 potentially alters the transcription networks of ETS1and HOXB4. miR-449a 
potentially regulates the transcriptional networks of known pro-inflammatory pathways 
Notch and Wnt/~-catenin through targeting of Jag1, notch1, and Myc in primary 
microglia[206,283 ,284]. However, our analysis also identifies 4 novel pathways that 
rniR-449a can also potentially regulate, the transcriptional networks of AHR, USF2, 
EZH2, and PRDM16, in primary microglia. Overall, our data suggests that down 
regulation of miRNAs is as critical in 'releasing' primary microglia from their MO-
Resting state, through down regulation of miR-711 and miR-124, to establishing the 
M2a-alterantively activated state by up-regulation of miRNAs miR-145 and miR-449a in 
primary microglia. Fmther studies will be necessary for the validation of our 
observations . 
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miR-155 The crossroads of adaptive Immunity and Innate Immunity 
The overall results identified in chapters 3 and 4 point to miR-155 being perhaps 
the sole miRNA regulator of the Ml-classically activated phenotype in microglia, along 
with in a few miRNAs , miR-124 and miR-689 , that seem to help maintain the resting MO 
state. This was both a surprise and somewhat a disappointment given the complexity 
observed in transcriptional regulation of the innate immune response/acute inflammation 
[229] . An interesting finding by Heimberg et al. , that found miR-155 to be evolutionarily 
conserved, at lest 78% commonality, with almost every species from human down to 
asci dian Ciona intestinalis (solitary tunicate) at the base of the chordata phyla [44,68]. It 
is surprising that miR-155 only stretches back, evolutionarily speaking, to the rise of 
chordata, considering the innate immune response can be traced as far back cnidaria, 
hydras [289]. The data presented in this research is suggesting miR-155 regulates the 
Ml-classically activate microglial state, which is also common to macrophages, and 
considered a key responsive feature of innate immunity [51] . Frazenburg, et al. 
demonstrate that cnidarians have homologs to all the elements of TLR signaling, 
including NF-KB , that are present in mammalian system, and function in pathogen 
recognition just as it does in mammalian systems [289] . These are core elements of what 
are considered innate immunity , which actually drives the expression of miR-155, yet no 
miR-155 . Curiously, the adaptive immune response also is known to have arisen at the 
base of the chordata phyla much around the same time and species as miR-155 appears 
within evolution [44,290,291]. In identifying when miR-155 arose evolutionarily 
speaking strongly suggests that its functionality is more tied to that of adaptive immunity. 
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In fact, there are multiple studies tying miR-155 to the differentiation and functionality of 
T-cells [68 ,74,82]. Perhaps the most succinct was by Rodriguez et al., described in 
chapter 1, with miR-155_,_ mice looking at T -cell alterations demonstrated significantly 
impaired T H 1 skewing and enhanced Th2 skewing [82]. Further, this suggests the 
application ofT Hl - Ml and T H2- M2 nomenclature may be more apt than people 
realized [24,32,34]. Its not hard to speculate that miR-155 potentially 'hooked' into 
existing innate processes in order to add features necessary to activate the adaptive T Hl , 
IFN-y driven adaptive immune response, e.g. antigen presentation or upregulation of 
MHC-II . Upregulation of MHC-II is a cardinal feature of microglial activation in the M1 
classically activated state.[8,36] 
miRNA as a Therapeutic Target 
The development of miRNA for therapeutics in disease modification has 
generated great interests . As a proof-of-concept of an anti-miRNA therapeutic , Kota et al 
demonstrated the application of an exogenous source of a miRNA, miR-26a, as a 
potential anti-cancer therapeutic in the treatment of liver cancer.[292]. Application of 
LNA versus natural nucleotides has several advantages, most importantly increased 
binding affinity and specificity to target miRNAs , coupled with low degradation and 
toxicity make LNA an ideal candidate as a therapeutic .[293-295] In perhaps, the first 
LNA anti-miRNA-based therapeutic entering human clinical trials Miravirsen , by 
Santaris Pharma a/s (www .santaris .com), is an LNA based anti-miR-122 targeting 
suppression of HCV virus.[296] Recently, a new approach has been taken to inhibit 
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endogenous miRNAs by targeting only the tiny 8-mer seed region of the miRNA, which 
is the key miRNA-mRNA target-determining region of the miRNA.[160,297,298l 
Further, Garchow et al., demonstrated that 8-mer LNA-based anti-miR-21 significantly 
ameliorated splenomegaly in mice, a hallmark manifestation of SLE.[299] Taken together 
these demonstrate the potential of clinical applications of anti-miRNA based therapeutics 
as potent disease modifiers. 
Overall Conclusion 
In conclusion, this research demonstrated how miR-155 prevents the suppression of 
neurongenesis, as demonstrated in chapter 6. However, more important this work has 
better elucidated the role and function of a critical regulator of not only the innate 
immune system, but also the adaptive immune response. This tiny little molecule may 
prove to be one of the most potent anti-inflammatory targets and certainly warrants 
· further study as a potential therapeutic target. 
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Figure 34: Current model for the integrated primary microglial state transitions 
Based the findings in this report we propose the following microglial phenotype (state) 
transition diagram. The resting state (MO) is regulated by miR-124, and upon LPS (Ml) 
or IL-4 (M2a) stimulation is selectively regulated by miR-689 and miR-711 respectively _ 
The M1 phenotype is regulated by miR-155 , whereas M2a phenotype is regulated by 
miR-145 and miR-449a. Fmther, nuclear receptor signaling is critical to maintaining the 
MO phenotype. Initially, both NF-kB and AP-1 signaling are critical to the Ml 
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phenotype and miR-155later aids in the transition to STAT3/STAT1 signaling. Lastly, 
IL-4 signaling is dependant on STAT6, TRIM24, and CREEl along with select nuclear 
receptor signaling: PPARa/y and RARa (A). 
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Pharamcodynamic concepts and problem set review. (Aug 2011) 
Industry Experience: 
GM/OnStar. Inc. (Oct 2002- Feb 2006) 
Staff Technologist responsible for leading, defining technical approaches, and managing 
two critical cross-functional teams focusing on a vehicle telematics. 
WorldCom, Inc. (April 2000- April2002) 
Lead Standards Manager focusing on emerging IP Telephony (SIP and H.323) I IP 
Quality of Service (QoS) and related PSTN Convergence standards like ENUM. Specific 
areas of emphasis focused on emerging IP telephony standards relating to the following 
technical areas: ENUM, VoiP signaling protocols SIP & H.323, and IF-Quality of 
Service (QoS). 
Lead Systems Engineer/Architect developing WorldCom's IP communications product. 
Defined initial architecture & design for WorldCom's integrated PSTN IP Integration 
(PINT) & Session Initiation Protocol (SIP) server architecture. 
SpectraPoint Wireless, LLC. (Feb 1996- Jan 2000) 
Program Manager & Lead Systems Engineer/Architect developing SpectraPoint's Local 
Multipoint Distribution System (LMDS) fixed wireless radio system. 
Lora! Space & Range Corporation, Inc. (1994-1996) 
Lead Reliability & Maintainability Engineer performing R&M tasks on six key 
subsystems to design and develop the US Air Force' s Range Standardization Automation 
(RSA) Program, the next generation Eastern Test Range. 
Harris Space Systems Corporation, Inc. (1990- 1994) 
Senior Engineer performing Reliability and Maintainability Engineering tasks to design 
and develop NASA's CORE Project, the next-generation Space Station and Space Shuttle 
ground-processing computer network. 
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